Engineered cd47 proteins and uses thereof

By engineering CD47 protein and adjusting its structure and glycosylation sites, the shortcomings of CD47 protein in the prior art in immune tolerance and cell therapy are solved, and more efficient immune regulation and cell engineering applications are achieved. .

CN119032102APending Publication Date: 2024-11-26SANA BIOTECHNOLOGY INC

Patent Information

Application Number
CN202380034675.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-02-17
Filing Date
2023-02-17
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

In the prior art, CD47 protein has insufficient application in immune tolerance and transplantation or cell therapy, and it is difficult to effectively regulate the immune response, resulting in immune surveillance and destruction problems.

Method used

The engineered CD47 protein is provided, delivered by integrating gene therapy vectors, reducing the number of amino acids, adjusting glycosylation modification sites and domain combinations, and enhancing its application efficiency in cell engineering.

Benefits of technology

A more effective cellular engineering method was achieved, which enhanced the role of CD47 protein in immune tolerance and cell therapy, reduced the risk of immune surveillance and destruction, and improved the therapeutic effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119032102A_ABST
    Figure CN119032102A_ABST
Patent Text Reader

Abstract

The present disclosure provides engineered CD47 proteins and uses thereof. Also disclosed are polynucleotides encoding the engineered CD47 proteins, vectors comprising the polynucleotides, cells comprising the engineered proteins and / or vectors, and compositions comprising the engineered CD47 proteins.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims priority to U.S. Provisional Application No. 63 / 311,143, filed on February 17, 2022, which is incorporated herein by reference. Field of the Invention

[0003] The present disclosure generally relates to engineered CD47 proteins and uses thereof. Also disclosed are polynucleotides encoding the engineered CD47 proteins, vectors comprising the polynucleotides, cells comprising the engineered proteins and / or vectors, and compositions comprising the engineered CD47 proteins.

[0004] International application PCT / US2021 / 065157 and U.S. applications 63 / 282,961, 63 / 270,956, and 63 / 222,954 are incorporated by reference in their entirety. Summary of the Invention

[0005] CD47 is a gene in the human body that is expressed by the CD47 gene ( Figure 1 ) is a transmembrane protein encoded by the cytoplasm. It is a member of the immunoglobulin (Ig) superfamily. The molecular weight of CD47 is approximately 50 kDa. It is glycosylated and ubiquitously expressed in almost all cells in the human body (Figure 2). It has a single IgV-like domain at its N-terminus, a highly hydrophobic segment with five transmembrane segments, and an alternatively spliced ​​cytoplasmic tail at its C-terminus ( Figure 4 ). In addition, it has two extracellular regions and two intracellular regions between adjacent transmembrane segments. The signal peptide, when present on CD47 isoforms, is located at the N-terminus of the IgV-like domain. The human CD47 gene has six naturally occurring transcripts, five of which each encode a protein isoform of CD47 (Ensembl, gene: CD47). Thus, human CD47 has five protein isoforms, each of which is differentially expressed across various cell and tissue types.

[0006] CD47 is involved in a range of cellular processes including apoptosis, proliferation, adhesion and migration. CD47 interacts with a variety of extracellular ligands, such as TSP-1, integrins, other CD47 proteins and SIRPα. The CD47 / SIRPα interaction regulates a variety of cell-to-cell interactions in many body systems, such as the immune system, where it regulates lymphocyte homeostasis, maturation and activation of dendritic cells (DCs), the correct positioning of certain DC subsets in secondary lymphoid organs, and cell migration. CD47 on cells (including donor cells in the context of transplantation or cell therapy applications) can act as a "self-marker" and regulate phagocytosis by binding to SIRPα on the surface of circulating immune cells to deliver an inhibitory "don't kill me" signal. CD47-SIRPα binding causes phosphorylation of the immunoreceptor tyrosine-based inhibitory motif (ITIM) on SIRPα, triggering the recruitment of SHP1 and SHP2 Src homologous phosphatases. These phosphatases, in turn, inhibit the accumulation of myosin II at the phagocytic synapse, thereby preventing phagocytosis (Fujioka et al., 1996). The phagocytosis of target cells by macrophages is ultimately regulated by a balance of activating signals (e.g., FcγR, CRT, LRP-1) and inhibitory signals (e.g., SIRPα-CD47). Elevated expression of CD47 can help cells escape immune surveillance, subsequent destruction, and killing by innate immune cells. Therefore, when the normal immune response becomes pathological or undesirable, CD47 can be used as a tolerogenic factor to induce immune tolerance. For example, this occurs when a patient develops an immune response to a donor antigen after receiving an allogeneic transplant or allogeneic cell therapy, or when the body responds inappropriately to self-antigens implicated in autoimmune diseases. However, there is a need in the art to improve such uses of CD47.

[0007] In one aspect, the present disclosure provides engineered CD47 proteins that have fewer amino acids than wild-type, full-length human CD47 proteins. Such engineered proteins provide more efficient cell engineering methods, including delivery via integrated gene therapy vectors.

[0008] In one aspect, the present disclosure provides an engineered CD47 protein comprising a human CD47 extracellular domain or a portion thereof, at least one human CD47 transmembrane domain or a portion thereof, and a portion of a human CD47 intracellular domain comprising at least one amino acid deletion, wherein the deletion is not a C-terminal 18 amino acid deletion.

[0009] In one aspect, the present disclosure provides an engineered CD47 protein comprising a portion of the human CD47 extracellular domain, at least one human CD47 transmembrane domain or a portion thereof, and a portion of the human CD47 intracellular domain comprising a C-terminal 18 amino acid deletion.

[0010] In one aspect, the present disclosure provides an engineered CD47 protein comprising a human CD47 extracellular domain or a portion thereof, at least one and less than five human CD47 transmembrane domains or a portion thereof, and a portion of a human CD47 intracellular domain comprising a C-terminal 18 amino acid deletion.

[0011] In one aspect, the present disclosure provides an engineered CD47 protein comprising a human CD47 extracellular domain or a portion thereof, at least one human CD47 transmembrane domain or a portion thereof, and a signal peptide, wherein the engineered CD47 protein does not comprise an intracellular domain.

[0012] In one aspect, the present disclosure provides an engineered CD47 protein comprising a human CD47 extracellular domain and at least one human CD47 transmembrane domain or a portion thereof, wherein the engineered CD47 protein does not comprise an intracellular domain.

[0013] In one aspect, the present disclosure provides an engineered CD47 protein comprising a human CD47 extracellular domain or a portion thereof, and at least one and less than five human CD47 transmembrane domains or a portion thereof, wherein the engineered CD47 protein does not comprise an intracellular domain.

[0014] In one aspect, the present disclosure provides an engineered CD47 protein comprising a human CD47 extracellular domain or a portion thereof, and at least one human CD47 transmembrane domain or a portion thereof, and no intracellular domain or a human CD47 intracellular domain comprising at least one amino acid deletion, wherein the engineered CD47 protein has an amino acid sequence that is at most 99% identical to SEQ ID NO: 1 and SEQ ID NO: 6.

[0015] In some embodiments, the engineered CD47 proteins disclosed herein comprise fewer glycosylation modification sites than wild-type CD47 proteins.

[0016] In some embodiments, the engineered CD47 proteins disclosed herein comprise fewer glycosylation modifications than wild-type human CD47 protein.

[0017] In some embodiments, the engineered CD47 proteins disclosed herein comprise fewer than two heparan sulfate and / or chondroitin sulfate glycosaminoglycan modification sites.

[0018] In some embodiments, the engineered CD47 proteins disclosed herein comprise fewer than two heparan sulfate and / or chondroitin sulfate glycosaminoglycan chains.

[0019] In some embodiments, the engineered CD47 proteins disclosed herein comprise fewer than five N-glycosylation modification sites.

[0020] In some embodiments, the engineered CD47 proteins disclosed herein comprise fewer than four N-glycosylation modified chains.

[0021] In some embodiments, the human CD47 extracellular domain, or portion thereof, in the engineered CD47 proteins disclosed herein lacks one or more thrombospondin-1 binding sites compared to wild-type human CD47 protein.

[0022] In some embodiments, the human CD47 extracellular domain or portion thereof in the engineered CD47 proteins disclosed herein lacks one or more integrin binding sites compared to wild-type human CD47 protein. In some embodiments, the integrin is selected from the group consisting of: αvβ3 integrin, αIIbβ3 integrin, α2β1 integrin, α4β1 integrin, α6β1 integrin, and α5 integrin.

[0023] In some embodiments, the human CD47 extracellular domain, or a portion thereof, in the engineered CD47 proteins disclosed herein comprises at least one SIRPα interaction motif.

[0024] In some embodiments, the engineered CD47 proteins disclosed herein comprise a disulfide bond between a cysteine ​​located within the human CD47 extracellular domain or portion thereof and a cysteine ​​located within or between one or more human CD47 transmembrane domains.

[0025] In some embodiments, the engineered CD47 proteins disclosed herein are tolerogenic factors.

[0026] In some embodiments, the engineered CD47 proteins disclosed herein are transmembrane proteins.

[0027] In some embodiments, the human CD47 extracellular domain in the engineered CD47 proteins disclosed herein comprises an amino acid sequence that is at least 80%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to amino acids 19-141 of SEQ ID NO:2.

[0028] In some embodiments, any of the at least one human CD47 transmembrane domains in the engineered CD47 proteins disclosed herein comprises an amino acid sequence selected from the group consisting of an amino acid sequence at least 80%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to amino acids 142-162 of SEQ ID NO: 2, an amino acid sequence at least 80%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to amino acids 177-197 of SEQ ID NO: 2, an amino acid sequence at least 80%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to amino acids 208-228 of SEQ ID NO: 2, an amino acid sequence at least 80%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to amino acids 209-210 of SEQ ID NO: 2, An amino acid sequence that is at least 80%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to amino acids 236-257 of SEQ ID NO:2, and an amino acid sequence that is at least 80%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to amino acids 269-289 of SEQ ID NO:2.

[0029] In some embodiments, the human CD47 intracellular domain in the engineered CD47 proteins disclosed herein comprises an amino acid sequence that is at least 80%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the sequence of amino acids 290-323 of SEQ ID NO:2.

[0030] In some embodiments, the engineered CD47 proteins disclosed herein comprise an amino acid sequence that is at least 80%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO:7.

[0031] In some embodiments, the engineered CD47 proteins disclosed herein comprise an amino acid sequence that is at least 80%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO:8.

[0032] In some embodiments, the engineered CD47 proteins disclosed herein comprise an amino acid sequence that is at least 80%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO:9.

[0033] In some embodiments, the engineered CD47 proteins disclosed herein comprise an amino acid sequence that is at least 80%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO:12.

[0034] In some embodiments, the engineered CD47 proteins disclosed herein comprise an amino acid sequence that is at least 80%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO:10.

[0035] In some embodiments, the engineered CD47 proteins disclosed herein comprise an amino acid sequence that is at least 80%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO: 11.

[0036] In some embodiments, the engineered CD47 protein is an engineered human CD47 protein, an engineered humanized CD47 protein, or an engineered partially humanized CD47 protein.

[0037] In another aspect, the present disclosure provides polynucleotides encoding the engineered CD47 proteins disclosed herein.

[0038] In another aspect, the present disclosure provides a vector comprising a polynucleotide encoding an engineered CD47 protein disclosed herein. In some embodiments, the vector is a plasmid or a viral vector. In some embodiments, the viral vector is a pseudotyped self-inactivating lentiviral vector. In some embodiments, the vector is a polycistronic vector. In some embodiments, the polycistronic vector is a bicistronic vector or a tricistronic vector.

[0039] In another aspect, the present disclosure provides cells comprising a polynucleotide encoding an engineered CD47 protein disclosed herein, and / or vectors comprising a polynucleotide encoding an engineered CD47 protein disclosed herein.

[0040] In another aspect, the present disclosure provides cells comprising the engineered CD47 protein disclosed herein.

[0041] In some embodiments, the cells disclosed herein are stem cells.

[0042] In some embodiments, the cells disclosed herein are pluripotent stem cells. In some embodiments, the pluripotent stem cells are induced pluripotent stem cells (iPSCs) or embryonic stem cells.

[0043] In some embodiments, the cells disclosed herein are pancreatic islet cells.

[0044] In some embodiments, the cells disclosed herein are primary pancreatic islet cells. In some embodiments, the pancreatic islet cells are differentiated from pluripotent stem cells. In some embodiments, the pluripotent stem cells are iPSCs or ESCs.

[0045] In some embodiments, the cells disclosed herein are T cells.

[0046] In some embodiments, the cells disclosed herein are primary T cells. In some embodiments, primary T cells are T cells containing chimeric antigen receptors. In some embodiments, T cells are CAR-T cells. In some embodiments, T cells are differentiated from pluripotent stem cells. In some embodiments, pluripotent stem cells are iPSCs or ESCs.

[0047] In some embodiments, the cells disclosed herein are selected from the group of cells consisting of stem cells, pancreatic islet cells, T cells, CAR-T cells, cardiac cells, cardiac progenitor cells, neural cells, glial progenitor cells, endothelial cells, B cells, retinal pigment epithelial cells, hepatocytes, thyroid cells, skin cells, blood cells, plasma cells, platelets, kidney cells, epithelial cells, natural killer cells (NK cells) and CAR-NK cells.

[0048] In some embodiments, the cell is in the form of a primary cell. In some embodiments, the cell is a differentiated cell.

[0049] In some embodiments, the cell is a low immunogenic cell.

[0050] In some embodiments, expression of one or more major histocompatibility (MHC) class I proteins and / or one or more MHC class II proteins is reduced compared to wild-type or control cells. In some embodiments, wild-type or control cells are starting materials. In some embodiments, cells disclosed herein do not express one or more major histocompatibility (MHC) class I proteins and / or one or more MHC class II proteins. In some embodiments, the MHC proteins are HLA proteins.

[0051] In some embodiments, expression of MHC class I proteins is reduced by knocking out or reducing expression of B2M in the cells described herein.

[0052] In some embodiments, expression of MHC class II proteins is reduced by knocking out or reducing expression of CIITA in the cells described herein.

[0053] In some embodiments, TRAC and / or TRBC are knocked out in the cells described herein or their expression is reduced in the cells described herein.

[0054] In another aspect, the present disclosure provides compositions comprising the engineered CD47 proteins disclosed herein.

[0055] In another aspect, the present disclosure provides a composition comprising the cells disclosed herein. BRIEF DESCRIPTION OF THE DRAWINGS

[0057] Figure 1 A map of the human CD47 gene is provided, which illustrates the protein-coding region of the human CD47 gene. The map is derived from the Ensembl genome database.

[0058] Figure 2A and Figure 2B The CD47 ENSG00000196776.14 isoform expression of the CD47 molecule (Source: HGNC symbol; Acc: HGNC: 1682) is provided, and the expression of each isoform in various human tissues and human cell types is shown. This data is from the Genotype-Tissue Expression (GTEx) project database.

[0059] Figure 3 The predicted CD47 transmembrane domain and human CD47 protein topology are provided. Specifically, Figure 3 The predicted locations of various domains in the human CD47 protein are provided. This prediction is from the Universal Protein Resource (UniProt).

[0060] Figure 4 The tertiary structure of human CD47 predicted based on the AlphaFold protein structure database is provided.

[0061] Figure 5A 、 Figure 5B 、 Figure 5C and Figure 5D A sequence alignment of isoform 201, isoform 202, isoform 203, isoform 205, and isoform 206 of the human CD47 protein is provided.

[0062] Figure 6 Exemplary graphs showing viral titers of LVV comprising exemplary CD47 truncation variants as assessed via the Ella automated immunoassay system are provided.

[0063] Figure 7An exemplary graph showing the percentage of CD47KO HEK293T cells expressing CD47 following treatment with truncated CD47 LVVs (as assessed by anti-CD47 flow cytometry) is provided. Various CD47 variants were tested, including several CD47 variants containing a GPI anchor.

[0064] Figure 8 An exemplary graph showing the percentage of CD47KO HEK293T cells expressing CD47 after treatment with truncated CD47 LVV (as assessed by anti-CD47 flow cytometry) is provided. Various CD47 variants were tested, including several containing a truncated intracellular domain and an alternative transmembrane domain.

[0065] Figure 9 An exemplary graph showing the percentage of CD47KO HEK293T cells expressing CD47 after treatment with truncated CD47 LVV (as assessed by anti-CD47 flow cytometry) is provided. Various CD47 variants were tested, including those containing truncated intracellular domains and alternative hinge domains.

[0066] Figure 10 An exemplary graph showing the percentage of CD47KO HEK293T cells expressing CD47 after treatment with truncated CD47 LVV (as assessed by anti-CD47 flow cytometry) is provided. Various CD47 variants were tested, including those containing truncated intracellular domains and alternative hinge domains.

[0067] Figure 11 An exemplary graph showing the percentage of CD47KO HEK293T cells expressing CD47 after treatment with truncated CD47 LVV (as assessed by anti-CD47 flow cytometry) is provided. Various CD47 variants were tested, including those containing truncated intracellular domains and alternative hinge domains.

[0068] Figure 12A 、 Figure 12B 、 Figure 12C 、 Figure 12D and Figure 12E An exemplary graph showing the percentage of CD47KO HEK293T cells expressing CD47 following treatment with truncated CD47 LVVs (as assessed by anti-CD47 flow cytometry) is provided.

[0069] Figure 13An exemplary graph showing the percentage of CD47KO HEK293T cells expressing CD47 following treatment with truncated CD47 LVVs (as assessed by anti-CD47 flow cytometry) is provided.

[0070] Figure 14 An exemplary graph showing the percentage of CD47KO HEK293T cells expressing CD47 following treatment with truncated CD47 LVVs (as assessed by anti-CD47 flow cytometry) is provided.

[0071] Figure 15 An exemplary graph showing the percentage of CD47KO HEK293T cells expressing CD47 following treatment with truncated CD47 LVVs (as assessed by SIRPα-FC flow cytometry) is provided.

[0072] Figure 16 An exemplary graph showing the percentage of CD47KO HEK293T cells expressing CD47 following treatment with truncated CD47 LVVs (as assessed by SIRPα-FC flow cytometry) is provided.

[0073] Figure 17 An exemplary graph showing the percentage of CD47KO HEK293T cells expressing CD47 following treatment with truncated CD47 LVVs (as assessed by SIRPα-FC flow cytometry) is provided.

[0074] Figure 18A An exemplary graph showing the percentage of CD47KO HEK293T cells expressing CD47 following treatment with truncated CD47 LVVs (as assessed by anti-CD47 flow cytometry) is provided.

[0075] Figure 18B An exemplary graph showing the percentage of CD47KO HEK293T cells expressing CD47 following treatment with truncated CD47 LVVs (as assessed by SIRPα-FC flow cytometry) is provided. DETAILED DESCRIPTION

[0076] I. Definition

[0077] All publications, patents, and patent applications cited herein are incorporated by reference in their entirety to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference in its entirety.

[0078] In this disclosure, unless otherwise indicated, the scientific and technical terms used herein have the meanings commonly understood by those skilled in the art. Although any methods and materials similar or equivalent to the methods and materials described herein can be used in the practice of this disclosure, preferred methods and materials are described herein. Therefore, the terms defined herein will be more fully described by reference to the entire specification.

[0079] As used herein, the singular terms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise.

[0080] As used herein, "and / or" refers to and encompasses any and all possible combinations of one or more of the relevant listed items, as well as the lack of combinations when interpreted in an alternative manner ("or / or"). Furthermore, the present invention contemplates that, in some embodiments of the present invention, any feature or combination of features set forth herein may be excluded or omitted.

[0081] The term "about," as used herein in reference to a measurable value (such as a sequence length, etc.), is intended to encompass variations of 5%, 1%, 0.5%, or even 0.1% of the specified amount.

[0082] Unless the context requires otherwise, the terms "comprise," "comprises," and "comprising" or similar terms are intended to mean non-exclusive inclusion, such that a recited list of elements or features includes not only those stated or recited elements, but may include additional elements or features that are not listed or recited.

[0083] Unless otherwise indicated, nucleic acids are written left to right in 5' to 3' orientation; and amino acid sequences are written left to right in amino to carboxyl orientation.

[0084] It is to be understood that this disclosure is not limited to the particular methodology, protocols, and reagents described, as these may vary depending upon the context in which they are used by one skilled in the art.

[0085] As used herein, "affinity" refers to the strength of the sum of non-covalent interactions between a single binding site of a molecule (e.g., a receptor) and its binding partner (e.g., a ligand). The affinity of a molecule for its partner can generally be expressed by the equilibrium dissociation constant (K D ) (or its reverse equilibrium binding constant, KA).

[0086] Affinity can be measured by common methods known in the art, including those described herein. See, for example, Pope ME, Soste MV, Eyford BA, Anderson NL, Pearson TW, (2009) J. Immunol. Methods. 341(1-2):86-96 and the methods described therein.

[0087] As used herein, the terms "percent identity" and "% identity" as applied to nucleic acid or polynucleotide sequences refer to the percentage of residue matches between at least two nucleic acid or polynucleotide sequences aligned using a standardized algorithm. Such an algorithm can insert gaps in the sequences being compared in a standardized and reproducible manner in order to optimize the alignment between the two sequences and thereby achieve a more meaningful comparison of the two sequences.

[0088] The percent identity between nucleic acid or polynucleotide sequences can be determined using a commonly used and freely available suite of sequence comparison algorithms provided by the National Center for Biotechnology Information (NCBI) Basic Local Alignment Search Tool (BLAST) (Altschul, SF et al. (1990) J. Mol. Biol. 215:403-410), which is available from a number of sources including NCBI in Bethesda, Md., and on the internet at http: / / www.ncbi.nlm.nih.gov / BLAST / .

[0089] Due to the degeneracy of the genetic code, nucleic acids or polynucleotide sequences that do not show a high degree of identity may still encode similar amino acid sequences. It should be understood that this degeneracy can be used to change the nucleic acid sequence to produce multiple nucleic acid sequences that all encode substantially the same protein. Specifically, degenerate codon substitutions (Batzer et al. (1991) Nucleic Acid Res 19:5081) can be achieved by generating a sequence in which the third position of one or more selected (or all) codons is replaced by mixed bases and / or deoxyinosine residues; Ohtsuka et al. (1985) J Biol Chem 260:2605-2608; Cassol et al. (1992); Rossolini et al. (1994) Mol Cell Probes 8:91-98). The term "nucleic acid" refers to deoxyribonucleotides or ribonucleotides and polymers thereof in single-stranded or double-stranded form. Unless otherwise specified, the term encompasses nucleic acids containing known analogs of natural nucleotides that have similar binding properties to reference nucleic acids and are metabolized in a manner similar to naturally occurring nucleotides. The term nucleic acid is used interchangeably with polynucleotide, and (in the appropriate context) gene, cDNA, and mRNA encoded by a gene.

[0090] As used herein, "percent (%) amino acid sequence identity" with respect to a peptide, polypeptide, or protein sequence is defined as the percentage of amino acid residues in a candidate sequence that are identical to the amino acid residues in another peptide or polypeptide sequence, after aligning the sequences and introducing gaps (if necessary) to achieve the maximum percent sequence identity and not considering any conservative substitutions as part of the sequence identity. The percent amino acid sequence identity in the present disclosure is measured using BLAST software. One skilled in the art can determine appropriate parameters for measuring alignment, including any algorithm required to achieve maximum alignment over the full length of the sequences being compared.

[0091] Amino acid substitution refers to the replacement of one amino acid in a polypeptide with another amino acid. Exemplary substitutions are shown in Table 1. Amino acid substitutions can be introduced into a protein of interest and the products screened for desired activity, such as retained / improved biological activity.

[0092] Table 1. Exemplary amino acid substitutions

[0093]

[0094]

[0095] Amino acids can be grouped according to common side chain properties:

[0096] (1) Hydrophobicity: norleucine, Met, Ala, Val, Leu, Ile;

[0097] (2) Neutral hydrophilicity: Cys, Ser, Thr, Asn, Gln;

[0098] (3) Acidic: Asp, Glu;

[0099] (4) Basic: His, Lys, Arg;

[0100] (5) Residues that affect chain orientation: Gly, Pro;

[0101] (6) Aromatic: Trp, Tyr, Phe.

[0102] Non-conservative substitutions will require exchanging a member of one of these categories for a member of another category. The term "corresponding to" with respect to a nucleotide or amino acid position of a sequence such as that shown in the sequence listing refers to a nucleotide or amino acid position identified after alignment with a target sequence based on structural sequence alignment or using a standard alignment algorithm (such as the GAP algorithm). For example, corresponding residues of similar sequences (e.g., fragments or species variants) can be determined by alignment with a reference sequence using structural alignment methods. By aligning the sequences, one skilled in the art can identify corresponding residues, for example, using conserved and identical amino acid residues as a guide.

[0103] As used herein, an isoform of the human CD47 protein refers to a protein that is translated from the human CD47 gene and processed by alternative splicing.

[0104] As used herein, wild-type human CD47 protein refers to a naturally occurring human CD47 protein in vivo, such as a wild-type human CD47 protein in the human genome / encoded by the human genome. Wild-type human CD47 protein can be any isoform of the naturally occurring human CD47 protein. The amino acid sequences of the five currently known naturally occurring isoforms of CD47 (isoforms 201, 202, 203, 205, 206) are shown in SEQ ID NOs: 1, 2, 4-5, respectively. Isoform CD47-202 (SEQ ID NO: 2) is a full-length wild-type human CD47 protein containing a signal sequence when translated. The sequence of the mature CD47-202 isoform lacking a signal sequence is shown in SEQ ID NO: 3. The wild-type human CD47 protein may or may not have a signal peptide when it is expressed. For example, CD47-206 lacks a signal peptide when it is translated. The wild-type human CD47 protein may or may not be glycosylated. Wild-type human CD47 protein may be a proteoglycan.

[0105] As used herein, engineered CD47 protein refers to a CD47 protein that does not naturally occur in any species. In other words, engineered CD47 protein is not a wild-type CD47 protein in any species. In some embodiments, engineered CD47 protein is an engineered human CD47 protein, which means that it is engineered by using human wild-type CD47 protein as a starting material and performing one or more modifications described herein. In some embodiments, engineered CD47 protein is an engineered humanized CD47 protein, which means that it is engineered by using non-human (e.g., mouse) CD47 protein as a starting material and by humanizing a non-human CD47 sequence and in addition performing one or more other modifications described herein. In some embodiments, engineered CD47 protein is a portion of an engineered humanized CD47 protein, which means that it is engineered by using non-human (e.g., mouse) CD47 protein as a starting material and by humanizing a portion of a non-human CD47 sequence and in addition performing one or more other modifications described herein.

[0106] As used herein, an engineered CD47 protein refers to a protein that is not a CD47 protein in / encoded by the native genome, e.g., a protein that is not a wild-type CD47 protein. Non-limiting examples of engineered CD47 proteins include engineered CD47 proteins having: (i) a human CD47 extracellular domain or a portion thereof, at least one human CD47 transmembrane domain or a portion thereof, and a portion of a human CD47 intracellular domain comprising at least one amino acid deletion, wherein the deletion is not a C-terminal 18 amino acid deletion; (ii) a portion of a human CD47 extracellular domain, at least one human CD47 transmembrane domain or a portion thereof, and a portion of a human CD47 intracellular domain comprising a C-terminal 18 amino acid deletion; (iii) a human CD47 extracellular domain or a portion thereof, at least one and less than five human CD47 transmembrane domains or a portion thereof, and a portion of a human CD47 intracellular domain comprising a C-terminal 18 amino acid deletion; (iv) a human CD47 cell extracellular domain or a portion thereof, at least one human CD47 transmembrane domain or a portion thereof, and a signal peptide, wherein the engineered CD47 protein does not comprise an intracellular domain, (v) a human CD47 extracellular domain, and at least one human CD47 transmembrane domain or a portion thereof, wherein the engineered CD47 protein does not comprise an intracellular domain, (vi) a human CD47 extracellular domain or a portion thereof, and at least one and fewer than five human CD47 transmembrane domains or portions thereof, wherein the engineered CD47 protein does not comprise an intracellular domain, (vii) a human CD47 extracellular domain or a portion thereof, and at least one human CD47 transmembrane domain or a portion thereof, a human CD47 intracellular domain that does not comprise an intracellular domain or comprises at least one amino acid deletion, wherein the engineered CD47 protein has an amino acid sequence that is at most 99% identical to SEQ ID NO: 1 and SEQ ID NO: 6.

[0107] As used herein, in the context of polynucleotides or polypeptides being expressed, the term "exogenous" is intended to mean that the referenced molecule or referenced polypeptide is introduced into the cell of interest. The polypeptide can be introduced, for example, by introducing the encoding nucleic acid into the genetic material of the cell (such as by integration into a chromosome or as non-chromosomal genetic material (such as a plasmid or expression vector)). Thus, when used in reference to the expression of a coding nucleic acid, the term refers to the introduction of the encoding nucleic acid into the cell in an expressible form. Exogenous polynucleotides can be inserted into at least one allele of a cell using viral transduction (e.g., using a vector). In some embodiments, the vector is a self-inactivating lentiviral vector pseudotyped with the vesicular stomatitis VSV-G envelope and carrying an exogenous polynucleotide. In some embodiments, exogenous polynucleotides are inserted into at least one allele of a cell using viral transduction. In some embodiments, exogenous polynucleotides are inserted into at least one allele of a cell using a lentiviral-based viral vector. In some embodiments, the exogenous polynucleotide is inserted into a target locus of at least one allele of the cell.

[0108] "Exogenous" molecules are molecules, constructs, factors, etc. that are not normally present in cells but can be introduced into cells by one or more genetic, biochemical or other methods. "Normal presence in cells" is determined relative to the specific developmental stage and environmental conditions of the cells. Thus, for example, molecules that only exist during embryonic development of neurons are exogenous molecules relative to adult neuronal cells. Exogenous molecules can include, for example, functional versions of malfunctioning endogenous molecules or malfunctioning versions of functionally normal endogenous molecules.

[0109] Exogenous molecules or factors can be, inter alia, small molecules, such as those produced by combinatorial chemistry processes, or can be macromolecules, such as proteins, nucleic acids, carbohydrates, lipids, glycoproteins, lipoproteins, polysaccharides, modified derivatives of any of the foregoing, or any complex comprising one or more of the foregoing. Nucleic acids include DNA and RNA; can be single-stranded or double-stranded; can be linear, branched, or circular; and can be of any length. Nucleic acids include those capable of forming duplexes, as well as triplexes. See, for example, U.S. Pat. Nos.

[0110] 5,176,996 and 5,422,251. Proteins include, but are not limited to, DNA binding proteins, transcription factors, chromatin remodeling factors, methylated DNA binding proteins, polymerases, methylases, demethylases, acetylases, deacetylases, kinases, phosphatases, integrases, recombinases, ligases, topoisomerases, gyrases, and helicases.

[0111] Exogenous molecule or construct can be molecules of the same type as endogenous molecule, for example exogenous protein or nucleic acid.In such cases, exogenous molecule is introduced into the cell with the concentration higher than the endogenous molecule in the cell.In some cases, exogenous nucleic acid can comprise the chromosome that does not exist usually in the infectious disease virus genome, plasmid or episome or the cell that are introduced into the cell.Being used for exogenous molecule is introduced into the method in the cell well known by persons skilled in the art and includes but not limited to lipid-mediated transfer (that is, liposome, comprises neutral and cationic lipid), electroporation, direct injection, cell fusion, particle bombardment, calcium phosphate coprecipitation, DEAE-dextran mediation and viral vector-mediated transfer.

[0112] As used herein, term " genetic modification " and grammatical equivalents thereof can refer to one or more changes of nucleic acid (such as nucleic acid in organism genome).For example, genetic modification can refer to the change, addition and / or disappearance of gene or gene part or other nucleotide sequence.Genetically modified cell can also refer to the cell with added, deleted and / or changed gene or gene part.Genetically modified cell can also refer to the cell with the nucleotide sequence that is not a gene or gene part added.Genetic modification includes such as transient knock-in or knock-down mechanism, and causes the mechanism of permanent knock-in, knock-down or knock-out of target gene or gene part or nucleotide sequence.Genetic modification includes such as transient knock-in and causes the mechanism of permanent knock-in of nucleotide sequence.Genetic modification also includes such as reducing or increasing transcription, reducing or increasing mRNA stability, reducing or increasing translation, and reducing or increasing protein stability.

[0113] As used herein, a portion of a peptide has fewer amino acids than a reference peptide and has at least one amino acid from that peptide.

[0114] As used herein, a composition refers to any mixture of two or more products, substances, or compounds, including cells.

[0115] II. CD47 protein

[0116] CD47 Protein Overview

[0117] The present disclosure relates to engineered CD47 proteins and uses thereof.

[0118] CD47, also known as integrin-associated protein (IAP) or MER6, is a transmembrane protein encoded by the human CD47 gene (SEQ ID NO: 19) in humans. Figure 1 CD47 is a member of the immunoglobulin (Ig) superfamily and is involved in a range of cellular processes including apoptosis, proliferation, adhesion and migration.

[0119] Human CD47 is approximately 50 kDa. It is glycosylated and ubiquitously expressed in almost all cells in the human body ( FIG. 2 ). Historical literature suggests that isoform 202 (i.e., CD47-202, SEQ ID NO: 2) is primarily expressed in the brain, but recent GTEx expression data do not support this conclusion ( FIG. 2 ). As shown in Example 1 herein, isoforms CD47-202 (SEQ ID NO: 2, SEQ ID NO: 14) and isoforms CD47-201 (SEQ ID NO: 1, SEQ ID NO: 13) are expressed at relatively equal levels in Gibco and Rues2 human stem cell lines. Isoforms CD47-206 (SEQ ID NO: 6, SEQ ID NO: 18), 205 (SEQ ID NO: 5, SEQ ID NO: 17), and 204 (SEQ ID NO: 16) also appear to be highly expressed in these stem cell lines. No evidence of isoform CD47-203 (SEQ ID NO: 4, SEQ ID NO: 15) was detected in the stem cell lines.

[0120] Human CD47 has a single IgV-like domain at its N-terminus, a highly hydrophobic segment with five transmembrane segments, and an alternatively spliced ​​cytoplasmic tail at its C-terminus ( Figure 4 ). In addition, it has two extracellular regions and two intracellular regions between adjacent transmembrane segments. The signal peptide, when present on CD47 isoforms, is located at the N-terminus of the IgV-like domain.

[0121] As used herein, the human CD47 extracellular domain refers to the IgV-like domain at the N-terminus of the human CD47 protein. Structurally, the human CD47 extracellular domain is the N-terminal portion of the human CD47 protein, which is located outside the cell when the human CD47 protein is anchored in the cell membrane. In some embodiments, the human CD47 extracellular domain has an amino acid sequence corresponding to amino acids 19-141 of SEQ ID NO: 2, or an amino acid sequence that is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to amino acids 19-141 of SEQ ID NO: 2. In some embodiments, the human CD47 extracellular domain has an amino acid sequence corresponding to amino acids 19-141 of SEQ ID NO:2, or an amino acid sequence that is 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to amino acids 19-141 of SEQ ID NO:2.

[0122] As used herein, the human CD47 intracellular domain refers to the cytoplasmic tail at the C-terminus of the human CD47 protein. Structurally, the human CD47 intracellular domain is the C-terminal portion of the human CD47 protein that is located inside the cell when the human CD47 protein is anchored in the cell membrane. The human CD47 intracellular domain is selectively spliced ​​in vivo. In some embodiments, the human CD47 intracellular domain has an amino acid sequence corresponding to amino acids 290-323 of SEQ ID NO: 2, or an amino acid sequence that is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to amino acids 290-323 of SEQ ID NO: 2. In some embodiments, the human CD47 intracellular domain has an amino acid sequence corresponding to amino acids 290-323 of SEQ ID NO: 2, or an amino acid sequence that is at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to amino acids 290-323 of SEQ ID NO: 2.

[0123] As used herein, a human CD47 transmembrane domain refers to one of the transmembrane segments of the human CD47 protein. In some embodiments, the human CD47 transmembrane domain has an amino acid sequence corresponding to amino acids 142-162, 177-197, 208-228, 236-257, or 269-289 of SEQ ID NO: 2, or an amino acid sequence that is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to amino acids 142-162, 177-197, 208-228, 236-257, or 269-289 of SEQ ID NO: 2. In some embodiments, the human CD47 transmembrane domain has an amino acid sequence corresponding to amino acids 142-162, 177-197, 208-228, 236-257, or 269-289 of SEQ ID NO: 2, or an amino acid sequence that is at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to amino acids 142-162, 177-197, 208-228, 236-257, or 269-289 of SEQ ID NO: 2.

[0124] As used herein, a signal peptide refers to a short peptide present at the N-terminus of a CD47 protein when it is initially translated. The signal peptide is typically cleaved from the protein by a signal peptidase during or immediately after insertion into the cell membrane. The function of the signal peptide is to encourage the cell to translocate the protein, usually to the plasma membrane. In some embodiments, the signal peptide of a human CD47 protein has an amino acid sequence corresponding to amino acids 1-18 of SEQ ID NO: 2, or an amino acid sequence having at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity with amino acids 1-18 of SEQ ID NO: 2. In some embodiments, the signal peptide of the human CD47 protein has an amino acid sequence corresponding to amino acids 1-18 of SEQ ID NO: 2, or an amino acid sequence that is at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to amino acids 1-18 of SEQ ID NO: 2.

[0125] The human CD47 gene has six transcripts, five of which encode protein isoforms of CD47 (Ensembl, gene: CD47). These six transcripts are designated CD47-201, CD47-202, CD47-203, CD47-204, CD47-205, and CD47-206 (Ensembl, gene: CD47, ENSG00000196776).

[0126] The coding DNA sequences (CDS) of these six transcripts are shown in SEQ ID NOs: 13 to 18, respectively. The amino acid sequences of these five protein isoforms are shown in SEQ ID NOs: 1, 2, 4, 5, and 6, respectively (Table 2).

[0127] The transcript CD47-202 (SEQ ID NO: 14) encodes the isoform CD47-202 (SEQ ID NO: 2) having 323 amino acids. CD47-202 is the longest transcript of the human CD47 gene. It is designated as a representative transcript in the Ensembl database. When identifying representative transcripts, Ensembl aims to identify transcripts with the highest overall conserved exon coverage, highest expression, longest coding sequence, and representation in other key resources such as NCBI and UniProt. All splice junctions of the CD47-202 transcript are supported by at least one non-suspected mRNA.

[0128] The transcript CD47-201 (SEQ ID NO: 13) encodes the 305-amino acid isoform CD47-201 (SEQ ID NO: 1). The isoform CD47-201 has an 18-amino acid C-terminal truncation of the isoform CD47-202. All splice junctions of the CD47-201 transcript are supported by at least one non-suspected mRNA.

[0129] The transcript CD47-203 (SEQ ID NO: 15) encodes the 86-amino acid isoform CD47-203 (SEQ ID NO: 4). The only support for the transcript model comes from a single expressed sequence tag (EST).

[0130] Transcript CD47-204 (SEQ ID NO: 16) does not encode a protein. All splice junctions for this transcript are supported by at least one non-suspected mRNA.

[0131] The transcript CD47-205 (SEQ ID NO: 17) encodes the 109-amino acid isoform CD47-205 (SEQ ID NO: 5). Isoform 205 contains three transmembrane domains and a truncated intracellular domain from isoform CD47-202 (SEQ ID NO: 2). The best supporting mRNAs for the transcriptional model are marked as questionable or supported from multiple ESTs.

[0132] The transcript CD47-206 (SEQ ID NO: 18) encodes the 183-amino acid isoform CD47-206 (SEQ ID NO: 6). Isoform 206 contains a truncated extracellular domain and five transmembrane domains from isoform CD47-202 (SEQ ID NO: 2).

[0133] The amino acid sequences of the five isoforms are listed in Table 2. The amino acids corresponding to the various domains in the human CD47 protein are also identified in Table 2 and depicted in Figure 5. "Intracellular connection" refers to the intracellular region connecting adjacent transmembrane domains, which region is located inside the cell (i.e., not outside the cell or within the cell membrane), but is not located at the N-terminus or C-terminus of the engineered CD47 protein. "Extracellular connection" refers to the extracellular region connecting adjacent transmembrane domains, which region is located outside the cell (i.e., not inside the cell or within the cell membrane). As used herein, the CD47 "intracellular domain" does not include the intracellular connection. Also as used herein, the CD47 "extracellular domain" does not include the extracellular connection.

[0134] Table 2. Amino acid SEQ ID NOs of CD47 domains

[0135]

[0136] Engineered CD47 protein

[0137] The present disclosure provides engineered CD47 proteins that have fewer amino acids than wild-type, full-length human CD47 proteins. Such engineered proteins provide more efficient cell engineering methods, including delivery via integrated gene therapy vectors.

[0138] As used herein, the wild-type full-length human CD47 protein refers to the isoform CD47-202 disclosed in the Ensembl database as of the date of filing of this patent application. The wild-type full-length human CD47 protein has the amino acid sequence of SEQ ID NO: 2, wherein amino acids 1-18 are a signal peptide, amino acids 19-141 are an extracellular domain, and amino acids 142-162, 177-197, 208-228, 236-257, and 269-289 are five transmembrane domains ( Figure 3 ), and amino acids 290-323 are the intracellular domain. Amino acids 163-176 and 229-235 are two intracellular linkers between the transmembrane domains, and amino acids 198-207 and 257-268 are two extracellular linkers between the transmembrane domains ( Figure 3 ).

[0139] In some embodiments, the engineered CD47 protein is a C-terminally truncated version of isoform 202 (SEQ ID NO: 2). For example, in some embodiments, the C-terminal truncations are consecutive and are 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85 2, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89 , 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127 7, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160 or 161 amino acids. Preferably, the C-terminal truncation is 158, 123, 92, 64, 31 or 95 amino acids in length, thereby generating an engineered CD47 protein having an amino acid sequence as shown in SEQ ID NOs: 7-12, respectively.In some embodiments, the engineered CD47 protein having a C-terminal truncation of SEQ ID NO: 2 further has 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76 , 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, or 140 consecutive amino acids.

[0140] In some embodiments, the engineered CD47 protein is a C-terminally truncated version of isoform 201 (SEQ ID NO: 1). For example, in some embodiments, the C-terminal truncations are continuous and have a length of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77 ,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, or 143 amino acids. In some embodiments, the amino acid sequence of SEQ ID NO: The engineered CD47 protein with a C-terminal truncation of NO: 1 further has 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, or 95 consecutive amino acids.

[0141] In some embodiments, the engineered CD47 protein is a C-terminally truncated version of isoform 206 (SEQ ID NO: 6). For example, in some embodiments, the C-terminal truncations are contiguous and are 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, or 66 amino acids in length. In some embodiments, the engineered CD47 protein having a C-terminal truncation of SEQ ID NO: 6 further has 1, 2, 3, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75 ,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112 , 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139 or 140 consecutive amino acids.

[0142] In some embodiments, the engineered CD47 protein comprises a minimal intracellular domain. As used herein, a minimal intracellular domain refers to an intracellular domain having the minimum number of amino acids required to maintain SIRPα binding of the engineered CD47 protein.

[0143] In some embodiments, the engineered CD47 protein comprises a minimal extracellular domain. As used herein, a minimal extracellular domain refers to an extracellular domain having the minimum number of amino acids required for the engineered CD47 protein to bind to SIRPα.

[0144] In one aspect, the present disclosure provides an engineered CD47 protein comprising a human CD47 extracellular domain or a portion thereof and at least one human CD47 transmembrane domain, wherein the intracellular domain, when present, is a human CD47 intracellular domain having at least one amino acid deletion. In some embodiments, when more than one transmembrane domain is present in the engineered CD47 protein, each of these transmembrane domains is interconnected with an intracellular and / or extracellular junction.

[0145] In one aspect, the present disclosure provides an engineered CD47 protein consisting essentially of a human CD47 extracellular domain or a portion thereof and at least one human CD47 transmembrane domain. In some embodiments, when more than one transmembrane domain is present in the engineered CD47 protein, each of these transmembrane domains is interconnected with an intracellular and / or extracellular junction. As used herein, the term "consisting essentially of" includes the specified elements and any additional elements that do not eliminate SIRPα binding of the engineered CD47 protein.

[0146] In one aspect, the present disclosure provides an engineered CD47 protein comprising a human CD47 extracellular domain or a portion thereof and at least one human CD47 transmembrane domain. In some embodiments, when more than one transmembrane domain is present in the engineered CD47 protein, each of these transmembrane domains is interconnected with an intracellular and / or extracellular junction.

[0147] In some embodiments, the engineered CD47 protein comprises a human CD47 extracellular domain or a portion thereof, at least one human CD47 transmembrane domain or a portion thereof, and a portion of a human CD47 intracellular domain comprising at least one amino acid deletion, wherein the deletion is not a C-terminal 18 amino acid deletion.

[0148] In some embodiments, the engineered CD47 protein comprises a portion of the human CD47 extracellular domain, at least one human CD47 transmembrane domain or a portion thereof, and a portion of the human CD47 intracellular domain comprising a C-terminal 18 amino acid deletion.

[0149] In some embodiments, the engineered CD47 protein comprises a human CD47 extracellular domain or a portion thereof, at least one and fewer than five human CD47 transmembrane domains or a portion thereof, and a portion of a human CD47 intracellular domain comprising a C-terminal 18 amino acid deletion.

[0150] In some embodiments, the engineered CD47 protein comprises a human CD47 extracellular domain or a portion thereof, at least one human CD47 transmembrane domain or a portion thereof, and a signal peptide, wherein the engineered CD47 protein does not comprise an intracellular domain.

[0151] In some embodiments, the engineered CD47 protein comprises a human CD47 extracellular domain and at least one human CD47 transmembrane domain or a portion thereof, wherein the engineered CD47 protein does not comprise an intracellular domain.

[0152] In some embodiments, the engineered CD47 protein comprises a human CD47 extracellular domain or a portion thereof, and at least one and fewer than five human CD47 transmembrane domains or a portion thereof, wherein the engineered CD47 protein does not comprise an intracellular domain.

[0153] In some embodiments, the engineered CD47 protein comprises a human CD47 extracellular domain, five human CD47 transmembrane domains, and a human CD47 intracellular domain with a C-terminal 18 amino acid deletion, wherein the amino acid sequence of the engineered CD47 protein is not SEQ ID NO: 1.

[0154] In some embodiments, the engineered CD47 protein comprises a human CD47 extracellular domain and five human CD47 transmembrane domains, wherein the amino acid sequence of the engineered CD47 protein is not SEQ ID NO:6.

[0155] In some embodiments, the engineered CD47 protein comprises a human CD47 extracellular domain or a portion thereof, at least one human CD47 transmembrane domain or a portion thereof, and no intracellular domain or a human CD47 intracellular domain comprising at least one amino acid deletion, wherein the amino acid sequence of the engineered CD47 protein is at most 99% identical to SEQ ID NO: 1 and SEQ ID NO: 6. In other words, in some embodiments, the engineered CD47 protein comprises a human CD47 extracellular domain or a portion thereof, at least one human CD47 transmembrane domain or a portion thereof, and no intracellular domain or a human CD47 intracellular domain comprising at least one amino acid deletion, wherein the amino acid sequence of the engineered CD47 protein is 99% or less identical to SEQ ID NO: 1 and 99% or less identical to SEQ ID NO: 6.

[0156] In some embodiments, the human CD47 extracellular domain in the engineered CD47 protein is a wild-type human CD47 extracellular domain. In some embodiments, the wild-type domain has an amino acid sequence corresponding to amino acids 19-141 of SEQ ID NO: 1 or amino acids 1-96 of SEQ ID NO: 6.

[0157] In some embodiments, the extracellular domain of human CD47 in the engineered CD47 protein has an amino acid sequence that is at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to amino acids 19-141 of SEQ ID NO: 1 or to amino acids 1-96 of SEQ ID NO: 6. In some embodiments, the extracellular domain of human CD47 in the engineered CD47 protein has an amino acid sequence that is at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to amino acids 19-141 of SEQ ID NO: 1 or to amino acids 1-96 of SEQ ID NO: 6.

[0158] In some embodiments, the human CD47 extracellular domain in the engineered CD47 protein is structurally equivalent to the wild-type human CD47 extracellular domain.

[0159] As used herein, "structurally equivalent" refers to two amino acid sequences that are at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical. Preferably, the sequence variation does not alter the biological activity of the engineered CD47 protein. In some embodiments, the sequence variation does not prevent the engineered human protein from binding to SIRPα. In some embodiments, the sequence variation does not prevent the engineered human protein from becoming a tolerogenic factor. In some embodiments, at least a portion of the sequence variation may occur through one or more conservative amino acid substitutions.

[0160] In some embodiments, the engineered proteins of the present disclosure comprise one or more membrane tethers. In some embodiments, the one or more membrane tethers are or comprise a transmembrane domain. In some embodiments, the transmembrane domain comprises a GPCR transmembrane domain selected from the group consisting of 5-hydroxytryptamine (serotonin) receptor 1A (HTR1A), 5-hydroxytryptamine (serotonin) receptor 1B (HTR1B), 5-hydroxytryptamine (serotonin) receptor 1D (HTR1D), 5-hydroxytryptamine (serotonin) receptor 1E (HTR1E), 5-hydroxytryptamine (serotonin) receptor 1F (HTR1F), 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A), 5-hydroxytryptamine (serotonin) receptor 2B (HTR2B), 5-hydroxytryptamine (serotonin) receptor 2C (HTR2C), 5-hydroxytryptamine (serotonin) receptor 4 (HTR4), 5-hydroxytryptamine (serotonin) receptor 5A (HTR5A), 5-hydroxytryptamine (serotonin) receptor 5B (HTR5BP), 5-hydroxytryptamine (serotonin) receptor 6 (HTR6), 5-hydroxytryptamine (serotonin) receptor 7 (HTR8), 5-hydroxytryptamine (serotonin) receptor 8 (HTR9), 5-hydroxytryptamine (serotonin) receptor 9 (HTR10), 5-hydroxytryptamine (serotonin) receptor 1A (HTR1A), 5-hydroxytryptamine (serotonin) receptor 1B (HTR1B), 5-hydroxytryptamine (serotonin) receptor 1D (HTR1D), 5-hydroxytryptamine (serotonin) receptor 1E (HTR1E), 5-hydroxytryptamine (serotonin) receptor 1F (HTR1F), Serotonin) receptor 7, adenylate cyclase-coupled (HTR7), cholinergic receptor, muscarinic 1 (CHRM1), cholinergic receptor, muscarinic 2 (CHRM2), cholinergic receptor, muscarinic 3 (CHRM3), cholinergic receptor, muscarinic 4 (CHRM4), cholinergic receptor, muscarinic 5 (CHRM5), adenosine A1 receptor (ADORA1), adenosine A2a receptor (ADORA2A), adenosine A2b receptor (ADORA2B), adenosine A3 receptor (ADORA3), adhesion G protein-coupled receptor A1 (ADGRA1), adhesion G protein-coupled receptor A2 (ADGRA2), adhesion G protein-coupled receptor A3 (ADGRA3), adhesion G protein-coupled receptor B1 (ADGRB1), adhesion G protein-coupled receptor B2 (ADGRB2), adhesion G protein-coupled receptor B3 (ADGRB3), cadherin EGF LAG seven-way G-type receptor 1 (CELSR1), cadherin EGF LAG seven-way G-type receptor 2 (CELSR2), cadherin EGF LAG seven-way G-type receptor 3 (CELSR3), adhesion G protein-coupled receptor D1 (ADGRD1), adhesion G protein-coupled receptor D2 (ADGRD2), adhesion G protein-coupled receptor E1 (ADGRE1), adhesion G protein-coupled receptor E2 (ADGRE2), adhesion G protein-coupled receptor E3 (ADGRE3), adhesion G protein-coupled receptor E4 (ADGRE4P), adhesion G protein-coupled receptor E5 (ADGRE5), adhesion G protein-coupled receptor F1 (ADGRF1), adhesion G protein-coupled receptor F2 (ADGRF2), adhesion G protein-coupled receptor F3 (ADGRF3), adhesion G protein-coupled receptor F4 (ADGRF4), adhesion G protein-coupled receptor F5 (ADGRF5),Adhesion G protein-coupled receptor G1 (ADGRG1), adhesion G protein-coupled receptor G2 (ADGRG2), adhesion G protein-coupled receptor G3 (ADGRG3), adhesion G protein-coupled receptor G4 (ADGRG4), adhesion G protein-coupled receptor G5 (ADGRG5), adhesion G protein-coupled receptor G6 (ADGRG6), adhesion G protein-coupled receptor G7 (ADGRG7), adhesion G protein-coupled receptor L1 (ADGRL1), adhesion G protein-coupled receptor L2 (ADGRL2), adhesion G protein-coupled receptor L3 (ADGRL3), adhesion G protein-coupled receptor L4 (ADGRL4), adhesion G protein-coupled receptor V1 (ADGRV1), adrenergic receptor Adrenergic receptor α1A (ADRA1A), adrenergic receptor α1B (ADRA1B), adrenergic receptor α1D (ADRA1D), adrenergic receptor α2A (ADRA2A), adrenergic receptor α2B (ADRA2B), adrenergic receptor α2C (ADRA2C), adrenergic receptor β1 (ADRB1), adrenergic receptor β2 (ADRB2), adrenergic receptor β3 (ADRB3), angiotensin II receptor type 1 (AGTR1), angiotensin II receptor type 2 (AGTR2), apelin receptor (APLNR), G protein-coupled bile acid receptor 1 (GPBAR1), neuregulin B receptor (NM BR), gastrin-releasing peptide receptor (GRPR), bombardmentin-like receptor 3 (BRS3), bradykinin receptor B1 (BDKRB1), bradykinin receptor B2 (BDKRB2), calcitonin receptor (CALCR), calcitonin receptor-like receptor (CALCRL), calcium-sensing receptor (CASR), G protein-coupled receptor class C (GPRC6A), cannabinoid receptor 1 (brain) (CNR1), cannabinoid receptor 2 (CNR2), chemokine-like receptor 1 (CMKLR1), chemokine (C-C motif) receptor 1 (CCR1), chemokine (C-C motif) receptor 2 (CCR2), chemokine (C-C motif) receptor 3 (CCR3), chemokine ( C—C motif) receptor 4 (CCR4), chemokine (C—C motif) receptor 5 (gene / pseudogene) (CCR5), chemokine (C—C motif) receptor 6 (CCR6), chemokine (C—C motif) receptor 7 (CCR7), chemokine (C—C motif) receptor 8 (CCR8), chemokine (C—C motif) receptor 9 (CCR9), chemokine (C—C motif) receptor 10 (CCR10), chemokine (C—X—C motif) receptor 1 (CXCR1), chemokine (C—X—C motif) receptor 2 (CXCR2), chemokine (C—X—C motif) receptor 3 (CXCR3), chemokine (C—X—C motif) receptor 4 (CXCR4),Chemokine (C-X-C motif) receptor 5 (CXCR5), chemokine (C-X-C motif) receptor 6 (CXCR6), chemokine (C-X3-C motif) receptor 1 (CX3CR1), chemokine (C motif) receptor 1 (XCR1), atypical chemokine receptor 1 (Duffy blood group) (ACKR1), atypical chemokine receptor 2 (ACKR2), atypical chemokine receptor 3 (ACKR3), atypical chemokine receptor 4 (ACKR4), chemokine (C-C motif) receptor-like 2 (CCRL2), cholecystokinin A receptor (CCKAR), cholecystokinin B receptor (CCKBR), G protein-coupled receptor 1 (GPR1), bombesin-like receptor BRS3, G protein-coupled receptor 3 (GPR3), G protein-coupled receptor 4 (GPR4), G protein-coupled receptor 6 (GPR6), G protein-coupled receptor 12 (GPR12), G protein-coupled receptor 15 (GPR15), G protein-coupled receptor 17 (GPR17), G protein-coupled receptor 18 (GPR18), G protein-coupled receptor 19 (GPR19), G protein-coupled receptor 20 (GPR20), G protein-coupled receptor 21 (GPR21), G protein-coupled receptor 22 (GPR22), G protein-coupled receptor 25 (GPR25), G protein-coupled receptor 26 (GPR26), G protein-coupled receptor 27 (GPR27), G protein-coupled receptor 31 (GPR31), G protein-coupled receptor 32 (GPR32), G protein-coupled receptor 33 (gene / pseudogene) (GPR33), G protein-coupled receptor 34 (GPR34), G protein-coupled receptor 35 (GPR35), G protein-coupled receptor 37 (endothelin receptor type B-like) (GPR37), G protein-coupled receptor 37-like 1 (GPR37L1), G protein-coupled receptor 39 (GPR39), G protein-coupled receptor 42 (gene / pseudogene) (GPR42), G protein-coupled receptor 45 (GPR45), G protein-coupled receptor 50 (GPR50), G protein-coupled receptor 52 (GPR52), G protein-coupled receptor 55 (GPR55), G protein-coupled receptor 61 (GPR61), G protein-coupled receptor 62 (GPR62), G protein-coupled receptor 63 (GPR63), G protein-coupled receptor 65 (GPR65), G protein-coupled receptor 68 (GPR68), G protein-coupled receptor 75 (GPR75), G protein-coupled receptor 78 (GPR78), G protein-coupled receptor 79 (GPR79), G protein-coupled receptor 82 (GPR82), G protein-coupled receptor 83 (GPR83), G protein-coupled receptor 84 (GPR84), G protein-coupled receptor 85 (GPR85), G protein-coupled receptor 87 (GPR87), G protein-coupled receptor 88 (GPR88), G protein-coupled receptor 101 (GPR101),G protein-coupled receptor 119 (GPR119), G protein-coupled receptor 132 (GPR132), G protein-coupled receptor 135 (GPR135), G protein-coupled receptor 139 (GPR139), G protein-coupled receptor 141 (GPR141), G protein-coupled receptor 142 (GPR142), G protein-coupled receptor 146 (GPR146), G protein-coupled receptor 148 (GPR148), G protein-coupled receptor 149 (GPR149), G protein-coupled receptor 150 (GPR150), G protein-coupled receptor 151 (GPR151), G protein-coupled receptor 152 (GPR152), G protein-coupled receptor 153 (GPR153) , G protein-coupled receptor 160 (GPR160), G protein-coupled receptor 161 (GPR161), G protein-coupled receptor 162 (GPR162), G protein-coupled receptor 171 (GPR171), G protein-coupled receptor 173 (GPR173), G protein-coupled receptor 174 (GPR174), G protein-coupled receptor 176 (GPR176), G protein-coupled receptor 182 (GPR182), G protein-coupled receptor 183 (GPR183), G protein-coupled receptor 4 containing leucine-rich repeats (LGR4), G protein-coupled receptor 5 containing leucine-rich repeats (LGR5), G protein-coupled receptor containing leucine-rich repeats 6 (LGR6), MAS1 proto-oncogene (MAS1), MAS1 proto-oncogene-like (MAS1L), MAS-related GPR family member D (MRGPRD), MAS-related GPR family member E (MRGPRE), MAS-related GPR family member F (MRGPRF), MAS-related GPR family member G (MRGPRG), MAS-related GPR family member X1 (MRGPRX1), MAS-related GPR family member X2 (MRGPRX2), MAS-related GPR family member X3 (MRGPRX3), MAS-related GPR family member X4 (MRGPRX4), opsin 3 (OPN3), opsin 4 (OPN4), OPN5, purinergic receptor P2Y (P2RY8), purinergic receptor P2Y (P2RY10), trace amine-associated receptor 2 (TAAR2), trace amine-associated receptor 3 (gene / pseudogene) (TAAR3), trace amine-associated receptor 4 (TAAR4P), trace amine-associated receptor 5 (TAAR5), trace amine-associated receptor 6 (TAAR6), trace amine-associated receptor 8 (TAAR8), trace amine-associated receptor 9 (gene / pseudogene) (TAAR9), G protein-coupled receptor 156 (GPR156), G protein-coupled receptor 158 (GPR158), G protein-coupled receptor 179 (GPR179), G protein-coupled receptor class C (GPRC5A),G protein-coupled receptor class C (GPRC5B), G protein-coupled receptor class C (GPRC5C), G protein-coupled receptor class C (GPRC5D), Frizzled receptor 1 (FZD1), Frizzled receptor 2 (FZD2), Frizzled receptor 3 (FZD3), Frizzled receptor 4 (FZD4), Frizzled receptor 5 (FZD5), Frizzled receptor 6 (FZD6), Frizzled receptor 7 (FZD7), Frizzled receptor 8 (FZD8), Frizzled receptor 9 (FZD9), Frizzled receptor 10 (FZD10), Smooth frizzled receptor (SMO), complement component 3a receptor 1 (C3AR1), complement component 5a receptor 1 (C5AR1), complement component 5a receptor 2 (C5AR2 ), corticotropin-releasing hormone receptor 1 (CRHR1), corticotropin-releasing hormone receptor 2 (CRHR2), dopamine receptor D1 (DRD1), dopamine receptor D2 (DRD2), dopamine receptor D3 (DRD3), dopamine receptor D4 (DRD4), dopamine receptor D5 (DRD5), endothelin receptor type A (EDNRA), endothelin receptor type B (EDNRB), formyl peptide receptor 1 (FPR1), formyl peptide receptor 2 (FPR2), formyl peptide receptor 3 (FPR3), free fatty acid receptor 1 (FFAR1), free fatty acid receptor 2 (FFAR2), free fatty acid receptor 3 (FFAR3), free fatty acid receptor 4 (FFAR4 ), G protein-coupled receptor 42 (gene / pseudogene) (GPR42), gamma-aminobutyric acid (GABA) B receptor 1 (GABBR1), gamma-aminobutyric acid (GABA) B receptor 2 (GABBR2), galanin receptor 1 (GALR1), galanin receptor 2 (GALR2), galanin receptor 3 (GALR3), growth hormone secretagogue receptor (GHSR), growth hormone-releasing hormone receptor (GHRHR), gastric inhibitory polypeptide receptor (GIPR), glucagon-like peptide 1 receptor (GLP1R), glucagon-like peptide 2 receptor (GLP2R), glucagon receptor (GCGR), secretin receptor (SCTR), follicle-stimulating hormone receptor (FSHR), luteinizing hormone Human chorionic gonadotropin receptor (LHCGR), thyroid stimulating hormone receptor (TSHR), gonadotropin-releasing hormone receptor (GNRHR), gonadotropin-releasing hormone receptor 2 (pseudogene) (GNRHR2), G protein-coupled receptor 18 (GPR18), G protein-coupled receptor 55 (GPR55), G protein-coupled receptor 119 (GPR119), G protein-coupled estrogen receptor 1 (GPER1), histamine receptor H1 (HRH1), histamine receptor H2 (HRH2), histamine receptor H3 (HRH3), histamine receptor H4 (HRH4), hydroxycarboxylic acid receptor 1 (HCAR1), hydroxycarboxylic acid receptor 2 (HCAR2), hydroxycarboxylic acid receptor 3 (HCAR3),KISS1 receptor (KISS1R), leukotriene B4 receptor (LTB4R), leukotriene B4 receptor 2 (LTB4R2), cysteinyl leukotriene receptor 1 (CYSLTR1), cysteinyl leukotriene receptor 2 (CYSLTR2), oxoeicosanoid (OXE) receptor 1 (OXER1), formyl peptide receptor 2 (FPR2), lysophosphatidic acid receptor 1 (LPAR1), lysophosphatidic acid receptor 2 (LPAR2), lysophosphatidic acid receptor 3 (LPAR3), lysophosphatidic acid receptor 4 (LPAR4), lysophosphatidic acid receptor 5 (LPAR5), lysophosphatidic acid receptor 6 (LPAR6), sphingosine-1-phosphate receptor 1 (S1P R1), sphingosine-1-phosphate receptor 2 (S1PR2), sphingosine-1-phosphate receptor 3 (S1PR3), sphingosine-1-phosphate receptor 4 (S1PR4), sphingosine-1-phosphate receptor 5 (S1PR5), melanin-concentrating hormone receptor 1 (MCHR1), melanin-concentrating hormone receptor 2 (MCHR2), melanocortin 1 receptor (α-melanocytic hormone receptor) (MC1R), melanocortin 2 receptor (adrenocorticotropic hormone) (MC2R), melanocortin 3 receptor (MC3R), melanocortin 4 receptor (MC4R), melanocortin 5 receptor (MC5R), melatonin receptor 1A (MTNR1A), melatonin receptor 1B (MTNR1B), metabotropic glutamate receptor 1 ( GRM1), metabotropic glutamate receptor 2 (GRM2), metabotropic glutamate receptor 3 (GRM3), metabotropic glutamate receptor 4 (GRM4), metabotropic glutamate receptor 5 (GRM5), metabotropic glutamate receptor 6 (GRM6), metabotropic glutamate receptor 7 (GRM7), metabotropic glutamate receptor 8 (GRM8), motilin receptor (MLNR), neuromodulatory peptide U receptor 1 (NMUR1), neuromodulatory peptide U receptor 2 (NMUR2), neuropeptide FF receptor 1 (NPFFR1), neuropeptide FF receptor 2 (NPFFR2), neuropeptide S receptor 1 (NPSR1), neuropeptide B / W receptor 1 (NPBWR1), neuropeptide B / W receptor 2 (NPBWR2), Neuropeptide Y receptor Y1 (NPY1R), neuropeptide Y receptor Y2 (NPY2R), neuropeptide Y receptor Y4 (NPY4R), neuropeptide Y receptor Y5 (NPY5R), neuropeptide Y receptor Y6 (pseudogene) (NPY6R), neurotensin receptor 1 (high affinity) (NTSR1), neurotensin receptor 2 (NTSR2), opioid receptor delta 1 (OPRD1), opioid receptor kappa 1 (OPRK1), opioid receptor μ 1 (OPRM1), opioid receptor-like 1 (OPRL1), hypocretin (orexin) receptor 1 (HCRTR1), hypocretin (orexin) receptor 2 (HCRTR2), G protein-coupled receptor 107 (GPR107),G protein-coupled receptor 137 (GPR137), olfactory receptor family 51 subfamily E member 1 (OR51E1), adipocyte-associated transmembrane protein 1 (TPRA1), G protein-coupled receptor 143 (GPR143), G protein-coupled receptor 157 (GPR157), oxyglutarate (α-ketoglutarate) receptor 1 (OXGR1), purinergic receptor P2Y (P2RY1), purinergic receptor P2Y (P2RY2), pyrimidine receptor P2Y (P2RY4), pyrimidine receptor P2Y (P2RY6), purinergic receptor P2Y (P2RY11), purinergic receptor P2Y (P2RY12), purinergic receptor P2Y (P2RY13), purinergic receptor P2Y ( P2RY14), parathyroid hormone 1 receptor (PTH1R), parathyroid hormone 2 receptor (PTH2R), platelet-activating factor receptor (PTAFR), prokineticin receptor 1 (PROKR1), prokineticin receptor 2 (PROKR2), prolactin-releasing hormone receptor (PRLHR), prostaglandin D2 receptor (DP) (PTGDR), prostaglandin D2 receptor 2 (PTGDR2), prostaglandin E receptor 1 (PTGER1), prostaglandin E receptor 2 (PTGER2), prostaglandin E receptor 3 (PTGER3), prostaglandin E receptor 4 (PTGER4), prostaglandin F receptor (PTGFR), prostaglandin 12 (prostacyclin) receptor (IP )(PTGIR), thromboxane A2 receptor (TBXA2R), coagulation factor II thrombin receptor (F2R), F2R-like trypsin receptor 1 (F2RL1), coagulation factor II thrombin receptor-like 2 (F2RL2), F2R-like thrombin / trypsin receptor 3 (F2RL3), pyroglutamylated RFamide peptide receptor (QRFPR), relaxin / insulin-like family peptide receptor 1 (RXFP1), relaxin / insulin-like family peptide receptor 2 (RXFP2), relaxin / insulin-like family peptide receptor 3 (RXFP3), relaxin / insulin-like family peptide receptor 4 (RXFP4), somatostatin receptor 1 (SSTR1), somatostatin receptor 2 (SSTR2) , somatostatin receptor 3 (SSTR3), somatostatin receptor 4 (SSTR4), somatostatin receptor 5 (SSTR5), succinate receptor 1 (SUCNR1), tachykinin receptor 1 (TACR1), tachykinin receptor 2 (TACR2), tachykinin receptor 3 (TACR3), taste 1 receptor member 1 (TAS1R1), taste 1 receptor member 2 (TAS1R2), taste 1 receptor member 3 (TAS1R3), taste 2 receptor member 1 (TAS2R1), taste 2 receptor member 3 (TAS2R3), taste 2 receptor member 4 (TAS2R4), taste 2 receptor member 5 (TAS2R5), taste 2 receptor member 7 (TAS2R7),Taste 2 receptor member 8 (TAS2R8), Taste 2 receptor member 9 (TAS2R9), Taste 2 receptor member 10 (TAS2R10), Taste 2 receptor member 13 (TAS2R13), Taste 2 receptor member 14 (TAS2R14), Taste 2 receptor member 16 (TAS2R16), Taste 2 receptor member 19 (TAS2R19), Taste 2 receptor member 20 (TAS2R20), Taste 2 receptor member 30 (TAS2R30), Taste 2 receptor member 31 (TAS2R31), Taste 2 receptor member 38 (TAS2R38), Taste 2 receptor member 39 (TAS2R39), Taste 2 receptor member 40 (TAS2R40), Taste 2 receptor member 41 (TAS2R41), Taste 2 receptor member 42 (TAS2R42), Taste Taste 2 receptor member 43 (TAS2R43), taste 2 receptor member 45 (TAS2R45), taste 2 receptor member 46 (TAS2R46), taste 2 receptor member 50 (TAS2R50), taste 2 receptor member 60 (TAS2R60), thyrotropin-releasing hormone receptor (TRHR), trace amine-associated receptor 1 (TAAR1), urotensin 2 receptor (UTS2R), arginine vasopressin receptor 1A (AVPR1A), arginine vasopressin receptor 1B (AVPR1B), arginine vasopressin receptor 2 (AVPR2), oxytocin receptor (OXTR), adenylate cyclase-activating polypeptide 1 (pituitary) receptor type 1 (ADCYAP1R1), vasoactive intestinal peptide receptor 1 (VIPR1), vasoactive intestinal peptide receptor 2 (VIPR2), and any variants thereof. In some embodiments, the transmembrane domain is or includes a CD3ζ, CD8a, CD16a, CD28, CD32a, CD32c, CD40, CD47, CD64, ICOS, Dectin-1, DNGR1, EGFR, GPCR, MyD88, PDGFR, SLAMF7, TRL1, TLR2, TLR3, TRL4, TLR5, TLR6, TLR7, TLR8, TLR9, or VEGFR transmembrane domain.

[0161] Plasma membrane proteins can be connected to the peripheral membrane or can be integral membrane proteins. See, for example, Komath SS, Fujita M, Hart GW et al., Glycosylphosphatidylinositol Anchors, in: Varki A, Cummings RD, Esko JD et al., eds., Essentials of Glycobiology. 4th edition. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press; 2022. Review in Chapter 12. GPI anchoring refers to the attachment of glycosylphosphatidylinositol or GPI to the C-terminus of a protein during post-translational modification. In some embodiments, the heterologous membrane attachment sequence is a GPI anchor attachment sequence. Proteins attached to the GPI anchor via the C-terminus are typically found in the outer lipid bilayer. The GPI anchor is an alternative to the single transmembrane domain of type I integral membrane proteins.

[0162] The heterologous GPI anchor sequence can be derived from any known GPI-anchored protein (reviewed in Ferguson MAJ, Kinoshita T, Hart GW. Glycosylphosphatidylinositol Anchors. In: Varki A, Cummings RD, Esko JD et al., eds., Essentials of Glycobiology. 2nd ed. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press; 2009. Chapter 11). In some embodiments, the heterologous GPI anchor sequence is a GPI anchor sequence from CD14, CD16, CD48, DAF / CD55, CD59, CD80, CD87, or TRAIL-R3. In some embodiments, the heterologous GPI anchor sequence is derived from DAF / CD55. In some embodiments, the heterologous GPI anchor sequence is derived from CD59. In some embodiments, the heterologous GPI anchor sequence is derived from TRAIL-R3. In exemplary embodiments, the heterologous GPI anchor linker sequence is derived from DAF / CD55, CD59, or TRAIL-R3. In some embodiments, one or both of the activation elements include a heterologous signal sequence to help direct the expression of the activation element to the cell membrane. Any signal sequence active in the packaging cell line can be used. In some embodiments, the signal sequence is the DAF / CD55 signal sequence. In some embodiments, the signal sequence is the CD59 signal sequence. In some embodiments, the signal sequence is the TRAIL-R3 signal sequence.

[0163] In some embodiments, the engineered CD47 protein comprises one or more wild-type human CD47 transmembrane domains. In some embodiments, the wild-type domain has an amino acid sequence corresponding to amino acids 142-162, 177-197, 208-228, 236-257, or 269-289 of SEQ ID NO: 2.

[0164] In some embodiments, the engineered CD47 protein comprises one or more transmembrane domains that are structurally equivalent to the wild-type human CD47 transmembrane domain. In some embodiments, the engineered CD47 protein comprises one or more transmembrane domains having an amino acid sequence that is at least 80%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to amino acids 142-162, 177-197, 208-228, 236-257 or 269-289 of SEQ ID NO: 2.

[0165] In some embodiments, the human CD47 intracellular domain in the engineered CD47 protein is a wild-type human CD47 intracellular domain. In some embodiments, the wild-type intracellular domain has an amino acid sequence corresponding to amino acids 290-323 of SEQ ID NO: 2.

[0166] In some embodiments, the human CD47 intracellular domain in the engineered CD47 protein is structurally equivalent to the wild-type human CD47 intracellular domain. In some embodiments, the human CD47 intracellular domain in the engineered CD47 protein has an amino acid sequence that is at least 80%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to amino acids 290-323 of SEQ ID NO: 2.

[0167] In some embodiments, the engineered CD47 protein comprises an amino acid sequence that is at least 80%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO:7.

[0168] In some embodiments, the engineered CD47 protein comprises an amino acid sequence that is at least 80%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO:8.

[0169] In some embodiments, the engineered CD47 protein comprises an amino acid sequence that is at least 80%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO:9.

[0170] In some embodiments, the engineered CD47 protein comprises an amino acid sequence that is at least 80%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO:12.

[0171] In some embodiments, the engineered CD47 protein comprises an amino acid sequence that is at least 80%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO:10.

[0172] In some embodiments, the engineered CD47 protein comprises an amino acid sequence that is at least 80%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO:11.

[0173] In some embodiments, the engineered CD47 protein is a transmembrane protein. A transmembrane protein is an integral membrane protein that spans the entire cell membrane and has an intracellular and an extracellular portion. As used herein, the "intracellular portion" can include the CD47 intracellular domain and the intracellular linker (when present in a molecule). As used herein, the "extracellular portion" can include the CD47 extracellular domain and the extracellular linker (when present in a molecule).

[0174] As used herein, the wild-type human CD47 extracellular domain refers to the extracellular domain of any of the wild-type human CD47 protein isoforms. The wild-type human CD47 transmembrane domain refers to the transmembrane domain of any of the wild-type human CD47 protein isoforms. The wild-type human CD47 intracellular domain refers to the intracellular domain of any of the wild-type human CD47 protein isoforms.

[0175] In some embodiments, the engineered CD47 protein is an engineered human CD47 protein, an engineered humanized CD47 protein, or an engineered partially humanized CD47 protein.

[0176] As used herein, "humanized" or "humanization" means that the amino acid sequence of the engineered CD47 protein is modified to reduce its immunogenicity in humans. As used herein, "partially humanized" or "partial humanization" means that a portion of the amino acid sequence of the engineered CD47 protein is modified to reduce the immunogenicity of the engineered CD47 protein in humans. For example, in some embodiments, the extracellular domain of the engineered CD47 protein is modified to reduce the immunogenicity of the engineered CD47 protein in humans. Humanization is typically achieved by modifying the sequence of a protein from a non-human source to increase its similarity to its corresponding protein that occurs naturally in humans. There are two main approaches to humanizing proteins: rational design and empirical methods. Rational design methods are characterized by protein structure modeling, generating several variants of the protein, and evaluating their binding or any other properties of interest. In contrast to rational design methods, empirical methods do not require structural information of the protein. They rely on the generation of large combinatorial libraries and the selection of desired variants through enrichment techniques such as phage, ribosome or yeast display or through high-throughput screening techniques. These methods are based on selection rather than making assumptions about the effects of mutations on protein structure. For example, in some embodiments, the humanization of the engineered CD47 protein comprises transplanting the SIRPα binding region in the engineered CD47 protein onto the human CD47 protein. In other embodiments, the humanization of the engineered CD47 protein comprises introducing one or more point mutations into the engineered CD47 protein such that one or more residues in the engineered CD47 protein are replaced by corresponding residues in the human CD47 protein.

[0177] In some embodiments, the engineered proteins of the present disclosure comprise a SIRPα interaction motif comprising a SIRPα antibody. In some embodiments, the SIRPα antibody is selected from Table 3.

[0178] Table 3. SIRPα Antibodies

[0179]

[0180]

[0181]

[0182]

[0183] Glycosylation

[0184] Human CD47 protein is glycosylated. Protein glycosylation involves the covalent attachment of glycans (also known as carbohydrates, saccharides, or sugars) to proteins. Based on the amino acid side chain atoms to which the glycans are attached, most protein glycosylation falls into two categories: N-linked glycosylation and O-linked glycosylation. In N-linked glycosylation, glycans are attached to the side chain nitrogen atoms of asparagine residues in the conserved consensus sequence Asn-Xaa-Ser / Thr (Xaa≠Pro), while in O-linked glycosylation, glycans are attached to the side chain oxygen atoms of hydroxyamino acids (primarily serine and threonine residues).

[0185] The IgV domain of wild-type human CD47 protein is N-glycosylated and modified with O-linked glycosaminoglycans. Human CD47 protein can be expressed as a protein with a molecular weight >250 kDa and a Ser 64 and Ser 79 Proteoglycans with heparan sulfate and chondroitin sulfate glycosaminoglycan (GAG) chains at the site (Kaur et al., J. Biological Chemistry, 2011). Heparan sulfate (HSGAG) and chondroitin sulfate (CSGAG) are synthesized in the Golgi apparatus, where protein cores made in the rough endoplasmic reticulum are post-translationally modified with O-linked glycosylation by glycosyltransferases that form proteoglycans. In addition, four of the five potential modification sites in the human CD47 protein (N 16 、N 32 、N 55 and N 93 ) N-linked glycosylation was identified at (Hatherley et al., Cell, 2008). The amino acid numbering in this paragraph is based on SEQ ID NO 3 (i.e., mature, full-length wild-type CD47).

[0186] In some embodiments, the engineered CD47 protein comprises fewer glycosylation modification sites than the wild-type human CD47 protein. A glycosylation modification site refers to a continuous amino acid sequence in a protein that can serve as a glycan attachment site. Glycosylation modification sites are also referred to as sequence segments (sequons). In some embodiments, one or more amino acids within a glycosaminoglycan modification site of a wild-type human CD47 protein are deleted or substituted in an engineered CD47 protein. In some embodiments, the engineered CD47 protein has 0, 1, 2, 3, 4, 5, or 6 glycosylation sites.

[0187] In some embodiments, the engineered CD47 protein comprises fewer glycosylation modifications than wild-type human CD47 protein. Glycosylation modifications include, but are not limited to, N-glycosylation, O-glycosylation, phosphoserine glycosylation, and C-glycosylation. In some embodiments, the engineered CD47 protein has 0, 1, 2, 3, 4, or 5 glycosylation modifications.

[0188] In some embodiments, the engineered CD47 protein comprises fewer glycosaminoglycan modification sites than the wild-type human CD47 protein. A glycosaminoglycan modification site refers to a contiguous amino acid sequence in a protein that can serve as a site for the attachment of glycosaminoglycans. In some embodiments, one or more amino acids within a glycosaminoglycan modification site of a wild-type human CD47 protein are deleted or substituted in the engineered CD47 protein. In some embodiments, the engineered CD47 protein has 0 or 1 glycosaminoglycan modification site.

[0189] In some embodiments, the engineered CD47 protein comprises fewer glycosaminoglycan chains than the wild-type human CD47 protein. Glycosaminoglycan chains include, but are not limited to, heparan sulfate (HSGAG), chondroitin sulfate (CSGAG), keratan sulfate, and hyaluronic acid. In some embodiments, the engineered CD47 protein has 0 or 1 glycosaminoglycan side chains.

[0190] In some embodiments, the engineered CD47 protein comprises less than two heparan sulfate and / or chondroitin sulfate glycosaminoglycan modification sites. In some embodiments, one or more amino acids within a glycosaminoglycan modification site of a wild-type human CD47 protein are deleted or substituted in the engineered CD47 protein. In some embodiments, the engineered CD47 protein comprises one heparan sulfate and / or chondroitin sulfate glycosaminoglycan modification site. In some embodiments, the engineered CD47 protein does not comprise a heparan sulfate and / or chondroitin sulfate glycosaminoglycan modification site.

[0191] In some embodiments, the engineered CD47 protein comprises fewer than two heparan sulfate and / or chondroitin sulfate glycosaminoglycan chains. In some embodiments, the engineered CD47 protein has 0 or 1 heparan sulfate and / or chondroitin sulfate glycosaminoglycan chains.

[0192] In some embodiments, the engineered CD47 protein comprises fewer N-linked glycosylation sites than the wild-type human CD47 protein. N-linked glycosylation sites are contiguous amino acid sequences in a protein that can serve as attachment sites for sugars, particularly N-glycans. In some embodiments, the engineered CD47 protein has 0, 1, 2, 3, or 4 N-linked glycosylation sites.

[0193] In some embodiments, the engineered CD47 protein comprises fewer N-linked glycosylation modifications than wild-type human CD47 protein. In some embodiments, the engineered CD47 protein has 0, 1, 2, or 3 N-linked glycosylation modifications.

[0194] Biological activity of engineered CD47 proteins

[0195] In some embodiments, the engineered CD47 protein is functionally equivalent to the wild-type human CD47 protein. As used herein, "functionally equivalent" means having at least one type of biological activity of the wild-type human CD47 protein. The types of biological activity of the wild-type human CD47 protein include, but are not limited to, the ability to interact with TSP-1, integrins, another CD47 protein, or SIRPα. Preferably, the engineered CD47 protein can bind to SIRPα.

[0196] Interaction with TSP-1

[0197] The primary secreted ligand for CD47 is thrombospondin-1 (TSP-1). TSP-1 is a homotrimeric glycoprotein, and its C-terminal domain mediates binding to CD47 (Isenberg et al., 2009). At least two other members of the thrombospondin family bind to CD47, albeit with lower affinity. TSP-1 is the prototypical member of the thrombospondin family of extracellular matrix glycoproteins implicated in regulating cell motility, proliferation, and differentiation. The extracellular IgV domain of CD47 is a receptor for the C-terminal cell-binding domain (CBD) of TSP-1. Mutagenesis studies have demonstrated that the high-affinity interaction of TSP-1 with CD47 requires heparan sulfate modification of CD47 (Kaur et al., 2011).

[0198] In some embodiments, the engineered CD47 protein lacks one or more thrombospondin-1 binding sites compared to the wild-type human CD47 protein. In some embodiments, one or more amino acids within the TSP-1 site of the wild-type human CD47 protein are deleted or substituted in the engineered CD47 protein. In some embodiments, the engineered CD47 protein lacking one or more TSP-1 binding sites is not glycosylated by one or more heparan sulfates.

[0199] In some embodiments, the engineered CD47 protein binds to TSP-1 with a lower affinity than wild-type human CD47 protein. In some embodiments, the engineered CD47 protein binds to TSP-1 with a KD greater than about 0.1 μM, 0.2 μM, 0.3 μM, 0.4 μM, 0.5 μM, 0.6 μM, 0.7 μM, 0.8 μM, 0.9 μM, 1 μM, 2 μM, 3 μM, 4 μM, 5 μM, 6 μM, 7 μM, 8 μM, 9 μM, 10 μM, 20 μM, 30 μM, 40 μM, 50 μM, 60 μM, 70 μM, 80 μM, 90 μM, 100 μM. In some embodiments, the engineered CD47 protein does not bind to TSP-1.

[0200] Interaction with integrins

[0201] Early studies of CD47 were based on the use of monoclonal antibodies (mAbs) raised against CD47 protein purified from the placenta. These studies showed that CD47 has the effect of enhancing IgG-mediated phagocytic responses in the presence of RGD-containing ligands (such as fibronectin, fibrinogen, vitronectin, or type IV collagen). The same mAb was also found to block transendothelial migration of neutrophils stimulated by interleukin 8 (IL-8) or the bacterial peptide N-formylmethionylleucylphenylalanine (f-Met-Leu-Phe), and inhibit neutrophil migration across endothelial cells stimulated by tumor necrosis factor alpha (TNFα). These studies indicate that CD47 on both neutrophils and endothelial cells is important. The generation of other anti-CD47 mAbs raised against epithelial membrane preparations showed that CD47 is present at the basolateral membrane of the epithelial cell monolayer, that mAbs that block CD47 on neutrophils or epithelial cells delay neutrophil transepithelial migration, and that effective neutrophil chemotaxis is associated with increased CD47 expression on the neutrophil surface. It was also found that the basement membrane protein entactin containing the RGD sequence stimulates neutrophil adhesion and chemotaxis in vitro in a CD47-dependent manner. The generation of CD47-deficient mice further demonstrated the importance of this protein in regulating neutrophil inflammatory responses by demonstrating increased sensitivity to bacterial infection caused by delayed neutrophil accumulation in bacterial peritonitis. CD47-deficient neutrophils also exhibited severe impairment of RGD-stimulated neutrophil adhesion, phagocytosis, and respiratory burst. For α v β3 integrin-mediated cellular responses to the extracellular matrix protein vitronectin, and the discovery that CD47 is α v Required for β3-mediated binding to vitronectin-coated beads, but not α v Required for β3-mediated adhesion to vitronectin-coated surfaces. In addition to α v In addition to its primary association with β3 integrin, CD47 has been shown to interact with and regulate the following proteins: integrins α2β1 and αII on platelets b β3, α2β1 integrin on smooth muscle cells, α4β1 integrin on sickle red blood cells and B lymphocytes, α6β1 integrin in microglia, and α5 integrin in chondrocytes.

[0202] In some embodiments, the engineered CD47 protein lacks one or more integrin binding sites compared to the wild-type human CD47 protein. In some embodiments, one or more amino acids within the integrin binding site of the wild-type human CD47 protein are deleted or substituted in the engineered CD47 protein.

[0203] In some embodiments, the engineered CD47 protein binds to an integrin with a lower affinity than that of a wild-type human CD47 protein. In some embodiments, the engineered CD47 protein binds to an integrin with a KD greater than about 0.1 μM, 0.2 μM, 0.3 μM, 0.4 μM, 0.5 μM, 0.6 μM, 0.7 μM, 0.8 μM, 0.9 μM, 1 μM, 2 μM, 3 μM, 4 μM, 5 μM, 6 μM, 7 μM, 8 μM, 9 μM, 10 μM, 20 μM, 30 μM, 40 μM, 50 μM, 60 μM, 70 μM, 80 μM, 90 μM, 100 μM. In some embodiments, the engineered CD47 protein is unable to bind to an integrin.

[0204] In some embodiments, the integrin is selected from the group consisting of: α v β3 integrin, αII b β3 integrin, α2β1 integrin, α4β1 integrin, α6β1 integrin and α5 integrin.

[0205] Interaction with SIRP proteins

[0206] The signal regulatory protein (SIRP) family contains three members, of which SIRPα and SIRPγ are known CD47 receptors. SIRP proteins belong to the Ig family of cell surface glycoproteins, and the first member to be identified was SIRPα (also known as SHPS-1, CD172a, BIT, MFR or P84). SIRPα is highly expressed in myeloid cells and neurons, but also in endothelial cells and fibroblasts, and has three extracellular Ig-like domains, one distal IgV-like domain and two membrane-proximal IgC-like domains. In addition, alternatively spliced ​​forms with only one IgV domain have also been reported. SIRPα has two immunoreceptor tyrosine-based inhibitory motifs (ITIMs) in its intracellular tail, which, when phosphorylated, can bind to the protein tyrosine phosphatases SHP-1 and SHP-2 containing the Src homology 2 (SH2) domain. Additional cytoplasmic binding partners of SIRPα are the 55kDa adaptor molecule Src kinase-related protein homolog / SKAP2 (SKAP55hom / R), the 130kDa Fyn binding protein / SLP-76-related phosphoprotein (FYB / SLAP-130), and the tyrosine kinase PYK2. SIRPα is also a substrate for the kinase activity of the insulin, EGF, and bPDGF receptors. Overexpression of SIRPα in fibroblasts reduces proliferation and other downstream events in response to insulin, EGF, and bPDGF. Since SIRPα is also constitutively associated with the M-CSF receptor c-fms, overexpression of SIRPα partially reverses the v-fms phenotype.

[0207] CD47 is a ligand for SIRPα. Glycosylation of either CD47 or SIRPα does not appear to be required for their interaction, but the level of N-glycosylation of SIRPα has an impact on the interaction, such that excessive glycosylation reduces CD47 binding. 33 Cys in the CD47 transmembrane domain 263 The long-range disulfide bond between them is also important for determining the orientation of the CD47 IgV domain, which enhances its binding to SIRPα. The amino acid numbering in this paragraph is based on SEQ ID NO: 3 (ie, the mature, wild-type, full-length CD47 protein).

[0208] The structures of CD47 and the CD47 / SIRPα complex have been revealed (Hatherley et al., 2008). Two β-strands corresponding to amino acids 92-100 and 103-113 of SEQ ID NO: 3 were identified as being located at the core of the CD47 / SIRPα interaction. Amino acids 97 (Glu), 99 (Thr), 100 (Glu), 103 (Arg), 104 (Glu) and 106 (Glu) of SEQ ID NO: 3 were identified as contact residues in the CD47 / SIRPα interaction and play a role in the binding affinity of CD47 to SIRPα (Hatherley et al., 2008). In a preferred embodiment, the two β-strands and the six contact residues therein are retained in the engineered CD47 protein disclosed herein to maintain SIRPα binding ability.

[0209] In some embodiments, the engineered CD47 protein comprises at least one SIRPα interaction motif in its extracellular domain. In some embodiments, the amino acids corresponding to amino acids 97, 99, 100, 103, 104, 106 of SEQ ID NO: 3 are retained in the engineered CD47 protein. In some embodiments, the two beta chains are retained in the engineered CD47 protein.

[0210] In some embodiments, the engineered CD47 protein comprises a disulfide bond between a cysteine ​​located within the extracellular domain of human CD47 or a portion thereof and a cysteine ​​located within or between one or more transmembrane domains of human CD47. In some embodiments, the two cysteines are Cys in the extracellular domain. 33 and Cys in the transmembrane domain 263 , where numbering is based on SEQ ID NO:3.

[0211] In some embodiments, the engineered CD47 protein can bind to SIRPα. In some embodiments, the engineered CD47 protein can bind to SIRPα with a binding affinity similar to that of the wild-type human CD47 protein. In some embodiments, the engineered CD47 protein binds to SIRPα with a KD of less than about 0.01 μM, 0.02 μM, 0.03 μM, 0.04 μM, 0.05 μM, 0.06 μM, 0.07 μM, 0.08 μM, 0.09 μM, 0.1 μM, 0.2 μM, 0.3 μM, 0.4 μM, 0.5 μM, 0.6 μM, 0.7 μM, 0.8 μM, 0.9 μM, 1 μM, 2 μM, 3 μM, 4 μM, 5 μM. In some embodiments, the engineered CD47 protein can bind to SIRPα with a higher binding affinity than the wild-type human CD47 protein.

[0212] Direct binding studies have shown that TSP-1 inhibits SIRPα binding to cells expressing CD47 (Isenberg et al., 2009). This data is consistent with competitive binding of TSP-1 and SIRPα to a single site on CD47, steric inhibition of binding to a different but proximal site, or allosteric inhibition. 64 Glycosylation with heparan sulfate chains at Ser is required for TSP-1 binding, but not for SIRPα binding (Soto-Pantoja et al., 2015). 64 The engineered CD47 protein glycosylated at the glycosylation site had enhanced SIRPα binding capacity because TSP-1 binding was hindered.

[0213] The CD47 / SIRPα interaction regulates a variety of cell-cell interactions in many body systems, such as the immune system, where it regulates lymphocyte homeostasis, maturation and activation of dendritic cells (DCs), the correct localization of certain DC subsets in secondary lymphoid organs, and cell migration. The CD47 / SIRPα interaction also regulates cells of the nervous system. The interaction between these two proteins also plays an important role in bone remodeling. Cellular responses regulated by the CD47 / SIRPα interaction often rely on bidirectional signaling through two receptors.

[0214] CD47 on host cells can act as a "self-marker" and regulate phagocytosis by binding to SIRPα on the surface of circulating immune cells to deliver inhibitory "don't kill me" signals. As disclosed above, SIRPα encodes an Ig superfamily receptor expressed on the surface of macrophages and dendritic cells, whose cytoplasmic region contains an immunoreceptor tyrosine-based inhibitory motif (ITIM) that can trigger a cascade reaction to inhibit phagocytosis. CD47-SIRPα binding leads to phosphorylation of ITIM on SIRPα, thereby triggering the recruitment of SHP1 and SHP2-Src homologous phosphatases. These phosphatases in turn inhibit the accumulation of myosin II at the phagocytic synapse, thereby preventing phagocytosis (Fujioka et al., 1996). The phagocytosis of target cells by macrophages is ultimately regulated by a balance of activation signals (FcγR, CRT, LRP-1) and inhibitory signals (SIRPα-CD47). Elevated CD47 expression can help cells escape immune surveillance and subsequent destruction. Increased CD47 expression can help cells evade killing by innate immune cells.

[0215] In some embodiments, the engineered CD47 protein is a tolerogenic factor. As used herein, a tolerogenic factor is a factor that induces immune tolerance when a normal immune response is pathologically or undesirably activated. For example, this occurs when a patient develops an immune response to a donor antigen after receiving an allogeneic transplant or allogeneic cell therapy, or when the body responds inappropriately to self-antigens implicated in autoimmune diseases. In some embodiments, "tolerogenic factors" include hypoimmunity factors, complement inhibitors, and other factors that regulate or affect the ability of cells to be recognized by the immune system of a host or recipient subject after administration, transplantation, or implantation. In some embodiments, the tolerogenic factors are genetically modified to achieve additional functions.

[0216] In some embodiments, the engineered CD47 protein can inhibit phagocytosis, release of cytotoxic agents, and / or other cell-mediated killing mechanisms.

[0217] Interactions between CD47 molecules

[0218] Studies have also shown that CD47 mediates cell-cell adhesion interactions in the absence of any known CD47 ligand. This cell-cell adhesion requires CD47, but not any of its known ligands, suggesting that homotypic binding can also occur between CD47 IgV domains on opposing cells (Rebres et al., 2005). This interaction may require an unidentified trypsin-sensitive protein (X) to mediate cell-cell adhesion, but the potential for this cell-cell interaction, as well as homotypic binding of proteolytically shed CD47 IgV domains (Maile et al., 2010) or exosome-derived CD47 (Kaur et al., 2014) to cell-surface CD47, should be considered to trigger CD47 signaling. However, direct evidence for CD47-CD47 binding and signaling resulting from homotypic CD47 binding is lacking. In some embodiments, the engineered CD47 protein is unable to interact with another CD47 molecule.

[0219] III. Polynucleotides

[0220] In another aspect, the present disclosure provides polynucleotides encoding the engineered CD47 proteins disclosed herein.

[0221] The polynucleotides encoding the engineered CD47 proteins disclosed herein can be obtained by methods known in the art. For example, the polynucleotides can be obtained from cloned DNA (e.g., from a DNA library), by chemical synthesis, by cDNA cloning, or by cloning genomic DNA purified from desired cells or fragments thereof. When the polynucleotides are produced by recombinant means, any method known to those skilled in the art for identifying nucleic acids encoding the desired gene can be used. Any method available in the art can be used to obtain cDNA or genomic DNA encoding the full length (i.e., encompassing the entire coding region) of the desired human CD47 protein, such as from a cell or tissue source. Modified or variant polynucleotides, including truncated forms of CD47 (such as those provided herein), can be engineered from wild-type polynucleotides using standard recombinant DNA methods. Polynucleotides can be cloned or isolated using any available method known in the art for cloning and isolating nucleic acid molecules. Such methods include PCR amplification of nucleic acids and library screening, including nucleic acid hybridization screening, antibody-based screening, and activity-based screening.

[0222] Methods for amplifying polynucleotides can be used to isolate polynucleotides encoding desired proteins, including, for example, polymerase chain reaction (PCR) methods. PCR can be performed using any method or procedure known in the art. Exemplary methods include using a Perkin-Elmer Cetus thermal cycler and Taq polymerase (Gene Amp). Nucleic acids containing the gene of interest can be used as source material, from which desired nucleic acid molecules encoding polypeptides can be amplified. For example, DNA and mRNA preparations, cell extracts, tissue extracts from appropriate sources (e.g., testis, prostate, breast), fluid samples (e.g., blood, serum, saliva), and samples from healthy and / or diseased subjects can be used for amplification methods. The source can be any eukaryotic species, including but not limited to vertebrates, mammals, humans, porcine, bovine, feline, avian, equine, canine, and other primate sources. Nucleic acid libraries can also be used as source material. Primers can be designed to amplify desired polynucleotides. For example, primers can be designed based on the expressed sequence from which the desired polynucleotides are generated. Primers can be designed based on the reverse translation of the polypeptide amino acid sequence. If desired, degenerate primers can be used for amplification. Oligonucleotide primers that hybridize to sequences located at the 3' and 5' ends of the desired sequence can be used as primers to amplify from a nucleic acid sample by PCR. Primers can be used to amplify the entire full-length polynucleotide or its truncated sequence. The nucleic acid molecules generated by amplification can be sequenced and confirmed to encode the desired polypeptide.

[0223] IV. Vector

[0224] In another aspect, the present disclosure provides a vector comprising a polynucleotide encoding an engineered CD47 protein disclosed herein.

[0225] Any method known to those skilled in the art for inserting DNA fragments into vectors can be used to construct expression vectors comprising the polynucleotides disclosed herein. These methods may include in vitro recombinant DNA and synthetic techniques as well as in vivo (gene) recombination. The polynucleotides disclosed herein may be operably linked to control sequences in one or more expression vectors to ensure expression of the engineered CD47 protein. Such control sequences may include, but are not limited to, leader or signal sequences, promoters (such as naturally associated or heterologous promoters), ribosome binding sites, enhancer or activator elements, translation start and stop sequences, and transcription start and stop sequences, and are selected to be compatible with the host cell selected for expression of the engineered CD47 protein. Constitutive or inducible promoters known in the art are also contemplated. The promoter may be a naturally occurring promoter, a hybrid promoter combining elements of more than one promoter, or a synthetic promoter. The expression construct may be present on an episome (such as a plasmid) in the cell, or the expression construct may be inserted into a chromosome, such as a locus. In some embodiments, the expression vector includes a selectable marker gene to allow selection of transformed host cells. Some embodiments include expression vectors comprising a nucleotide sequence encoding a variant polypeptide operably linked to at least one regulatory control sequence. Regulatory control sequences used herein include promoters, enhancers, and other expression control elements. In some embodiments, expression vectors are designed to select the host cell to be transformed, the specific variant polypeptide desired to be expressed, the copy number of the vector, the ability to control the copy number, and / or the expression of any other protein encoded by the vector (such as an antibiotic marker).

[0226] Examples of suitable mammalian promoters include, for example, promoters from the following genes: elongation factor 1 alpha (EF1 alpha) promoter, CAG promoter, hamster ubiquitin / S27a promoter (WO 97 / 15664), simian vacuolating virus 40 (SV40) early promoter, adenovirus major late promoter, mouse metallothionein-I promoter, Rous sarcoma virus (RSV) long terminal repeat region, mouse mammary tumor virus promoter (MMTV), Moloney murine leukemia virus long terminal repeat region and human cytomegalovirus (CMV) early promoter. Other examples of heterologous mammalian promoters are actin, immunoglobulin or one or more heat shock promoters. In another embodiment, promoters for mammalian host cells can be obtained from the genome of viruses such as polyoma virus, fowlpox virus (UK 2,211,504 published on July 5, 1989), bovine papilloma virus, avian sarcoma virus, cytomegalovirus, retrovirus, hepatitis B virus, and simian virus 40 (SV40). In a further embodiment, heterologous mammalian promoters are used. Examples include actin promoters, immunoglobulin promoters, and heat shock promoters. The early and late promoters of SV40 are conveniently obtained as SV40 restriction fragments that also contain the SV40 viral replication origin (Fiers et al., Nature 273:113-120 (1978)). The immediate early promoter of human cytomegalovirus is conveniently obtained as a HindIII restriction enzyme fragment (Greenaway et al., Gene 18:355-360 (1982)). The aforementioned references are incorporated by reference in their entirety.

[0227] In some embodiments, the vector is a self-inactivating lentiviral vector pseudotyped with the exogenous polynucleotide. In some embodiments, the vector is a self-inactivating lentiviral vector pseudotyped with the vesicular stomatitis VSV-G envelope and carrying the exogenous polynucleotide.

[0228] The vector may include, but is not limited to, viral vectors and plasmid DNA. Viral vectors may include, but are not limited to, adenoviral vectors, lentiviral vectors, retroviral vectors, and adeno-associated viral vectors. Typically, the expression vector contains a selected

[0229] Markers such as ampicillin resistance, hygromycin resistance, tetracycline resistance, kanamycin resistance, or neomycin resistance are used to allow detection of cells transformed with the desired DNA sequence. Suitable vectors, promoters, and enhancer elements are known in the art; many are commercially available for use in generating subject recombinant constructs. In some embodiments, the vector is a polycistronic vector. In some embodiments, the vector is a bicistronic or polycistronic expression vector. Bicistronic or polycistronic expression vectors can include (1) multiple promoters fused to each open reading frame; (2) insertion of splicing signals between genes; (3) fusion of genes whose expression is driven by a single promoter; and (4) insertion of proteolytic cleavage sites (self-cleaving peptides) between genes or insertion of internal ribosome entry sites (IRES) between genes.

[0230] Polycistronic vectors are used to co-express multiple genes in the same cell. Two strategies are most commonly used to construct polycistronic vectors. First, internal ribosome entry site (IRES) elements are commonly used in bicistronic vectors. The IRES element serves as another ribosome recruitment site, allowing translation to be initiated from the internal region of the mRNA. Thus, two proteins are translated from one mRNA. The IRES element is quite large (typically 500-600bp) (Pelletier et al., 1988; Jang et al., 1988). The engineered CD47 protein disclosed herein has a smaller size than wild-type full-length human CD47 and can therefore be used in polycistronic vectors with limited packaging capacity together with the IRES element.

[0231] The second strategy relies on "self-cleaving" 2A peptides. These peptides were first discovered in picornaviruses. They are short (about 20 amino acids) and can produce equimolar levels of multiple genes from the same mRNA. The term "self-cleaving" is not entirely accurate, as these peptides are thought to work by causing the ribosome to skip the peptide bond synthesis at the C-terminus of the 2A element, resulting in a separation between the end of the 2A sequence and the next peptide downstream (Kim et al., 2011). The "cleavage" occurs between the glycine and proline residues found at the C-terminus. Therefore, the upstream cistron will have several additional residues added to the end, while the downstream cistron will start at the proline.

[0232] In some embodiments, the polycistronic vectors used in the context of the present disclosure are those described in U.S. applications 63 / 270,956 and 63 / 222,954.

[0233] In some embodiments, the vector herein is a nucleic acid molecule that can transfer or transport another nucleic acid molecule (including transfer or transport to cell or cell genome). The nucleic acid transferred is usually connected to the carrier nucleic acid molecule, for example, is inserted into the carrier nucleic acid molecule. The vector may include a sequence that guides autonomous replication in the cell, or may include a sequence that is enough to allow integration into the host cell DNA. Useful vectors include, for example, plasmids (for example, DNA plasmids or RNA plasmids), transposons, cosmids, bacterial artificial chromosomes, and viral vectors. Useful viral vectors include, for example, replication-defective retroviruses and slow viruses. Non-viral vectors may need to deliver a vehicle to promote nucleic acid molecules to enter the cell.

[0234] Viral vector can comprise nucleic acid molecule, and this nucleic acid molecule comprises the nucleic acid element of virus origin that promotes nucleic acid molecule transfer or is integrated into the genome of cell or transfers or is integrated into the virion of mediation nucleic acid transfer.Except one or more nucleic acids, virion will comprise various viral components and sometimes also comprise host cell components usually.Viral vector can comprise virus or virion (for example, as naked DNA) that can transfer nucleic acid into cell or transfer into the nucleic acid that is transferred.Viral vector and transfer plasmid can comprise the structure and / or function genetic elements that are mainly derived from virus.Retroviral vector can comprise the structure and function genetic elements that contain mainly derive from retrovirus or its part or viral vector or the plasmid.

[0235] In some vectors described herein, at least a portion of one or more protein coding regions that contribute to or are required for replication may be absent compared to the corresponding wild-type virus. This renders the viral vector replication-defective. In some embodiments, the vector is capable of transducing a target non-dividing host cell and / or integrating its genome into the host genome.

[0236] In some embodiments, the retroviral nucleic acid comprises one or more (e.g., all) of the following: a 5' promoter (e.g., for controlling expression of the entire packaged RNA), a 5' LTR (e.g., comprising an R (polyadenylation tail signal) and / or a U5 comprising a primer activation signal), a primer binding site, a psi packaging signal, an RRE element for nuclear export, a promoter directly upstream of the transgene to control transgene expression, a transgene (or other exogenous agent element), a polypurine tract, and a 3' LTR (e.g., comprising mutated U3, R, and U5). In some embodiments, the retroviral nucleic acid further comprises one or more of a cPPT, a WPRE, and / or an insulator element (e.g., as described in Browning et al., "Insulators to Improve the Safety of Retroviral Vectors for HIV Gene Therapy", Biomedicines, 4(1):4(2016)).

[0237] Retrovirus is usually copied and subsequently its genomic DNA is covalently integrated into the host genome by reverse transcription of its genomic RNA into linear double-stranded DNA copies.The structure of wild-type retrovirus genome usually includes 5' long terminal repeats (LTR) and 3'LTR, between or within the 5' long terminal repeats (LTR) and 3'LTR there are packaging signals, primer binding sites, gag, pol and env genes that enable genome to be packaged, integration sites, and encoding for promoting viral particle assembly to be integrated into the host cell genome. More complex retroviruses have other features, such as the rev and RRE sequences in HIV, which enable the RNA transcripts of the protovirus to be integrated to be effectively exported to cytoplasm from the nucleus of infected target cells. In the protovirus, the viral gene is flanked by a region called long terminal repeats (LTR) at both ends. LTR participates in protovirus integration and transcription. LTR also serves as enhancer-promoter sequence and can control the expression of viral genes. The encapsidation of retroviral RNA occurs by the psi sequence located at the 5' end of the viral genome.

[0238] The LTR itself is typically a similar (e.g., identical) sequence that can be divided into three elements, called U3, R, and U5. U3 is derived from a sequence unique to the 3' end of the RNA. R is derived from a sequence that repeats at both ends of the RNA, and U5 is derived from a sequence unique to the 5' end of the RNA. The sizes of these three elements can vary considerably among different retroviruses.

[0239] For viral genomes, the transcription start site is usually at the boundary between U3 and R in one LTR, while the poly(A) addition (termination) site is at the boundary between R and U5 in the other LTR. U3 contains most of the transcriptional control elements of the provirus, including a promoter and multiple enhancer sequences that respond to cellular and, in some cases, viral transcriptional activator proteins. Some retroviruses contain any one or more of the following genes encoding proteins involved in regulating gene expression: tot, rev, tax, and rex.

[0240] Regarding the structural genes gag, pol, and env themselves, gag encodes the internal structural proteins of the virus. The gag protein is proteolytically processed into the mature proteins MA (matrix), CA (capsid), and NC (nucleocapsid). The pol gene encodes reverse transcriptase (RT), which contains the DNA polymerase, the associated RNase H, and the integrase (IN) that mediate genome replication. The env gene encodes the surface (SU) glycoprotein and transmembrane (TM) protein of the virion, which form a complex that specifically interacts with cellular receptor proteins. This interaction promotes infection, for example, by fusion of the viral membrane with the cell membrane.

[0241] In replication-deficient retroviral vector genomes, gag, pol, and env may not be present or functional. The R regions at both ends of the RNA are typically repetitive sequences. U5 and U3 represent unique sequences at the 5' and 3' ends of the RNA genome, respectively. Retroviruses may also contain additional genes encoding proteins other than gag, pol, and env. Examples of additional genes include (in HIV) one or more of vif, vpr, vpx, vpu, tat, rev, and nef. EIAV has, in particular, an additional gene, S2.

[0242] Exemplary retroviruses suitable for use in specific embodiments include, but are not limited to, Moloney murine leukemia virus (M-MuLV), Moloney murine sarcoma virus (MoMSV), Harvey murine sarcoma virus (HaMuSV), murine mammary tumor virus (MuMTV), gibbon ape leukemia virus (GaLV), feline leukemia virus (FLV), spumavirus, Friend murine leukemia virus, murine stem cell virus (MSCV), Rous sarcoma virus (RSV), and human immunodeficiency virus (HIV).

[0243] In some embodiments, the retrovirus is a gamma retrovirus. In some embodiments, the retrovirus is an epsilon retrovirus. In some embodiments, the retrovirus is an alpha retrovirus. In some embodiments, the retrovirus is a beta retrovirus. In some embodiments, the retrovirus is a delta retrovirus. In some embodiments, the retrovirus is a foamy retrovirus. In some embodiments, the retrovirus is an endogenous retrovirus. In some embodiments, the retrovirus is a lentivirus.

[0244] In some embodiments, the retroviral or lentiviral vector further comprises one or more insulator elements, e.g., the insulator elements described in Browning et al., “Insulators to Improve the Safety of Retroviral Vectors for HIV Gene Therapy,” Biomedicines, 4(1):4 (2016). In various embodiments, the vector comprises a promoter operably linked to a polynucleotide encoding an exogenous agent. The vector may have one or more LTRs, any of which comprises one or more modifications, such as one or more nucleotide substitutions, additions, or deletions. The vector may further comprise one or more auxiliary elements for increasing transduction efficiency (e.g., cPPT / FLAP), viral packaging (e.g., Psi(Y) packaging signal, RRE), and / or other elements that increase exogenous gene expression (e.g., poly(A) sequence), and may optionally comprise a WPRE or HPRE. In some embodiments, the lentiviral nucleic acid comprises, e.g., from 5' to 3', one or more (such as all) of the following: a promoter (e.g., CMV), an R sequence (e.g., comprising a TAR), a U5 sequence (e.g., for integration), a PBS sequence (e.g., for reverse transcription), a DIS sequence (e.g., for genome dimerization), a psi packaging signal, a partial gag sequence, an RRE sequence (e.g., for nuclear export), a cPPT sequence (e.g., for nuclear import), a promoter driving expression of an exogenous agent, a gene encoding the exogenous agent, a WPRE sequence (e.g., for efficient transgene expression), a PPT sequence (e.g., for reverse transcription), an R sequence (e.g., for polyadenylation and termination), and a U5 signal (e.g., for integration).

[0245] Exemplary lentiviruses include, but are not limited to, HIV (human immunodeficiency virus; including HIV type 1 and HIV type 2); visna-maedi virus (VMV); caprine arthritis-encephalitis virus (CAEV); equine infectious anemia virus (EIAV); feline immunodeficiency virus (FIV); bovine immunodeficiency virus (BIV); and simian immunodeficiency virus (SIV). In some embodiments, an HIV-based vector backbone (i.e., HIV cis-acting sequence elements) is used. Lentiviral vectors may comprise viral vectors or plasmids containing structural and functional genetic elements or portions thereof, including LTRs primarily derived from lentiviruses.

[0246] In embodiments, a lentiviral vector (e.g., a lentiviral expression vector) may comprise a lentiviral transfer plasmid (e.g., as naked DNA) or an infectious lentiviral particle. With respect to elements such as cloning sites, promoters, regulatory elements, heterologous nucleic acids, etc., it should be understood that the sequences of these elements can be present in RNA form in the lentiviral particle and can be present in DNA form in the DNA plasmid.

[0247] In an embodiment, a lentiviral vector is a vector having sufficient retroviral genetic information to allow the RNA genome to be packaged into viral particles capable of infecting target cells in the presence of packaging components. The infection of the target cell can include reverse transcription and integration into the target cell genome. Recombinant lentiviral vectors (RLVs) typically carry non-viral coding sequences to be delivered to the target cell by the vector. In an embodiment, RLVs cannot replicate independently in the target cell to produce infectious retroviral particles. Typically, RLVs lack functional gag-pol and / or env genes and / or other genes involved in replication. The vector can be configured as a split intron vector, for example, as described in PCT patent application WO 99 / 15683, which is incorporated herein by reference in its entirety.

[0248] In some embodiments, the lentiviral vector comprises a minimal viral genome, e.g., a viral vector that has been manipulated to remove nonessential elements and retain essential elements in order to provide the functions required to infect, transduce, and deliver the nucleotide sequence of interest to the target host cell, e.g., as described in WO 98 / 17815, which is incorporated herein by reference in its entirety.

[0249] The minimal lentiviral genome may comprise, for example, (5')R-U5-one or more first nucleotide sequences-U3-R(3'). However, the plasmid vector used to produce the lentiviral genome in the source cell may also comprise a transcriptional regulatory control sequence operably linked to the lentiviral genome to guide the transcription of the genome in the source cell. These regulatory sequences may comprise a natural sequence associated with the transcribed retroviral sequence, such as the 5'U3 region, or these regulatory sequences may comprise a heterologous promoter, such as another viral promoter, such as the CMV promoter. Some lentiviral genomes comprise additional sequences that promote efficient viral production. For example, in the case of HIV, rev and RRE sequences may be included.

[0250] V. Cells

[0251] In another aspect, the present disclosure provides cells comprising a polynucleotide encoding an engineered CD47 protein disclosed herein, and / or vectors comprising a polynucleotide encoding an engineered CD47 protein disclosed herein.

[0252] In some embodiments, the engineered CD47 protein is introduced into the cell in the form of a nucleic acid molecule encoding the engineered CD47 protein. The process of introducing the nucleic acid molecule into the cell can be achieved by any suitable technique. Suitable techniques include calcium phosphate or lipid-mediated transfection, electroporation, and transduction or infection using viral vectors. In some embodiments, the nucleic acid molecule comprises DNA. In some embodiments, the nucleic acid molecule comprises modified DNA. In some embodiments, the nucleic acid molecule comprises mRNA. In some embodiments, the nucleic acid molecule comprises modified mRNA.

[0253] In some embodiments, the engineered CD47 protein is delivered using viral transduction (e.g., using a vector). In some embodiments, the vector is a self-inactivating lentiviral vector pseudotyped with a vesicular stomatitis virus (VSV)-G envelope and carrying an exogenous polynucleotide.

[0254] In some embodiments, engineered CD47 proteins are delivered using one or more gene editing systems. In some embodiments, the gene editing system is CRISPR / Cas. In some embodiments, the gene editing system is one or more of the CRISPR / Cas systems described herein. In some embodiments, engineered CD47 proteins are delivered using a transcription activator-like effector nuclease (TALEN) method. In some embodiments, the gene editing system is one or more of the TALEN methods described herein.

[0255] In some embodiments, the engineered CD47 protein is delivered using zinc finger nucleases (ZFNs).In some embodiments, the gene editing system is one or more of the ZFN methods described herein.

[0256] In some embodiments, the engineered CD47 protein is delivered using a meganuclease. In some embodiments, the gene editing system is one or more of the meganuclease methods described herein.

[0257] In some embodiments, the cells are stem cells.

[0258] In some embodiments, the cell is a pluripotent stem cell. Pluripotent stem cells are cells that have the ability to self-renew by dividing and develop into the three primary germ cell layers of the early embryo and thus develop into all cells of the adult body, but cannot develop into extraembryonic tissues such as the placenta. Embryonic stem cells and induced pluripotent stem cells are both pluripotent stem cells.

[0259] In some embodiments, the cell is an embryonic stem cell (ESC). Embryonic stem cells are pluripotent stem cells derived from the inner cell mass of a blastocyst (an early preimplantation embryo).

[0260] In some embodiments, the cells are induced pluripotent stem cells (iPSCs). iPSCs are derived from adult somatic cells that have been genetically reprogrammed back to an embryonic-like pluripotent state, which enables the development of an unlimited source of any type of cell desired for therapeutic purposes.

[0261] As used herein, "pluripotent stem cells" have the potential to differentiate into any of the following three germ layers: endoderm (e.g., stomach lining, gastrointestinal tract, lungs, etc.), mesoderm (e.g., muscle, bone, blood, urogenital tissue, etc.), or ectoderm (e.g., epidermal tissue and nervous system tissue). As used herein, the term "pluripotent stem cell" also encompasses induced pluripotent stem cells (iPSC or iPS cells), or a class of pluripotent stem cells derived from non-pluripotent cells. In some embodiments, pluripotent stem cells are produced or generated by cells that are not pluripotent cells. In other words, pluripotent stem cells can be the direct or indirect offspring of non-pluripotent cells. The example of parental cell includes somatic cells that have been reprogrammed to induce a pluripotent, undifferentiated phenotype by various means. Such "iPS" or "iPSC" cells can be produced by inducing the expression of certain regulatory genes or by the exogenous application of certain proteins. Methods for inducing iPS cells are known in the art and are further described below. (See, e.g., Zhou et al., Stem Cells 27(11):2667-74 (2009); Huangfu et al., Nature Biotechnol. 26(7):795 (2008); Woltjen et al., Nature 458(7239):766-770 (2009); and Zhou et al., Cell Stem Cell 8:381-384 (2009); each of which is incorporated herein by reference in its entirety.) As used herein, "hiPSC" is a human induced pluripotent stem cell. In some embodiments, "pluripotent stem cells" as used herein also encompass mesenchymal stem cells (MSCs) and / or embryonic stem cells (ESCs).

[0262] In some embodiments, the cells are pancreatic islet cells. In some embodiments, the cells are primary pancreatic islet cells.

[0263] In some embodiments, the cells are differentiated from pluripotent stem cells. In some embodiments, the pluripotent stem cells are iPSCs or ESCs.

[0264] In some embodiments, the cell is a T cell. In some embodiments, the cell is a primary T cell. In some embodiments, the cell is a T cell comprising a chimeric antigen receptor (CAR), such as a polynucleotide encoding a CAR and / or comprising a CAR, or otherwise expressing a CAR from a polynucleotide. In some embodiments, the cell is a CAR-T cell. In some embodiments, T cells are differentiated from pluripotent stem cells. In some embodiments, pluripotent stem cells are iPSCs or ESCs.

[0265] T cells are a type of lymphocyte. T cells are one of the white blood cells (white blood cell) of the immune system and play a central role in the adaptive immune response. CAR-T cells are T cells that have been genetically engineered to produce artificial T cell receptors. Chimeric antigen receptors (CAR, also referred to as chimeric immune receptors, chimeric T cell receptors or artificial T cell receptors) are receptor proteins that have been engineered to give T cells the ability to target specific proteins. These receptors are chimeric because they combine antigen binding and T cell activation functions in a single receptor. CAR-T cells can be two cell types with a ratio of 1: 1 of CD4+ and CD8+, thereby providing a synergistic anti-tumor effect. CAR-T cells can be derived from the T cells (autologous) in the patient's own blood, or from the T cells (allogeneic) of another healthy donor. T cells can be obtained from many sources, including but not limited to peripheral blood mononuclear cells, bone marrow, lymph node tissue, umbilical cord blood, thymus tissue, tissue from the site of infection, ascites, pleural effusion, spleen tissue and tumor. In certain embodiments, T cells can be obtained from a unit of blood collected from a subject using a number of techniques known to those of skill, such as sedimentation methods (e.g., FICOLL TM Separation methods), antibody-conjugated bead-based methods (such as MACS TM Separation method (Miltenyi)).

[0266] In some embodiments, the cell is selected from, but is not limited to, cardiac cells, cardiac progenitor cells, neural cells, glial progenitor cells, endothelial cells, T cells, B cells, pancreatic islet cells, retinal pigment epithelial cells, hepatocytes, thyroid cells, skin cells, blood cells, plasma cells, platelets, kidney cells, epithelial cells, CAR-T cells, NK cells, and CAR-NK cells.

[0267] In some embodiments, the cells are primary cells. Primary cells are isolated directly from human or animal tissue using enzymatic or mechanical methods. Once isolated, they are placed in an artificial environment within a plastic or glass container containing a specialized culture medium containing essential nutrients and growth factors to support proliferation. Primary cells can be of two types: adherent or suspension cells. Adherent cells require attachment to grow and are known as anchorage-dependent cells. Adherent cells are typically derived from organ tissue. Suspension cells do not require attachment to grow and are known as anchorage-independent cells. Most suspension cells are isolated from the blood system, but some tissue-derived cells, such as hepatocytes or intestinal cells, can also be used in suspension form. Although primary cells generally have a limited lifespan, they offer many advantages over cell lines. Primary cell culture allows researchers to study the donor, not just the cells themselves. Factors such as age, medical history, race, and gender can be considered when establishing experimental models. With the growing trend toward personalized medicine, this donor variability and tissue complexity can be achieved through the use of primary cells but is difficult to reproduce using cell lines, which are inherently more systematic and uniform, and fail to capture the true diversity of living tissues.

[0268] In some embodiments, the cell is a differentiated cell. Differentiated cells are cells that have undergone differentiation. They are mature cells that perform specialized functions. Some examples of differentiated cells are epithelial cells, skin fibroblasts, endothelial cells lining blood vessels, smooth muscle cells, liver cells, nerve cells, human cardiac muscle cells, etc. Typically, these cells have unique morphology, metabolic activity, membrane potential, and responsiveness to signals that promote their function in body tissues or organs.

[0269] Low immunogenic cells

[0270] In some embodiments, the cells described herein are low immunogenic cells. As used herein to characterize cells, the term "low immunogenicity" generally means that such cells are less susceptible to the innate or adaptive immune rejection of a subject having transplanted such cells, for example, the cell is less susceptible to allogeneic rejection of a subject having transplanted such cells. For example, in some embodiments, relative to cells of the same cell type not comprising modification, such low immunogenic cells may be about 2.5%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 97.5%, 99%, 100%, or any amount therebetween are less susceptible to the innate or adaptive immune rejection of a subject having transplanted such cells. In some embodiments, genome editing technology is used to regulate the expression of MHC I and MHC II genes, thereby promoting the generation of low immunogenic cells. In some embodiments, low immunogenic cells escape immune rejection in allogeneic recipients of MHC mismatches. In some embodiments, when administered (e.g., transplanted or implanted) to an MHC-mismatched allogeneic recipient, the differentiated cells produced by the low immunogenic stem cells outlined herein escape immune rejection. In some embodiments, the low immunogenic cells are protected from T cell-mediated adaptive immune rejection and / or innate immune cell rejection. For detailed descriptions of low immunogenic cells, methods for producing such cells, and methods for using such cells, see WO2016183041, filed May 9, 2015; WO2018132783, filed January 14, 2018; WO2018176390, filed March 20, 2018; WO2020018615, filed July 17, 2019; WO2020018620, filed July 17, 2020; WO20200186391, filed March 20, 2020; WO2020018640, filed July 17, 2020; WO2020018650, filed July 17, 2020; WO2020018666, filed July 17, 2020. PCT / US2020 / 44635, filed July 31, 2020; US62 / 881,840, filed August 1, 2019; US62 / 891,180, filed August 23, 2019; US63 / 016,190, filed April 27, 2020; and US63 / 052,360, filed July 15, 2020, the disclosures of which, including the Examples, Sequence Listing, and Figures, are incorporated herein by reference in their entirety.

[0271] The low immunogenicity of a cell can be determined by evaluating the immunogenicity of the cell (such as the ability of the cell to trigger adaptive and innate immune responses or to avoid triggering such adaptive and innate immune responses). This immune response can be measured using a determination approved by those skilled in the art. In some embodiments, immune response determination measures the impact of low immunogenic cells on T cell proliferation, T cell activation, T cell killing, donor-specific antibody generation, NK cell proliferation, NK cell activation and macrophage activity. In some cases, low immunogenic cells and their derivatives experience reduced T cells and / or NK cell killing after being administered to a subject. In some cases, the cell and its derivatives show reduced macrophage phagocytosis compared to unmodified or wild-type cells. In some embodiments, compared to corresponding unmodified wild-type cells, low immunogenic cells trigger a reduced or weakened immune response in recipient subjects. In some embodiments, low immunogenic cells are non-immunogenic or can not trigger an immune response in recipient subjects.

[0272] In some embodiments, the expression of major histocompatibility (MHC) class I and MHC class II proteins is destroyed in the cell. MHC class I and class II proteins play a role in the adaptive branch of the immune system. The common task of these two types of proteins is to present peptides on the cell surface for T cell recognition. Immunogenic peptide-MHC class I (pMHCI) complexes are presented on nucleated cells and recognized by cytotoxic CD8+ T cells. On the other hand, antigen presenting cells (such as dendritic cells (DC), macrophages or B cells) can activate CD4+ T cells to the presentation of peptide-MHC class II (pMHCII), thereby causing the coordination and regulation of effector cells. In all cases, it is to interact with a given pMHC complex, thereby potentially causing the clonal T cell receptor of continuous cell-cell contact formation and T cell activation.

[0273] In some embodiments, the cells described herein express reduced levels of MHC class I proteins relative to wild-type or control cells. In some embodiments, the cells express reduced levels of MHC class II proteins relative to wild-type or control cells. In some embodiments, the cells express reduced levels of both MHC class I and MHC class II proteins relative to wild-type or control cells.

[0274] In some embodiments, the cell does not express any MHC class I protein. In some embodiments, the cell does not express any MHC class II protein. In some embodiments, the cell does not express any MHC class I protein and does not express any MHC class II protein.

[0275] In some embodiments, the MHC proteins discussed herein are HLA proteins.

[0276] The "HLA," or "human leukocyte antigen," complex is a gene complex that encodes MHC proteins in humans. The cell-surface proteins that make up the HLA complex are responsible for regulating the immune response to antigens. In humans, there are two types of MHC: class I and class II, or "HLA-I" and "HLA-II." HLA-I consists of three proteins: HLA-A, HLA-B, and HLA-C, which present peptides from within the cell. Antigens presented by the HLA-I complex attract killer T cells (also known as CD8+ T cells or cytotoxic T cells). HLA-I proteins are associated with beta-2 microglobulin (B2M). HLA-II consists of five proteins: HLA-DP, HLA-DM, HLA-DOB, HLA-DQ, and HLA-DR, which present antigens from outside the cell to T lymphocytes. HLA-II proteins are associated with class II transactivator (CIITA). This stimulates CD4+ cells (also known as helper T cells). It should be understood that the use of "MHC" or "HLA" is not meant to be limiting, although the term "HLA" generally indicates that the gene is from a human. Therefore, when it comes to mammalian cells, these terms are used interchangeably herein.

[0277] In some embodiments, the expression of MHC II class proteins is reduced by knocking out or reducing the expression of CIITA. In some embodiments, the expression of MHC II class genes is regulated (for example, reduced or eliminated) by targeting and regulating the expression of (for example, reducing or eliminating) class II transactivator (CIITA). In some embodiments, CRISPR / Cas systems are used to regulate. CIITA is a member of LR or nucleotide binding domain (NBD) leucine-rich repeat (LRR) protein family, and is regulated by associating with MHC enhancer to regulate the transcription of MHC II. In some embodiments, the polynucleotide sequence targeted for regulation is a variant of CIITA, a homologue of CIITA, or an orthologue of CIITA.

[0278] In some embodiments, reduction or elimination of expression of CIITA reduces or eliminates expression of one or more of the following MHC class II molecules: HLA-DP, HLA-DM, HLA-DOA, HLA-DOB, HLA-DQ, and HLA-DR.

[0279] In some embodiments, the cell described herein is included in a genetic modification at the locus encoding the CIITA protein. In other words, the cell is included in a genetic modification at the CIITA locus. In some cases, the nucleotide sequence encoding the CIITA protein is shown in RefSeq. numbering NM_000246.4 and NCBI Genbank numbering U18259. In some cases, the CIITA locus is described in NCBI Gene ID numbering 4261. In some cases, the amino acid sequence of CIITA is depicted as NCBI GenBank numbering AAA88861.1. Additional descriptions of the CIITA protein and locus can be found in Uniprot numbering P33076, HGNC reference numbering 7067, and OMIM reference numbering 600005.

[0280] In some embodiments, the low immunogenicity cells outlined herein include the genetic modification of targeting CIITA genes. In some embodiments, the genetic modification of targeting CIITA genes is generated by rare cutting endonucleases, which include the polynucleotides of Cas protein or encoding Cas protein, and at least one for specifically targeting the guidance ribonucleic acid sequence of CIITA genes. In some embodiments, the at least one guidance ribonucleic acid sequence for specifically targeting CIITA genes is selected from the group consisting of the SEQ ID NO:5184-36352 of the table 12 of WO2016183041 (which is incorporated herein by reference). In some embodiments, the cell induces innate and / or adaptive immune response in recipient subjects. In some embodiments, an exogenous nucleic acid encoding a polypeptide as disclosed herein (e.g., chimeric antigen receptor, CD47, or another tolerogenic factor disclosed herein) is inserted at the CIITA gene.

[0281] The determination of whether the CIITA gene has been inactivated is known and described in this article. In some embodiments, the genetic modification of the CIITA gene produced can be confirmed by PCR, and the reduction of HLA-II expression can be confirmed by FACS analysis. In another embodiment, the protein blot of the cell lysate probed with the antibody for CIITA protein is used to detect CIITA protein expression. In another embodiment, the presence of the inactivation genetic modification is confirmed using reverse transcriptase polymerase chain reaction (RT-PCR). In some embodiments, exogenous polynucleotides are inserted into at least one allele of the cell by viral transduction (for example, using a vector). In some embodiments, the vector is a self-inactivation lentiviral vector pseudotyped with exogenous polynucleotides. In some embodiments, the vector is a self-inactivation lentiviral vector pseudotyped with vesicular stomatitis VSV-G envelope and carrying exogenous polynucleotides. In some embodiments, exogenous polynucleotides are inserted into at least one allele of the cell using viral transduction. In some embodiments, exogenous polynucleotides are inserted into at least one allele of the cell using a lentiviral vector based on a lentiviral vector.

[0282] In some embodiments, the expression of MHC class I proteins is reduced by knocking out or reducing the expression of B2M. In some embodiments, the expression of MHC-I genes is regulated (e.g., reduced or eliminated) by targeting and regulating the expression of auxiliary chain B2M. In some embodiments, the CRISPR / Cas system is used for regulation. By regulating (e.g., reducing or missing) the expression of B2M, the surface transport of MHC-I molecules is blocked and the cells exhibit low immunogenicity. In some embodiments, the ability of the cell to induce innate and / or adaptive immune responses in recipient subjects is reduced.

[0283] In some embodiments, the polynucleotide sequence targeted for regulation is a variant of B2M, a homolog of B2M, or an ortholog of B2M.

[0284] In some embodiments, reduction or elimination of expression of B2M reduces or eliminates expression of one or more of the following MHC I molecules: HLA-A, HLA-B, and HLA-C.

[0285] In some embodiments, the cells described herein are included in a genetic modification at a locus encoding a B2M protein. In other words, the cell is included in a genetic modification at a B2M locus. In some cases, the nucleotide sequence encoding the B2M protein is shown in RefSeq. No. NM_004048.4 and Genbank No. AB021288.1. In some cases, the B2M locus is described in NCBI Gene ID No. 567. In some cases, the amino acid sequence of B2M is shown in NCBI GenBank No. BAA35182.1. Additional descriptions of the B2M protein and locus can be found in Uniprot No. P61769, HGNC Reference No. 914, and OMIM Reference No. 109700.

[0286] In some embodiments, the low immunogenicity cells outlined herein include genetic modifications targeting B2M genes. In some embodiments, the genetic modifications targeting B2M genes are generated by rare cutting endonucleases, which include Cas proteins or polynucleotides encoding Cas proteins, and at least one guide ribonucleic acid sequence for specifically targeting B2M genes. In some embodiments, the at least one guide ribonucleic acid sequence for specifically targeting B2M genes is selected from the group consisting of SEQ ID NO:81240-85644 of Table 15 of WO2016183041 (which is incorporated herein by reference). In some embodiments, an exogenous nucleic acid encoding a polypeptide as disclosed herein (e.g., a chimeric antigen receptor, CD47, or another tolerogenic factor disclosed herein) is inserted at the B2M gene. In some embodiments, exogenous polynucleotides are inserted into at least one allele of a cell using viral transduction (e.g., using a vector). In some embodiments, the vector is a pseudotyped self-inactivating lentiviral vector carrying exogenous polynucleotides. In some embodiments, the vector is a self-inactivating lentiviral vector pseudotyped with the vesicular stomatitis virus (VSV)-G envelope and carrying an exogenous polynucleotide. In some embodiments, viral transduction is used to insert the exogenous polynucleotide into at least one allele of the cell. In some embodiments, a lentiviral-based viral vector is used to insert the exogenous polynucleotide into at least one allele of the cell.

[0287] Assays for testing whether the B2M gene has been inactivated are known and described herein. In some embodiments, the genetic modification of the B2M gene produced can be confirmed by PCR, and the reduction of HLA-I expression can be confirmed by FACS analysis. In another embodiment, B2M protein expression is detected using Western blot of cell lysates probed with antibodies against the B2M protein. In another embodiment, the presence of the inactivating genetic modification is confirmed using reverse transcriptase polymerase chain reaction (RT-PCR).

[0288] In some embodiments of the T cells, iPSCs, or ESCs described herein, the T cell receptor alpha chain (TRAC) and / or T cell receptor beta chain (TRBC) genes are knocked out, or their expression in the cell is reduced.

[0289] The T cell receptor (TCR) is a protein complex found on the surface of T cells that recognizes peptide antigen fragments bound to MHC molecules. The TCR is a disulfide-linked, membrane-anchored heterodimeric protein typically composed of highly variable alpha (α) and beta (β) chains (encoded by the TRAC and TRBC genes, respectively), expressed as part of a complex with the invariant CD3 chain molecule. T cells expressing this receptor are known as α:β (or αβ) T cells, but a minority of T cells express alternative receptors formed by variable gamma (γ) and delta (δ) chains and are known as γδ T cells. Each chain consists of two extracellular domains: a variable region and a constant region, both of which are immunoglobulin superfamily (IgSF) domains that form antiparallel β-sheets. The constant region resides near the cell membrane, followed by a transmembrane region and a short cytoplasmic tail, while the variable region binds to the peptide / MHC complex. Knockout of the endogenous TRAC and / or TRBC genes has been reported to increase the expression and function of transgenic T cell receptor-expressing T cells. In some embodiments, the cells described herein express reduced levels of MHC class I protein and / or MHC class II protein relative to wild-type or control cells.

[0290] In some embodiments, the cell comprises increased expression of wild-type and / or engineered CD47 protein relative to wild-type cells or control cells of the same cell type. In some embodiments, the wild-type cell or control cell is the starting material. As used herein, starting material refers to a raw material to which one or more of the modifications described herein are made to produce an engineered CD47 protein as described herein, a polynucleotide encoding an engineered CD47 protein as described herein, a vector as described herein, a cell comprising an engineered CD47 protein as described herein, or a composition comprising an engineered CD47 protein or cell as described herein.

[0291] As used herein, "wild-type cell" or "wt cell" means any cell found in nature. In some embodiments, wild-type cells include primary cells and T cells found in nature. As used herein, "control cells" are cells whose CD47 gene has not been altered but to which other modifications may have been made. In some embodiments, control cells are engineered cells that may contain nucleic acid changes that result in reduced expression of MHC I protein and / or MHC II protein and / or T cell receptor. In some embodiments, control cells are engineered cells in which B2M is knocked out or comprises reduced B2M expression. In some embodiments, control cells are engineered cells in which CIITA is knocked out or comprises reduced CIITA expression. In some embodiments, control cells are engineered cells in which TRAC and / or TRBC are knocked out or comprises reduced TRAC and / or TRBC expression.

[0292] In some embodiments, the control cell is an iPSC, ESC or offspring containing nucleic acid changes that cause pluripotency. In some embodiments, the control cell is an iPSC, ESC or offspring in which B2M is knocked out or the B2M expression comprising reduction is expressed. In some embodiments, the control cell is an iPSC, ESC or offspring in which CIITA is knocked out or the CIITA expression comprising reduction is expressed. In some embodiments, the control cell is an iPSC, ESC or offspring in which TRAC and / or TRBC are knocked out or the TRAC and / or TRBC expression comprising reduction is expressed.

[0293] In some embodiments, the control cell is a primary T cell or progeny containing a nucleic acid change that results in reduced expression of MHC I protein and / or MHC II protein and / or T cell receptor. In some embodiments, the control cell is a primary T cell or progeny in which B2M is knocked out or comprises reduced B2M expression. In some embodiments, the control cell is a primary T cell or progeny in which CIITA is knocked out or comprises reduced CIITA expression. In some embodiments, the control cell is a primary T cell or progeny in which TRAC and / or TRBC are knocked out or comprises reduced TRAC and / or TRBC expression.

[0294] In some embodiments, the starting material is primary cells collected from a donor. In some embodiments, the starting material is, for example, primary blood cells collected from a donor via leukopak. For example, in some embodiments, the starting material is unmodified T cells obtained from a donor. In some embodiments, the starting material is an iPSC cell line. In some embodiments, the starting material is otherwise modified or engineered to have altered expression of one or more genes other than the human CD47 gene.

[0295] In some embodiments, the cell through through engineering approaches and low immunogenicity described is derived from iPSC or its offspring.As used herein, the term "derived from iPSC or its offspring" covers the initial iPSC generated and any subsequent offspring thereof.As used herein, the term "offspring" covers, for example, first generation offspring, i.e., directly derived from, obtained from, obtainable from, or can be derived from the offspring of initial iPSC by, for example, traditional breeding methods. The term "offspring" also covers further generations, such as second generation, third generation, fourth generation, fifth generation, sixth generation, seventh generation or more generations, i.e., derived from, obtained from, obtainable from, or can be derived from the cell generations of previous generations by, for example, traditional breeding methods. The term "offspring" also covers the modified cells produced due to the modification or change of initial iPSC or its offspring.

[0296] In some embodiments, knocking down (for example, reducing, eliminating or suppressing) gene expression can be achieved by RNA silencing or RNA interference (RNAi). Useful RNAi methods include methods utilizing synthetic RNAi molecules, short interfering RNA (siRNA), PIWI interaction NRA (piRNA), short hairpin RNA (shRNA), microRNA (miRNA), and other transient knocking down methods recognized by those skilled in the art. Reagents for RNAi including sequence-specific shRNA, siRNA, miRNA, etc. are commercially available.

[0297] As used herein, the term "engineered cell" refers to a cell that has been altered in at least some way by human intervention, including, for example, by genetic alteration or modification, such that the engineered cell differs from a wild-type cell.

[0298] The terms "decrease," "reduced," "reduction," and "decreased" are all generally used herein to mean a decrease in a statistically significant amount. However, for the avoidance of doubt, "decrease," "reduced," "reduction," "decreased" means a decrease of at least 10% compared to a reference level, such as at least about 20% compared to a reference level, or at least about 30%, or at least about 40%, or at least about 50%, or at least about 60%, or at least about 70%, or at least about 80%, or at least about 90% or up to and including a 100% decrease (i.e., a level that is absent compared to a reference sample) or any decrease between 10-100%. In some embodiments, cells are engineered to have expression of one or more targets that is reduced relative to unaltered or unmodified wild-type cells.

[0299] In some embodiments, the modified cells provided are modified so that they can escape immune recognition and reaction when being administered to a patient (e.g., a recipient subject). The cell can escape the killing of immune cells in vitro and in vivo. In some embodiments, the cell escapes the killing of macrophages and NK cells. In some embodiments, the cell is ignored by immune cells or the immune system of the experimenter. In other words, the cells used according to the methods described herein can not be detected by the immune cells of the immune system. In some embodiments, the cell is shielded and therefore avoids immune rejection.

[0300] Methods for determining whether the modified cells provided herein escape immune recognition include, but are not limited to, IFN-γ Elispot assays, microglial killing assays, cell implantation animal models, cytokine release assays, ELISA, killing assays using bioluminescence imaging or chromium release assays or Xcelligence analysis, mixed lymphocyte reaction, immunofluorescence analysis, and the like.

[0301] In some embodiments, the immunogenicity of cells is evaluated in a complement-dependent cytotoxicity (CDC) assay. CDC can be measured in vitro by incubating cells with IgG or IgM antibodies against HLA-independent antigens expressed on the cell surface in the presence of complement-containing serum and analyzing cell killing. In some embodiments, CDC can be measured by incubating cells with ABO-incompatible serum, wherein the cells comprise A antigens or B antigens, and the serum comprises antibodies against the A antigens and / or B antigens of the cells.

[0302] In some embodiments, once the modified cells are modified or generated as described herein, their low immunogenicity can be determined. Any of a variety of assays can be used to assess whether a cell has low immunogenicity or can evade the immune system. Exemplary assays include any assays described in WO2016183041 and WO2018132783.

[0303] In some embodiments, the modified cells described herein survive in the host for one week or longer (e.g., one week, two weeks, one month, two months, three months, six months, one year, two years, three years, four years, five years or longer, e.g., the lifetime of the cell and / or its offspring) without stimulating a host immune response. As long as the cell survives in the host, the cell maintains expression of the transgene and / or expression of the target gene in the cell is deleted or reduced. In some aspects, if the transgene is no longer expressed and / or if the target gene is expressed, the modified cell can be removed by the host's immune system. In some embodiments, after the modified cells are administered to a recipient, the persistence or survival of the modified cells can be monitored by further expressing a transgene encoding a protein that allows the cell to be detected in vivo (e.g., a fluorescent protein (such as GFP), a truncated receptor or other alternative marker or other detectable marker).

[0304] Low immunogenic cells are used in a manner that allows them to be implanted into the expected tissue site and to rebuild the functional defect area or to regenerate the functional defect area. In some embodiments, the implantation (for example, successful implantation) of low immunogenic cells is measured. In some embodiments, the implantation of low immunogenic cells is evaluated after the preselected amount of time. In some embodiments, the cell survival of the cells implanted is monitored. For example, cell survival can be monitored via bioluminescence imaging (BLI), wherein cells are transduced with luciferase expression constructs to monitor cell survival. In some embodiments, the implanted cells are visualized by immunostaining and imaging methods known in the art. In some embodiments, the implanted cells express known biomarkers, which can be detected to determine successful implantation. For example, flow cytometry can be used to determine the surface expression of specific biomarkers. In some embodiments, low immunogenic cells are implanted into the expected tissue site (for example, the successful implantation of low immunogenic cells) as expected. In some embodiments, low immunogenic cells are implanted into the expected tissue site as required, such as implanted at the cell defect site. In some embodiments, low immunogenic cells are implanted into the expected tissue site in the same manner as cells of the same type that do not comprise modification.

[0305] In some embodiments, administration of a modified cell population (e.g., modified beta islet cells comprising modifications including reduced CD142 expression) or a combination (e.g., administration of a modified cell population in combination with an anticoagulant) improves survival and engraftment by allowing the cells to avoid or reduce IBMIR that occurs due to exposure of the cells to blood during transplantation. In some embodiments, reduction in IBMIR reduces the amount of cell loss (e.g., loss of transplanted islets) that occurs during transplantation.

[0306] In some embodiments, the function of low immunogenic cells is measured. In some embodiments, before low immunogenic cells are implanted into the expected tissue site, their function is measured. In some embodiments, after low immunogenic cells are implanted into the expected tissue site, their function is measured. In some embodiments, the function of low immunogenic cells is evaluated after a preselected amount. In some embodiments, the function of the implanted cells is evaluated by the ability of the cells to produce a detectable phenotype. For example, the function of the implanted β islet cells can be evaluated based on the recovery of the glucose loss control caused by diabetes. In some embodiments, the function of low immunogenic cells is as expected (for example, low immunogenic cells successfully play a role while avoiding antibody-mediated rejection). In some embodiments, the function of low immunogenic cells is as needed, such as having enough function at the cell defect site while avoiding antibody-mediated rejection. In some embodiments, modified cells play a role in the same manner as the non-modified cells of the same type.

[0307] Immediate blood-mediated inflammatory response

[0308] In some embodiments, the modified cells provided herein escape immediate blood-mediated inflammatory response. A major cause of poor clinical islet transplantation outcomes is the occurrence of destructive immediate blood-mediated inflammatory response (IBMIR), which causes the loss of transplanted tissue when islets encounter blood in the portal vein (Bennet et al., (1995) Diabetes 48:1907-1914; Moberg et al., (2002) Lancet 360:2039-2045). This response is triggered by the expression of tissue factor (TF) by endocrine cells of the islets in combination with a series of other proinflammatory events, such as expression of MCP-1 (Piemonti et al., (2002) Diabetes 51:55-65), IL-8, and MIF (Waeber et al., (1997) Proc Natl Acad Sci USA 94:4782-4787; Johansson et al., (2006) Am J Transplantation 6(2):305).

[0309] Immediate blood-mediated inflammatory response (IBMIR) is a nonspecific inflammatory and thrombotic reaction that can occur when cells expressing CD142 come into contact with blood. IBMIR is rapidly initiated by human blood exposed to the portal vein. It is characterized by activation of complement, platelets, and coagulation pathways, which in turn leads to the recruitment of neutrophils. IBMIR results in a significant loss of transplanted islets. In some embodiments, provided herein are compositions (e.g., modified cells comprising reduced expression of CD142 and a combination of one or more other modifications described herein), combinations (e.g., combinations comprising any modified cell population in a modified cell population described herein and an anticoagulant that reduces coagulation), and methods for reducing IBMIR associated with cell transplantation or cell exposure to blood (e.g., methods for treating patients, the methods comprising administering any modified cell population in a modified cell population described herein and an anticoagulant that reduces coagulation).

[0310] In some embodiments, IBMIR can be measured in vitro, for example, in an in vitro tubing loop model of IBMIR, which has been previously described in US Pat. No. 7,045,502, which is incorporated herein by reference in its entirety.

[0311] In some embodiments, IBMIR can be measured in vivo (e.g., in mammals or in human patients) by drawing a blood sample during the peri-transplant period and evaluating the following plasma levels: thrombin-antithrombin III complex (TAT), C-peptide, XIa factor-antithrombin (FXIa-AT), XIIa factor-antithrombin (FXIIa-AT), thrombin-antithrombin (TAT) plasmin-α2 antiplasmin (PAP) and / or complement C3a. In some embodiments, IBMIR is associated with an increase in the level of TAT, C-peptide, FXIa-AT, FXIIa-AT, PAP and / or complement C3a during the infusion of the transplanted cells and / or in a post-transplant period (e.g., up to 3, 5, 10 or more than 10 hours after transplantation). In some embodiments, IBMIR can be measured by monitoring the count of free circulating platelets, wherein a decrease in platelet count during or after transplantation is associated with IBMIR (e.g., associated with platelet consumption caused by IBMIR).

[0312] Complement-dependent cytotoxicity

[0313] In some embodiments, the modified cells provided herein (e.g., beta islets) escape complement-dependent cytotoxicity (CDC). In some embodiments, CDC is secondary to a thrombotic reaction to IBMIR. In some embodiments, CDC occurs independently of IBMIR.

[0314] In some embodiments, the sensitivity of cells to CDC can be analyzed according to standard protocols understood by those of ordinary skill in the art. In some embodiments, CDC can be analyzed in vitro by mixing serum (e.g., human serum) comprising complement system components with target cells bound by antibodies (e.g., IgG or IgM antibodies) and then determining cell death. In some embodiments, the sensitivity of cells to CDC can be analyzed in vitro by incubating cells in the presence of ABO-incompatible or Rh factor-incompatible serum, the serum comprising components of the complement system and antibodies to the ABO A type, ABO B type, and / or Rh factor antigens of the cells.

[0315] Common CDC assays determine cell death by preloading target cells with radioactive compounds. When cells die, the radioactive compound is released from them. Therefore, the efficacy of the antibody-mediated cell death is determined by the level of radioactivity. Unlike radioactive CDC assays, non-radioactive CDC assays typically determine the release of a large number of cellular components (such as GAPDH) through fluorescence or luminescence assays. In some embodiments, label-free platforms (such as xCELLigence) can be used. TM (Agilent)) to analyze cell killing by CDC.

[0316] VI. Composition

[0317] In another aspect, the present disclosure provides a composition comprising an engineered CD47 protein disclosed herein.

[0318] In another aspect, the present disclosure provides compositions comprising cells comprising a polynucleotide encoding an engineered CD47 protein disclosed herein, and / or a vector comprising the polynucleotide.

[0319] As used herein, the term "composition" includes but is not limited to pharmaceutical compositions." pharmaceutical composition " refers to an active agent for being formulated into a pharmaceutically acceptable or physiologically acceptable solution for being administered to a cell or animal alone or in combination with one or more other therapeutic modalities. It should also be understood that, if necessary, the compositions of the present invention can be administered in combination with other agents (such as, for example, cytokines, growth factors, hormones, small molecules, chemotherapeutic agents, prodrugs, drugs, antibodies or other various pharmaceutically active agents). There is almost no restriction on other components that can also be included in the composition, as long as these other agents do not adversely affect the ability of the composition to deliver the intended therapy. The term "pharmaceutically acceptable" is used herein to refer to being suitable for contacting the tissues of humans and animals within the scope of reasonable medical judgment, without excessive toxicity, irritation, allergic response or other problems or complications and with those compounds, materials, compositions and / or dosage forms of a reasonable benefit / risk ratio.

[0320] The composition may further comprise a pharmaceutically acceptable carrier, diluent, or excipient. As used herein, "pharmaceutically acceptable carrier, diluent, or excipient" includes, but is not limited to, any adjuvant, carrier, excipient, glidant, sweetener, diluent, preservative, dye / colorant, flavor enhancer, surfactant, wetting agent, dispersant, suspending agent, stabilizer, isotonic agent, solvent, surfactant, or emulsifier approved by the United States Food and Drug Administration for use in humans or livestock. Exemplary pharmaceutically acceptable carriers include, but are not limited to, sugars such as lactose, glucose, and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethylcellulose, ethylcellulose, and cellulose acetate; gum tragacanth; malt; gelatin; talc; cocoa butter; waxes; animal and vegetable fats; paraffins; silicones; bentonite; silicic acid; zinc oxide; oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and soybean oil; glycols such as propylene glycol; polyols such as glycerol, sorbitol, mannitol, and polyethylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffers such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethanol; phosphate buffered saline; and any other compatible substance used in pharmaceutical formulations.

[0321] Liquid pharmaceutical compositions, whether solutions, suspensions or other similar forms, may contain one or more of the following: sterile diluents such as water for injection, saline solutions, preferably physiological saline; Ringer's solution; isotonic sodium chloride; fixed oils such as synthetic mono- or diglycerides that can be used as solvents or suspending media; polyethylene glycol; glycerol; propylene glycol or other solvents; antibacterial agents such as benzyl alcohol or methylparaben; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates; and agents for adjusting tonicity such as sodium chloride or dextrose. Parenteral preparations may be packaged in ampoules, disposable syringes or multiple-dose vials made of glass or plastic. Injectable pharmaceutical compositions are preferably sterile.

[0322] The compositions may be suitably developed for intravenous, intratumoral, oral, rectal, vaginal, parenteral, topical, pulmonary, intranasal, buccal, ocular or other routes of administration.

[0323] VII. Gene Editing Methods

[0324] In some embodiments, methods for genetically modifying cells to knock out, knock down, or otherwise modify one or more genes include the use of site-directed nucleases, including, for example, zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), meganucleases, transposases, and clustered regularly interspaced short palindromic repeats (CRISPR) / Cas systems, as well as nickase systems, base editing systems, prime editing systems, and any other gene editing systems known in the art.

[0325] ZFN is a fusion protein comprising a series of site-specific DNA binding domains that are modified from zinc finger transcription factors connected to the endonuclease domain of the bacterial FokI restriction enzyme. ZFN can have one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) DNA binding domains or zinc finger domains. See, for example, Carroll et al., Genetics Society of America (2011) 188: 773-782; Kim et al., Proc. Natl. Acad. Sci. USA (1996) 93: 1156-1160. A single DNA binding domain is commonly referred to as a "finger" or "zinc finger". Each zinc finger domain is a small protein structural motif stabilized by one or more zinc ions and typically recognizes a DNA sequence of 3 to 4 bp. Therefore, the tandem domain can potentially bind to a unique extended nucleotide sequence within the cell genome. Each finger binds two to four DNA base pairs, typically three or four DNA base pairs. The DNA binding domain binds to a nucleic acid sequence known as a target site or target segment. Each finger typically contains a zinc-chelating DNA-binding subdomain of approximately 30 amino acids. Studies have shown that this type of single zinc finger consists of an alpha helix containing two invariant histidine residues that coordinate zinc and two cysteine ​​residues in a single beta turn (see, e.g., Berg and Shi, Science 271: 1081-1085 (1996)).

[0326] Various zinc fingers with known specificities can be combined to produce multi-fingered polypeptides that recognize sequences of about 6, 9, 12, 15, or 18 bp. Various selection and modular assembly techniques can be used to generate zinc fingers (and combinations thereof) that recognize specific sequences, including phage display, yeast one-hybrid systems, bacterial one-hybrid and two-hybrid systems, and mammalian cells. Zinc fingers can be engineered to bind to predetermined nucleic acid sequences. Standards for engineering zinc fingers to bind to predetermined nucleic acid sequences are known in the art. See, for example, Sera et al., Biochemistry (2002) 41: 7074-7081; Liu et al., Bioinformatics (2008) 24: 1850-1857.

[0327] ZFNs containing FokI nuclease domains or other dimeric nuclease domains function as dimers. Therefore, a pair of ZFNs is needed to target non-palindromic DNA sites. Two separate ZFNs must bind to the opposite strands of DNA with their appropriately spaced nucleases. See Bitinaite et al., Proc. Natl. Acad. Sci. USA (1998) 95: 10570-10575. In order to cut a specific site in the genome, a pair of ZFNs are designed to recognize two sequences flanking the site, one on the forward strand and the other on the reverse strand. After the ZFN binds on either side of the site, the nuclease domain dimerizes and cuts the DNA at the site, thereby generating a DSB with a 5' overhang. Specific mutations can then be introduced using HDR with the aid of a repair template containing the desired mutation flanked by homology arms. The repair template is typically an exogenous double-stranded DNA vector introduced into the cell. See Miller et al., Nat. Biotechnol. (2011) 29: 143-148; Hockemeyer et al., Nat. Biotechnol. (2011) 29: 731-734.

[0328] TALEN is another example of an artificial nuclease that can be used to edit a target gene. "TALE nuclease" (TALEN) is a fusion protein consisting of a nucleic acid binding domain generally derived from a transcription activator-like effector (TALE) and a nuclease catalytic domain for cutting a nucleic acid target sequence. The catalytic domain is preferably a nuclease domain, and more preferably a domain with endonuclease activity, such as I-TevI, ColE7, NucA and Fok-I. In various embodiments, the TALE domain can be fused to a large range of nucleases, such as I-CreI and I-Onul or functional variants thereof. In a more preferred embodiment, the nuclease is a monomeric TALE nuclease. Monomeric TALE nucleases are TALE nucleases that do not require dimerization for specific recognition and cutting, such as a fusion of the engineered TAL repeat sequence described in WO2012138927 with the catalytic domain of I-TevI.

[0329] Transcription activator-like effectors (TALEs) are proteins from the bacterial species Xanthomonas and contain multiple repeated sequences. Each repeat sequence is 33 to 35 amino acids in length, with two adjacent amino acids in positions 12 and 13 (called repeat variable diresidues or RVDs) that are specific for each nucleotide base of the sequence targeted by the nucleic acid. Binding domains with similar modular base-by-base nucleic acid binding properties (MBBBDs) can also be derived from new modular proteins recently discovered in different bacterial species. This new modular protein has the advantage of exhibiting more sequence variability than TAL repeat sequences. Preferably, the RVDs associated with recognition of different nucleotides are HD for recognizing C; NG for recognizing T; NI for recognizing A; NN for recognizing G or A; NS for recognizing A, C, G, or T; HG for recognizing T; IG for recognizing T; NK for recognizing G; HA for recognizing C; ND for recognizing C; HI for recognizing C; HN for recognizing G; NA for recognizing G; SN for recognizing G or A; and YG for recognizing T; TL for recognizing A; VT for recognizing A or G; and SW for recognizing A. In another embodiment, key amino acids 12 and 13 can be mutated to other amino acid residues in order to adjust their specificity for the nucleotides A, T, C, and G, and in particular, to enhance such specificity. TALEN kits are commercially available.

[0330] TALENs are artificially generated by fusing one or more TALE DNA binding domains (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) to a nuclease domain (e.g., a FokI endonuclease domain). See Zhang, Nature Biotech. (2011) 29: 149-153. In order to use FokI in TALENs, several mutations have been made to FokI; for example, these mutations improve cleavage specificity or activity. See Cermak et al., Nucl. Acids Res. (2011) 39:e82; Miller et al., Nature Biotech. (2011) 29:143-148; Hockemeyer et al., Nature Biotech. (2011) 29:731-734; Wood et al., Science (2011) 333:307; Doyon et al., Nature Methods (2010) 8:74-79; Szczepek et al., Nature Biotech (2007) 25:786-793; Guo et al., J. Mol. Biol. (2010) 200:96. The FokI domain functions as a dimer, and two constructs with distinct DNA binding domains are required to target sites in the genome with the correct orientation and spacing. The number of amino acid residues between the TALE DNA binding domain and the FokI nuclease domain, as well as the number of bases between two individual TALEN binding sites, appear to be important parameters for achieving high levels of activity. Miller et al., Nature Biotech. (2011) 29: 143-148.

[0331] By combining engineered TALE repeats with nuclease domains, site-specific nucleases specific for any desired DNA sequence can be produced. Similar to ZFNs, TALENs can be introduced into cells to generate DSBs at desired target sites in the genome, and therefore can be used to knock out genes or knock in mutations with similar HDR-mediated pathways. See Boch, Nature Biotech. (2011) 29: 135-136; Boch et al., Science (2009) 326: 1509-1512; Moscou et al., Science (2009) 326: 3501.

[0332] Meganucleases are sequence-specific enzymes in the endonuclease family, characterized by their ability to recognize and cleave large DNA sequences (14 to 40 base pairs). (Chevalier, BS and BL S Toddard, Nucleic Acids Res., 2001, 29, 3757-3774). They can cleave unique sites in living cells, thereby enhancing gene targeting near the cleavage site by 1000-fold or more (Puchta et al., Nucleic Acids Res., 1993, 21, 5034-5040; Rouet et al., Mol. Cell. Biol., 1994, 14, 8096-8106; Choulika et al., Mol. Cell. Biol., 1995, 15, 1968-1973; Puchta et al., Proc. Natl. Acad. Sci. USA, 1996, 93, 5055-5060; Sargent ... Sargent et al., Nucleic Acids Res., 1993, 21, 5034-5040; Rouet et al., Mol. Cell. Bio et al., Mol. Cell. Biol., 1997, 17, 267-77; Donoho et al., Mol. Cell. Biol., 1998, 18, 4070-4078; Elliott et al., Mol. Cell. Biol., 1998, 18, 93-101; Cohen-Tannoudji et al., Mol. Cell. Biol., 1998, 18, 1444-1448).

[0333] Based on the structural motifs that affect nuclease activity and / or DNA recognition of meganucleases, meganucleases are divided into multiple families. The most extensive and famous meganucleases are proteins in the LAGLIDADG family, whose names are derived from conserved amino acid sequences. See Chevalier et al., Nucleic Acids Res. (2001) 29 (18): 3757-3774. On the other hand, GIY-YIG family members have a GIY-YIG module with a length of 70-100 residues and include four or five conserved sequence motifs with four invariant residues, two of which are required for activity. See Van Roey et al., Nature Struct. Biol. (2002) 9: 806-811. The His-Cys family meganucleases are characterized by a series of highly conserved histidines and cysteines in a region covering hundreds of amino acid residues. See Chevalier et al., Nucleic Acids Res. (2001) 29(18):3757-3774. Members of the NHN family are defined by a motif containing two pairs of conserved histidines surrounded by asparagine residues. See Chevalier et al., Nucleic Acids Res. (2001) 29(18):3757-3774.

[0334] Because of the high specificity requirement, the chance of identifying a natural meganuclease for a particular target DNA sequence is low, and therefore various methods, including mutagenesis and high-throughput screening methods, have been used to generate meganuclease variants that recognize unique sequences. Strategies for engineering meganucleases with altered DNA binding specificity (e.g., to bind to a predetermined nucleic acid sequence) are known in the art. See, e.g., Chevalier et al., Mol. Cell. (2002) 10:895-905; Epinat et al., Nucleic Acids Res (2003) 31:2952-2962; Silva et al., J Mol. Biol. (2006) 361:744-754; Seligman et al., Nucleic Acids Res (2002) 30:3870-3879; Sussman et al., J Mol Biol (2004) 342:31-41; Doyon et al., J Am Chem Soc (2006) 128:2477-2484; Chen et al., Protein Eng Des Sel (2009) 22:249-256; Arnould et al., J Mol Biol (2008) 34:350-357; Biol. (2006) 355:443-458; Smith et al., Nucleic Acids Res. (2006) 363(2):283-294.

[0335] Like ZFN and TALEN, meganucleases can generate DSBs in genomic DNA. If improperly repaired (e.g., via NHEJ), it can produce frameshift mutations, thereby reducing the expression of the target gene in the cell. Alternatively, foreign DNA can be introduced into the cell together with the meganuclease. Depending on the sequence of the foreign DNA and the chromosomal sequence, this process can be used to modify the target gene. See Silva et al., Current Gene Therapy (2011) 11: 11-27.

[0336] Transposase is an enzyme that is attached to the end of a transposon and catalyzes the transposon to move to another part of the genome by a cut and paste mechanism or a replicative transposition mechanism. By connecting transposase to other systems (such as CRISPER / Cas systems), new gene editing tools can be developed to achieve site-specific insertion or operation of genomic DNA. There are two known DNA integration methods using transposons, which use catalytically inactive Cas effector proteins and Tn7-like transposons. Transposase-dependent DNA integration does not cause DSB in the genome, which can ensure safer and more specific DNA integration.

[0337] The CRISPR system, originally discovered in prokaryotes (e.g., bacteria and archaea) as a form of acquired immunity involved in defense against invading phages and plasmids, has now been adapted and used as a popular gene-editing tool in research and clinical applications.

[0338] CRISPR / Cas systems typically consist of at least two components: one or more guide RNAs (gRNAs) and a Cas protein. The Cas protein is a nuclease that introduces DSBs into the target site. There are two main categories of CRISPR-Cas systems: Type 1 systems use a complex of multiple Cas proteins to degrade nucleic acids; Type 2 systems use a single, large Cas protein to achieve the same goal. Type 1 systems are divided into types I, III, and IV; Type 2 systems are divided into types II, V, and VI. Different Cas proteins suitable for gene editing applications include, but are not limited to, Cas3, Cas4, Cas5, Cas8a, Cas8b, Cas8c, Cas9, Cas10, Cas12, Cas12a (Cpf1), Cas12b (C2c1), Cas12c (C2c3), Cas12d (CasY), Cas12e (CasX), Cas12f (C2c10), Cas12g, Cas12h, Cas12i, Cas12k (C2c5), Cas13, Cas13a (C2c2), Cas13b, Cas13c, Cas13d, C2c4, C2c8, C2c9, Cmr5, Cse1, Cse2, Csf1, Csm2, Csn2, Csx10, Csx11, Csy1, Csy2, Csy3, and Mad7. The most widely used Cas9 is described herein as exemplary. These Cas proteins can be derived from different source species. For example, Cas9 can be derived from Streptococcus pyogenes (S. pyogenes) or Staphylococcus aureus (S. aureus).

[0339] In the original microbial genome, the type II CRISPR system incorporates sequences from invading DNA into the host genome between CRISPR repeats encoded as an array. Transcripts from the CRISPR repeat array are processed into CRISPR RNA (crRNA), each of which carries a variable sequence transcribed from the invading DNA (called a "protospacer" sequence) and a portion of the CRISPR repeat sequence. Each crRNA hybridizes with a second trans-activated CRISPR RNA (tracrRNA), and the two RNAs form a complex with the Cas9 nuclease. The protospacer-encoding portion of the crRNA guides the Cas9 complex to cut the complementary target DNA sequence, provided that the sequence is adjacent to a short sequence called a "protospacer adjacent motif" (PAM).

[0340] Since its discovery, the CRISPR system has been modified to induce sequence-specific DSBs and targeted genome editing in a wide range of cells and organisms from bacteria to eukaryotic cells (including human cells). In its use in gene editing applications, artificially designed synthetic gRNAs have replaced the original crRNA:tracrRNA complex. For example, gRNA can be a single guide RNA (sgRNA) consisting of crRNA, tetracyclic and tracrRNA. crRNA generally includes a complementary region (also referred to as a spacer, generally about 20 nucleotides in length) designed by the user to identify the target DNA of interest. The tracrRNA sequence includes a scaffold region for Cas nuclease binding. The crRNA sequence and the tracrRNA sequence are connected by tetracyclics and each have a short repeat sequence for hybridizing to each other, thereby generating a chimeric sgRNA. The genomic target of the Cas nuclease can be changed by simply changing the spacer or complementary region sequence present in the gRNA. The complementary region will guide the Cas nuclease to the target DNA site by standard RNA-DNA complementary base pairing rules.

[0341] In order for the Cas nuclease to work, a PAM must be present immediately downstream of the target sequence in the genomic DNA. Recognition of the PAM by the Cas protein is thought to destabilize the adjacent genomic sequence, allowing the gRNA to interrogate the sequence and resulting in gRNA-DNA pairing when a matching sequence is present. The specific sequence of the PAM varies depending on the type of Cas gene. For example, the most commonly used Cas9 nuclease derived from Streptococcus pyogenes recognizes a PAM sequence of 5'-NGG-3', or with lower efficiency a PAM sequence of 5'-NAG-3', where "N" can be any nucleotide. Other Cas nuclease variants with alternative PAMs have also been characterized and successfully used for genome editing, which are summarized in Table 4 below.

[0342] Table 4. Exemplary Cas nuclease variants and their PAM sequences

[0343] CRISPR nucleases Source organism PAM sequence (5'→3') SpCas9 Streptococcus pyogenes NGG or NAG SaCas9 Staphylococcus aureus NGRRT or NGRRN NmeCas9 Neisseria meningitidis NNNNGATT CjCas9 Campylobacter jejuni NNNNRYAC StCas9 Streptococcus thermophilus NNAGAAW TdCas9 Treponema denticola NAAAAC LbCas12a(Cpf1) Lachnospiraceae bacterium TTTV AsCas12a(Cpf1) Acidaminococcus sp. TTTV AacCas12b Alicyclobacillus acidiphilus TTN BhCas12b v4 Bacillus hisashii ATTN, TTTN, or GTTN

[0344] R = A or G; Y = C or T; W = A or T; V = A or C or G; N = any base

[0345] In some embodiments, the Cas nuclease may comprise one or more mutations to alter their activity, specificity, recognition, and / or other characteristics. For example, the Cas nuclease may have one or more mutations that alter its fidelity to mitigate off-target effects (e.g., eSpCas9, SpCas9-HF1, HypaSpCas9, HeFSpCas9, and evoSpCas9 high-fidelity variants of SpCas9). For another example, the Cas nuclease may have one or more mutations that alter its PAM specificity.

[0346] The nuclease domain of Cas (particularly Cas9) nuclease can be independently mutated to generate an enzyme known as DNA "nickase". Nickase can introduce single-stranded cleavage with the same specificity as conventional CRISPR / Cas nuclease systems (including, for example, CRISPR / Cas9). Nickase can be used to generate double-strand breaks that can be used in gene editing systems (Mali et al., Nat Biotech, 31 (9): 833-838 (2013); Mali et al., Nature Methods, 10: 957–963 (2013); Mali et al., Science, 339 (6121): 823-826 (2013)). In some cases, when two Cas nickases are used, long overhangs are generated on each cleaved end rather than blunt ends, allowing additional control over precise gene integration and insertion (Mali et al., Nat Biotech, 31(9):833-838 (2013); Mali et al., Nature Methods, 10:957–963 (2013); Mali et al., Science, 339(6121):823-826 (2013)). Because both nicking Cas enzymes must efficiently cleave their target DNA, paired nicking enzymes can have lower off-target effects compared to systems based on double-stranded nicking Cas (Ran et al., Cell, 155(2):479-480 (2013); Mali et al., Nat Biotech, 31(9):833-838 (2013); Mali et al. Nature Methods, 10:957–963 (2013); Mali et al., Science, 339(6121):823-826 (2013)).

[0347] The molecular mechanism that allows the CRISPR / Cas system to change the target polynucleotide sequence in the cell of such Cas proteins includes RNA binding proteins, endonucleases and exonucleases, helicases and polymerases. In some embodiments, the CRISPR / Cas system includes Cas proteins and at least one to two ribonucleic acids that can guide the Cas protein to the target motif of the target polynucleotide sequence and hybridize therewith. As used herein, "protein" and "polypeptide" can be used interchangeably to refer to a series of amino acid residues (i.e., polymers of amino acids) connected by peptide bonds, and include modified amino acids (e.g., phosphorylation, saccharification, glycosylation, etc.) and amino acid analogs. Exemplary polypeptides or proteins include gene products, naturally occurring proteins, homologues, paralogues, fragments and other equivalents, variants and analogs of the above-mentioned items.

[0348] In some embodiments, the Cas protein comprises one or more amino acid substitutions or modifications. In some embodiments, the one or more amino acid substitutions include conservative amino acid substitutions. In some cases, substitutions and / or modifications can prevent or reduce proteolytic degradation and / or extend the half-life of the polypeptide in the cell. In some embodiments, the Cas protein may include peptide bond replacements (e.g., urea, thiourea, carbamate, sulfonylurea, etc.). In some embodiments, the Cas protein may include naturally occurring amino acids. In some embodiments, the Cas protein may include alternative amino acids (e.g., D-amino acids, β-amino acids, homocysteine, phosphoserine, etc.). In some embodiments, the Cas protein may include modifications (e.g., pegylation, glycosylation, lipidation, acetylation, end-capping, etc.) incorporated into a moiety.

[0349] In some embodiments, the Cas protein comprises a core Cas protein, an isoform thereof, or any Cas-like protein having a similar function or activity of any Cas protein or its isoform. In some embodiments, the Cas protein comprises a core Cas protein. Exemplary Cas core proteins include, but are not limited to, Cas1, Cas2, Cas3, Cas4, Cas5, Cas6, Cas7, Cas8, and Cas9. In some embodiments, the Cas protein comprises a V-type Cas protein. In some embodiments, the Cas protein comprises a Cas protein of the Escherichia coli (E. coli) subtype (also referred to as CASS2). Exemplary Cas proteins of the E. coli subtype include, but are not limited to, Cse1, Cse2, Cse3, Cse4, and Cas5e. In some embodiments, the Cas protein comprises a Cas protein of the Ypest subtype (also referred to as CASS3). Exemplary Cas proteins of the Ypest subtype include, but are not limited to, Csy1, Csy2, Csy3, and Csy4. In some embodiments, the Cas protein comprises a Cas protein of the Nmeni subtype (also referred to as CASS4). Exemplary Cas proteins of the Nmeni subtype include, but are not limited to, Csn1 and Csn2. In some embodiments, the Cas protein comprises a Cas protein of the Dvulg subtype (also known as CASS1). Exemplary Cas proteins of the Dvulg subtype include Csd1, Csd2, and Cas5d. In some embodiments, the Cas protein comprises a Cas protein of the Tneap subtype (also known as CASS7). Exemplary Cas proteins of the Tneap subtype include but are not limited to Cst1, Cst2, and Cas5t. In some embodiments, the Cas protein comprises a Cas protein of the Hmari subtype. Exemplary Cas proteins of the Hmari subtype include but are not limited to Csh1, Csh2, and Cas5h. In some embodiments, the Cas protein comprises a Cas protein of the Apern subtype (also known as CASS5). Exemplary Cas proteins of the Apern subtype include but are not limited to Csa1, Csa2, Csa3, Csa4, Csa5, and Cas5a. In some embodiments, the Cas protein comprises a Cas protein of the Mtube subtype (also known as CASS6). Exemplary Cas proteins of the Mtube subtype include but are not limited to Csm1, Csm2, Csm3, Csm4, and Csm5. In some embodiments, the Cas protein includes a RAMP module Cas protein. Exemplary RAMP module Cas proteins include, but are not limited to, Cmr1, Cmr2, Cmr3, Cmr4, Cmr5, and Cmr6. See, for example, Klompe et al., Nature 571, 219–225 (2019); Strecker et al., Science 365, 48–53 (2019).Examples of Cas proteins include, but are not limited to, Cas3, Cas8a, Cas5, Cas8b, Cas8c, Cas10d, Cse1, Cse2, Csy1, Csy2, Csy3, and / or GSU0054. In some embodiments, Cas proteins include Cas3, Cas8a, Cas5, Cas8b, Cas8c, Cas10d, Cse1, Cse2, Csy1, Csy2, Csy3, and / or GSU0054. Examples of Cas proteins include, but are not limited to, Cas9, Csn2, and / or Cas4. In some embodiments, Cas proteins include, but are not limited to, Cas10, Csm2, Cmr5, Cas10, Csx11, and / or Csx10. In some embodiments, Cas proteins include, but are not limited to, Cas10, Csm2, Cmr5, Cas10, Csx11, and / or Csx10. In some embodiments, examples of Cas proteins include, but are not limited to, Csf1. In some embodiments, Cas proteins include Csf1. In some embodiments, examples of Cas proteins include, but are not limited to, Cas12a, Cas12b, Cas12c, C2c4, C2c8, C2c5, C2c10, and C2c9; and CasX (Cas12e) and CasY (Cas12d). See also, for example, Koonin et al., Curr Opin Microbiol. 2017; 37: 67-78: “Diversity, classification and evolution of CRISPR-Cas systems”. In some embodiments, Cas proteins include Cas12a, Cas12b, Cas12c, Cas12d, Cas12e, Cas12d, and / or Cas12e. In some embodiments, Cas proteins include Cas13, Cas13a, C2c2, Cas13b, Cas13c, and / or Cas13d.In some embodiments, the CRISPR / Cas system includes a Cas effector protein selected from the group consisting of: a) Cas3, Cas8a, Cas5, Cas8b, Cas8c, Cas10d, Cse1, Cse2, Csy1, Csy2, Csy3, and GSU0054; b) Cas9, Csn2, and Cas4; c) Cas10, Csm2, Cmr5, Cas10, Csx11, and Csx10; d) Csf1; e) Cas12a, Cas12b, Cas12c, C2c4, C2c8, C2c5, C2c10, C2c9, CasX (Cas12e), and CasY (Cas12d); and f) Cas13, Cas13a, C2c2, Cas13b, Cas13c, and Cas13d.

[0350] In some embodiments, Cas protein includes any one of Cas protein described herein or its functional part.As used herein, "functional part" refers to the part of the peptide that retains its ability to compound with at least one ribonucleic acid (e.g., guide RNA (gRNA)) and cut the target polynucleotide sequence. In some embodiments, the functional part includes a combination of operably connected Cas9 protein functional domains, and the Cas9 protein functional domains are selected from the group consisting of DNA binding domain, at least one RNA binding domain, helicase domain and endonuclease domain. In some embodiments, the functional part includes a combination of operably connected Cas12a (also referred to as Cpf1) protein functional domains, and the Cas12a protein functional domains are selected from the group consisting of DNA binding domain, at least one RNA binding domain, helicase domain and endonuclease domain. In some embodiments, the functional domain forms a complex. In some embodiments, the functional part of Cas9 protein includes the functional part of RuvC-like domain. In some embodiments, the functional part of Cas9 protein includes the functional part of HNH nuclease domain. In some embodiments, the functional part of Cas12a protein includes the functional part of RuvC-like domain.

[0351] In some embodiments, an exogenous Cas protein can be introduced into a cell in the form of a polypeptide. In certain embodiments, the Cas protein can be conjugated or fused to a cell-penetrating polypeptide or cell-penetrating peptide. As used herein, "cell-penetrating polypeptide" and "cell-penetrating peptide" refer to polypeptides or peptides that promote the uptake of molecules into cells, respectively. The cell-penetrating polypeptide may contain a detectable label.

[0352] In many embodiments, the Cas protein can be conjugated or fused to a charged protein (e.g., one that carries a positive charge, a negative charge, or an overall neutral charge). Such a linkage can be covalent. In some embodiments, the Cas protein can be fused to a superpositively charged GFP to significantly increase the ability of the Cas protein to penetrate cells (Cronican et al. ACS Chem Biol. 2010; 5(8): 747-52). In certain embodiments, the Cas protein can be fused to a protein transduction domain (PTD) to facilitate entry of the Cas protein into cells. Exemplary PTDs include Tat, oligoarginine, and penetrating peptides. In some embodiments, the Cas9 protein comprises a Cas9 polypeptide fused to a cell penetrating peptide. In some embodiments, the Cas9 protein comprises a Cas9 polypeptide fused to a PTD. In some embodiments, the Cas9 protein comprises a Cas9 polypeptide fused to a tat domain. In some embodiments, the Cas9 protein comprises a Cas9 polypeptide fused to an oligoarginine domain. In some embodiments, the Cas9 protein comprises a Cas9 polypeptide fused to a penetrating peptide domain. In some embodiments, the Cas9 protein comprises a Cas9 polypeptide fused to a superpositively charged GFP. In some embodiments, the Cas12a protein comprises a Cas12a polypeptide fused to a cell penetrating peptide. In some embodiments, the Cas12a protein comprises a Cas12a polypeptide fused to a PTD. In some embodiments, the Cas12a protein comprises a Cas12a polypeptide fused to a tat domain. In some embodiments, the Cas12a protein comprises a Cas12a polypeptide fused to an oligoarginine domain. In some embodiments, the Cas12a protein comprises a Cas12a polypeptide fused to a penetrating peptide domain. In some embodiments, the Cas12a protein comprises a Cas12a polypeptide fused to a superpositively charged GFP.

[0353] In some embodiments, the Cas protein can be introduced into a cell containing a target polynucleotide sequence in the form of a nucleic acid encoding the Cas protein. The process of introducing the nucleic acid into the cell can be achieved by any suitable technique. Suitable techniques include those described herein.

[0354] In some embodiments, the Cas protein is complexed with one to two ribonucleic acids. In some embodiments, the Cas protein is complexed with two ribonucleic acids. In some embodiments, the Cas protein is complexed with one ribonucleic acid. In some embodiments, the Cas protein is encoded by a modified nucleic acid as described herein (e.g., a synthetic modified mRNA).

[0355] The method of the present disclosure contemplates the use of any ribonucleic acid capable of guiding the Cas protein to the target motif of the target polynucleotide sequence and hybridizing therewith. In some embodiments, at least one of the ribonucleic acids comprises tracrRNA. In some embodiments, at least one of the ribonucleic acids comprises CRISPR RNA (crRNA). In some embodiments, a single ribonucleic acid comprises a guide RNA that guides the Cas protein to the target motif of the target polynucleotide sequence in the cell and hybridizes therewith. In some embodiments, at least one of the ribonucleic acids comprises a guide RNA that guides the Cas protein to the target motif of the target polynucleotide sequence in the cell and hybridizes therewith. In some embodiments, the one to two ribonucleic acids all comprise a guide RNA that guides the Cas protein to the target motif of the target polynucleotide sequence in the cell and hybridizes therewith. As will be understood by those skilled in the art, the ribonucleic acids of the present disclosure can be selected to hybridize with a variety of different target motifs, depending on the specific CRISPR / Cas system and the sequence of the target polynucleotide employed. The one to two ribonucleic acids can also be selected to minimize hybridization with nucleic acid sequences other than the target polynucleotide sequence. In some embodiments, when compared to all other genomic nucleotide sequences in the cell, the one to two ribonucleic acids hybridize to a target motif containing at least two mismatches. In some embodiments, when compared to all other genomic nucleotide sequences in the cell, the one to two ribonucleic acids hybridize to a target motif containing at least one mismatch. In some embodiments, the one to two ribonucleic acids are designed to hybridize to a target motif adjacent to a deoxyribonucleic acid motif recognized by a Cas protein. In some embodiments, each of the one to two ribonucleic acids is designed to hybridize to a target motif adjacent to a deoxyribonucleic acid motif recognized by a Cas protein, and the deoxyribonucleic acid motif is flanked by a mutant allele located between the target motifs.

[0356] In some embodiments, each of the one to two ribonucleic acids comprises a guide RNA that guides the Cas protein to and hybridizes to a target motif of a target polynucleotide sequence in the cell.

[0357] In some embodiments, one or two ribonucleic acids (e.g., guide RNA) are complementary to and / or hybridize with the sequence on the same chain of the target polynucleotide sequence. In some embodiments, one or two ribonucleic acids (e.g., guide RNA) are complementary to and / or hybridize with the sequence on the relative chain of the target polynucleotide sequence. In some embodiments, the one or two ribonucleic acids (e.g., guide RNA) are not complementary to and / or hybridize with the sequence on the relative chain of the target polynucleotide sequence. In some embodiments, the one or two ribonucleic acids (e.g., guide RNA) are complementary to and / or hybridize with the overlapping target motifs of the target polynucleotide sequence. In some embodiments, the one or two ribonucleic acids (e.g., guide RNA) are complementary to and / or hybridize with the compensation target motifs of the target polynucleotide sequence.

[0358] VIII. Methods for Expressing Engineered CD47 Proteins

[0359] The engineered CD47 proteins provided herein can be produced by any method known to those skilled in the art, including in vivo and in vitro methods. The desired protein can be expressed in any organism suitable for producing the desired amount and form of protein. Expression hosts include prokaryotes and eukaryotes, such as Escherichia coli, yeast, plants, insect cells, mammalian cells, including human cell lines and transgenic animals. Expression hosts may differ in their protein production levels and the types of post-translational modifications present on the expressed proteins. The choice of expression host can be made based on these and other factors, such as regulatory and safety considerations, production costs, and the need and method for purification.

[0360] In some embodiments, the polynucleotide encoding the engineered CD47 protein described herein can be introduced into the cell by any suitable technique. Suitable techniques include calcium phosphate, lipid-mediated transfection, electroporation, fusogens, and transduction or infection using viral vectors, as discussed herein. In some embodiments, the polynucleotide is introduced into the cell via viral transduction (e.g., AAV transduction, lentiviral transduction) or otherwise delivered on a viral vector (e.g., fusogen-mediated delivery). In some embodiments, the polynucleotide is introduced into the cell via fusogen-mediated delivery or a transposase system selected from the group consisting of: conditional or inducible transposase, conditional or inducible PiggyBac transposon, conditional or inducible Sleeping Beauty (SB11) transposon, conditional or inducible Mos1 transposon, and conditional or inducible Tol2 transposon.

[0361] Many expression vectors are available and known to those skilled in the art, and can be used for expressing proteins.The selection of expression vector can be subject to the influence of the selection of host expression system.In general, expression vector can comprise transcription promoter and optional enhancer, translation signal and transcription and translation termination signal.Expression vector used for stable conversion usually has the selectable marker that allows to select and maintain the cell through transformation.In some cases, can utilize replication origin to increase the copy number of vector.

[0362] The expression vector can be introduced into the host cell via, for example, transformation, transfection, transduction, infection, electroporation, and sonoporation. Those skilled in the art can select methods and conditions suitable for introducing the expression vector into the host cell.

[0363] In some embodiments, the engineered CD47 protein is delivered using viral transduction (e.g., using a vector). In some embodiments, the vector is a self-inactivating lentiviral vector pseudotyped with a vesicular stomatitis virus (VSV)-G envelope and carrying an exogenous polynucleotide.

[0364] In some embodiments, the engineered CD47 protein is delivered using one or more gene editing systems. In some embodiments, the gene editing system is CRISPR / Cas. In some embodiments, the gene editing system includes TALEN. In some embodiments, the gene editing system includes zinc finger nucleases. In some embodiments, the gene editing system includes a meganuclease.

[0365] After the introduction of the vector containing the selectable marker, the cells can be grown in an enriched culture medium for 1-2 days and then switched to a selective culture medium. The purpose of the selectable marker is to confer resistance to selection, and its presence allows the growth and recovery of cells that successfully express the introduced sequence. Tissue culture techniques suitable for the cell type can be used to proliferate resistant cells of stably transformed cells. In some embodiments, the engineered CD47 protein is expressed in a mammalian expression system. The expression construct can be transferred to mammalian cells by viral infection (such as by an adenovirus construct) or by direct DNA transfer (such as liposomes, calcium phosphate, DEAE-dextran) and by physical means (such as electroporation and microinjection). In some embodiments, viral transduction (e.g., using a vector) is used to deliver the engineered CD47 protein. In some embodiments, the vector is a pseudotyped self-inactivating lentiviral vector carrying an exogenous polynucleotide. In some embodiments, the vector is a self-inactivating lentiviral vector pseudotyped with the vesicular stomatitis VSV-G envelope and carrying an exogenous polynucleotide. In some embodiments, the engineered CD47 protein is delivered using one or more gene editing systems. In some embodiments, the gene editing system is CRISPR / Cas. In some embodiments, the gene editing system includes TALEN. In some embodiments, the gene editing system includes zinc finger nucleases. In some embodiments, the gene editing system includes a meganuclease.

[0366] In some embodiments, the expression systems used in the context of the present disclosure are disclosed in U.S. Application No. 63 / 270,454.

[0367] Expression vectors for mammalian cells typically include an mRNA cap site, a TATA box, a translation initiation sequence (Kozak consensus sequence) and a polyadenylation element. IRES elements can also be added to allow bicistronic expression with another gene (such as a selectable marker). Such vectors typically include transcription promoter enhancers for high-level expression, such as the long terminal repeats of the SV40 promoter enhancer, human cytomegalovirus (CMV) promoter, and Rous sarcoma virus (RSV). These promoter enhancers are active in many cell types. Tissue and cell type promoters and enhancer regions can also be used for expression. Exemplary promoter / enhancer regions include, but are not limited to, promoter / enhancer regions from genes controlled by genes such as elastase I, insulin, immunoglobulin, mouse mammary tumor virus, albumin, alpha-fetoprotein, α1 antitrypsin, β-globin, myelin basic protein, myosin light chain 2, and gonadotropin-releasing hormone gene. Selectable markers can be used to select and maintain cells with expression constructs. Examples of selectable marker genes include, but are not limited to, hygromycin B phosphotransferase, adenosine deaminase, xanthine-guanine phosphoribosyltransferase, aminoglycoside phosphotransferase, dihydrofolate reductase (DHFR), and thymidine kinase. For example, expression can be performed in the presence of methotrexate to select only those cells that express the DHFR gene.

[0368] Once the vector has been incorporated into a suitable host cell, the host cell is maintained under conditions suitable for expression of the engineered CD47 protein encoded by the incorporated polynucleotide. A skilled artisan is able to select conditions suitable for expression of the engineered CD47 protein.

[0369] IX. Other Features

[0370] It should be understood that in the process of manufacturing cell therapy, certain modifications that are considered to be necessary for cell therapy products can be introduced into the cells. The cells subjected to analysis for donor capability can be edited cells or unedited cells. Profiling of cells can occur before or after cell editing. The edited cells include one or more modifications, such as HIP modification (low immune gene modification that can achieve immune escape). When transplanted in vivo in the absence of immunosuppression, the HIP-modified cells have reduced expression of one or more molecules in MHC class I and / or MHC class II molecules, and therefore there may be no evidence of systemic immune response, such as no T cell activation, antibody production or NK cell activity. Disclosures related to edited cells are provided herein. Such disclosures are applicable to the methods, uses and cells described herein. The methods disclosed herein for characterizing cell populations for donor capability are advantageous for many cell types as described herein. In some embodiments, the cells are T cells (e.g., CAR-T cells). Engineered cells and methods for engineering cells

[0371] One modification considered desirable for cell therapy products is that the engineered cells and populations thereof exhibit reduced expression of one or more of MHC class I and / or MHC class II molecules. A further modification considered desirable for cell therapy products is that the engineered cells and populations thereof exhibit increased expression of at least one tolerogenic factor, such as the tolerogenic factors described herein.

[0372] Provided herein are methods and compositions for alleviating and / or escaping the impact of the immune system response for allografts.In order to overcome the immune rejection problem of the transplant and / or tissue graft of cell origin, disclosed herein is a kind of engineered immune escape cell (for example, engineered primary low immunogenicity cell) or its colony or pharmaceutical composition, which represents the feasible source of any transplantable cell type. The engineered cell disclosed herein realizes the recognition that reduces the recipient subject's immune system, regardless of the subject's genetic makeup, or any existing response to one or more previous allografts in the subject, previous autologous chimeric antigen receptor (CAR) T rejection, and / or other autologous or allogeneic therapies wherein expressing transgenic. Engineered cells can include but are not limited to β islet cells, B cells, T cells, NK cells, retinal pigment epithelial cells, glial progenitor cells, endothelial cells, hepatocytes, thyroid cells, skin cells and blood cells (for example, plasma cells or platelets).

[0373] In some embodiments, the engineered cells described herein further comprise increased expression and / or overexpression of one or more complement inhibitors. In some embodiments, the one or more complement inhibitors are selected from CD46, CD59, and DAF / CD55. In some embodiments, the engineered cells comprise increased expression of two or more complement inhibitors in combination, such as increased expression of CD46 and CD59 or increased expression of CD46, CD59, and CD55.

[0374] The engineered cells provided herein utilize the expression of tolerogenic factors and can also regulate (e.g., reduce or eliminate) one or more MHC class I molecules and / or one or more MHC class II molecule expression (e.g., surface expression). In some embodiments, genome editing techniques utilizing rare cutting endonucleases (e.g., CRISPR / Cas, TALEN, zinc finger nucleases, large-range nucleases, and homing endonuclease systems) are also used to reduce or eliminate the expression of key immune genes in human cells (e.g., by deleting genomic DNA of key immune genes). In certain embodiments, genome editing techniques or other gene regulation techniques are used to insert tolerance-inducing (tolerogenic) factors (e.g., CD47) in human cells to produce engineered cells that can escape immune recognition after implantation into recipient subjects. Thus, the engineered cells provided herein exhibit modulated expression of one or more genes and factors that affect one or more MHC class I molecules and / or one or more MHC class II molecules (e.g., reduced or eliminated expression of the one or more genes and factors), modulated expression of tolerogenic factors (e.g., reduced) and / or modulated expression of the tolerogenic factors (e.g., overexpression of the tolerogenic factors), and achieve reduced recognition by the immune system of a recipient subject. In some embodiments, the engineered cells provided herein exhibit modulated expression of CD142 (e.g., reduced expression of CD142). In some embodiments, the engineered cells provided herein exhibit modulated expression of one or more complement inhibitors selected from CD46, CD59, and DAF / CD55 (e.g., increased expression of the one or more complement inhibitors).

[0375] In some aspects, provided herein are engineered cells that show reduced innate immune cell rejection and / or adaptive immune cell rejection (e.g., low immunogenicity cells). For example, in some embodiments, engineered cells show reduced sensitivity to NK cell-mediated lysis and / or macrophage engulfment. In some embodiments, engineered cells can be used as the source of generally compatible cells or tissues (e.g., universal donor cells or tissues), which are transplanted into recipient subjects and require little to no immunosuppressants. Such low immunogenicity cells retain cell-specific characteristics and properties after transplantation.

[0376] Also provided herein are methods for treating a disorder comprising administering engineered cells (e.g., engineered primary cells) that escape immune rejection in an MHC-mismatched allogeneic recipient. In some embodiments, the engineered cells produced by any of the methods described herein escape immune rejection when repeatedly administered (e.g., transplanted or implanted) to an MHC-mismatched allogeneic recipient.

[0377] Unless otherwise indicated, the practice of the embodiments described herein will employ conventional methods of chemistry, biochemistry, organic chemistry, molecular biology, microbiology, recombinant DNA technology, genetics, immunology, and cell biology, which are within the skill of the art, many of which are described below for illustrative purposes. Such techniques are fully explained in the literature.See, e.g., Sambrook et al., Molecular Cloning: A Laboratory Manual (3rd ed., 2001); Sambrook et al., Molecular Cloning: A Laboratory Manual (2nd ed., 1989); Maniatis et al., Molecular Cloning: A Laboratory Manual (1982); Ausubel et al., Current Protocols in Molecular Biology (John Wiley and Sons, updated July 2008); Short Protocols in Molecular Biology: A Compendium of Methods from Current Protocols in Molecular Biology, Greene Pub. Associates and Wiley-Interscience; Glover, DNA Cloning: A Practical Approach, Vol. I and Vol. II (IRL Press, Oxford, 1985); Anand, Techniques for the Analysis of Complex Genomes, (Academic Press, New York, 1992); Transcription and Translation (B. Hames and S. Higgins, eds., 1984); Perbal, A Practical Guide to Molecular Cloning (1984); Harlow and Lane, Antibodies, (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1998) Current Protocols in Immunology (QE Coligan, AM Kruisbeek, DH Margulies, E.M. Shevach and W. Strober, eds., 1991); Annual Review of Immunology; and monographs in journals such as Advances in Immunology.

[0378] All publications (including patent documents, scientific articles, and databases) mentioned in this application are incorporated by reference in their entirety for all purposes to the same extent as if each individual publication were individually incorporated by reference. If a definition set forth herein is contrary to or otherwise inconsistent with a definition set forth in patents, applications, published applications, and other publications incorporated by reference herein, the definition set forth herein takes precedence over the definition incorporated by reference herein.

[0379] The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described. Those skilled in the art will recognize that several embodiments are possible within the scope and spirit of the present disclosure. The following description illustrates the present disclosure and certainly should not be construed as limiting the scope of the contemplated embodiments described herein in any way.

[0380] Described herein are engineered cells comprising one or more modifications. In some embodiments, provided engineered cells further comprise modifications of one or more target polynucleotide sequences that modulate the expression of one or more MHC class I molecules, one or more MHC class II molecules, or one or more MHC class I molecules and one or more MHC class II molecules.

[0381] In some embodiments, the engineered cells provided further comprise modifications for increasing the expression of one or more tolerogenic factors. In some embodiments, the tolerogenic factors are one or more of the following: A20 / TNFAIP3, B2M-HLA-E, CD16, CD16 Fc receptor, CD24, CD27, CD35, CD39, CD46, CD47, CD52, CD55, CD59, CD64, CD200, CCL21, CCL22, CTLA4-Ig, C1 inhibitor, CR1, DUX4, FASL, HLA-C, HLA-E, HLA-E heavy chain, HLA-F, HLA-G, H2-M3, IDO1, IL-10, IL15-RF, IL-35, IL-39, MANF, Mfge8, PD-L1, Serpinb9, or any combination thereof. In some embodiments, the modifications for increasing the expression of one or more tolerogenic factors are or include increased expression of CD47. In some embodiments, the modification for increasing the expression of one or more tolerogenic factors is or includes increased expression of PD-L1. In some embodiments, the modification for increasing the expression of one or more tolerogenic factors is or includes increased expression of HLA-E. In some embodiments, the modification for increasing the expression of one or more tolerogenic factors is or includes increased expression of HLA-G. In some embodiments, the modification for increasing the expression of one or more tolerogenic factors is or includes increased expression of CCL21, PD-L1, FasL, Serpinb9, H2-M3 (HLA-G), CD47, CD200 and Mfge8.

[0382] In some embodiments, the cell comprises one or more genomic modifications that reduce the expression of one or more MHC class I molecules and a modification that increases the expression of CD47. In other words, the engineered cell comprises an exogenous CD47 protein and exhibits reduced or silenced surface expression of one or more MHC class I molecules. In some embodiments, the cell comprises one or more genomic modifications that reduce the expression of one or more MHC class II molecules and a modification that increases the expression of CD47. In some cases, the engineered cell comprises exogenous CD47 nucleic acids and proteins and exhibits reduced or silenced surface expression of one or more MHC class I molecules. In some embodiments, the cell comprises one or more genomic modifications that reduce or eliminate the expression of one or more MHC class II molecules, one or more genomic modifications that reduce or eliminate the expression of one or more MHC class II molecules, and a modification that increases the expression of CD47. In some embodiments, the engineered cell comprises an exogenous CD47 protein, exhibits reduced or silenced surface expression of one or more MHC class I molecules, and exhibits reduced surface expression of one or more MHC class II molecules or lacks such surface expression. In many embodiments, the cell is a B2M 插入缺失 / 插入缺失 、CIITA 插入缺失 / 插入缺失 , CD47tg cells.

[0383] In some embodiments, any gene editing technology can be used to reduce the expression of one or more target polynucleotides or target proteins as described. In some embodiments, gene editing technology can include systems involving nucleases, integrases, transposases, recombinases. In some embodiments, gene editing technology can be used for knocking out or knocking down genes. In some embodiments, gene editing technology can be used for knocking DNA into or integrating it into the region of the genome. In some embodiments, gene editing technology mediates single-strand breaks (SSBs). In some embodiments, gene editing technology mediates double-strand breaks (DSBs), including double-strand breaks related to non-homologous end joining (NHEJ) or homology-directed repair (HDR). In some embodiments, gene editing technology can include editing or lead editing based on DNA. In some embodiments, gene editing technology can include programmable addition (PASTE) via site-specific targeting elements.

[0384] In some embodiments, gene editing technology is associated with base editing. Base editors (BE) are typically fusions of Cas (“CRISPR associated”) domains and nucleobase modification domains (e.g., natural or evolved deaminases, such as cytidine deaminases, including APOBEC1 (“Apolipoprotein B mRNA editing enzyme, catalytic polypeptide 1”), CDA (“Cytidine deaminase”), and AID (“Activation-induced cytidine deaminase”) domains). In some cases, base editors may also include proteins or domains that alter the cellular DNA repair process to improve the efficiency and / or stability of the resulting single nucleotide changes.

[0385] In some aspects, currently available base editors include cytidine base editors (e.g., BE4) that convert target C·G to T·A and adenine base editors (e.g., ABE7.10) that convert A·T to G·C. In some aspects, it was first confirmed that Cas9 targeted deamination is related to a base editor (BE) system designed to induce base changes without introducing double-stranded DNA breaks. Further, rat deaminase APOBEC1 (rAPOBEC1) fused to an inactivated Cas9 (dCas9) was used to successfully convert cytidine upstream of the PAM of sgRNA into thymidine. In some aspects, this first BE system was optimized by changing dCas9 to a “nickase” Cas9 D10A, which cuts on the chain opposite to the deaminated cytidine. Without being bound by theory, this is expected to initiate long-patch base excision repair (BER), in which the deaminated chain is preferentially used to template the repair to produce a U:A base pair, which is then converted to T:A during DNA replication.

[0386] In some embodiments, the base editor is a nuclear base editor containing a catalytically inactive first DNA binding protein domain, a domain with base editing activity, and a second DNA binding protein domain with nickase activity, wherein the DNA binding protein domains are expressed on a single fusion protein or expressed separately (e.g., on separate expression vectors). In some embodiments, the base editor is a fusion protein comprising a domain with base editing activity (e.g., cytidine deaminase or adenosine deaminase) and two nucleic acid programmable DNA binding protein domains (napDNAbp), the first of which has nickase activity and the second napDNAbp is catalytically inactive, wherein at least two napDNAbp are connected by a linker. In some embodiments, the base editor is a fusion protein comprising a DNA domain of a CRISPR-Cas (e.g., Cas9) (nCas; nCas9) having nickase activity, a catalytically inactive domain of a CRISPR-Cas protein (e.g., Cas9) (dCas; e.g., dCas9) having nucleic acid programmable DNA binding activity, and a deaminase domain, wherein dCas is connected to nCas via a linker and dCas is adjacent to the deaminase domain. In some embodiments, the base editor is an adenine to thymine or "ATBE" (or thymine to adenine or "TABE") transversion base editor. Exemplary base editors and base editor systems include any base editors and base editor systems described in patent publication numbers US20220127622, ​​US20210079366, US20200248169, US20210093667, US20210071163, WO2020181202, WO2021158921, WO2019126709, WO2020181178, WO2020181195, WO2020214842, WO2020181193, which are hereby incorporated in their entirety.

[0387] In some embodiments, the gene editing technology is target-triggered reverse transcription (TPRT) or "prime editing." In some embodiments, prime editing mediates targeted insertions, deletions, all 12 possible base-to-base transitions, and combinations thereof in human cells without the need for DSBs or a donor DNA template.

[0388] Lead editing is a genome editing method that uses a nucleic acid programmable DNA binding protein ("napDNAbp") that works in conjunction with a polymerase (i.e., in the form of a fusion protein provided in trans with napDNAbp or otherwise) to write new genetic information directly into a specified DNA site, wherein the lead editing system is programmed with a lead editing (PE) guide RNA ("PEgRNA") that both specifies the target site and templates the synthesis of the desired edit by engineering an extension (DNA or RNA) onto the guide RNA (e.g., at the 5' or 3' end, or at the internal portion of the guide RNA) in the form of a replacement DNA chain. The replacement chain containing the desired edit (e.g., a single nucleobase substitution) shares the same sequence (except that it contains the desired edit) with the endogenous chain of the target site to be edited. Through DNA repair and / or replication mechanisms, the endogenous chain of the target site is replaced by the newly synthesized replacement chain containing the desired edit. In some cases, lead editing can be considered a "search and replace" genome editing technology because the lead editor searches for and locates the desired target site to be edited and encodes a replacement strand containing the desired edit, which is simultaneously installed to replace the endogenous DNA strand of the corresponding target site. For example, lead editing can be suitable for performing precise CRISPR / Cas-based genome editing to avoid double-strand breaks. In some embodiments, the homologous protein is a Cas protein-reverse transcriptase fusion or related system, or encodes a Cas protein-reverse transcriptase fusion or related system to target a specific DNA sequence with a guide RNA, generate a single-stranded nick at the target site, and use the nicked DNA as a primer for reverse transcription of an engineered reverse transcriptase template integrated with the guide RNA. In some embodiments, the lead editor protein is paired with two lead editing guide RNAs (pegRNAs) that template the synthesis of complementary DNA flaps on opposite strands of the genomic DNA, resulting in the endogenous DNA sequence between the PE-induced nick sites being replaced with a sequence encoded by the pegRNA.

[0389] In some embodiments, gene editing technology is associated with a lead editor, which is a reverse transcriptase or any DNA polymerase known in the art. Therefore, in one aspect, the lead editor can include Cas9 (or equivalent napDNAbp), which is programmed to target the DNA sequence by associating the DNA sequence with a special guide RNA (i.e., PEgRNA) containing a spacer sequence annealed to the complementary protospacer in the target DNA. Such methods include any method disclosed in Anzalone et al. (doi.org / 10.1038 / s41586-019-1711-4) or PCT Publication Nos. WO2020191248, WO2021226558 or WO2022067130, and these documents are hereby incorporated by reference in their entirety.

[0390] In some embodiments, gene editing technology is programmable addition (PASTE) via site-specific targeting elements. In some aspects, PASTE is a platform for guiding genome insertion via the CRISPR-Cas9 nickase fused with both reverse transcriptase and serine integrase. As described in Ioannidi et al. (doi.org / 10.1101 / 2021.11.01.466786), PASTE does not produce double-strand breaks, but allows integration of sequences as large as about 36kb. In some embodiments, serine integrase can be any serine integrase known in the art. In some embodiments, serine integrase has enough orthogonality so that PASTE can be used for multiple gene integration, integrating at least two different genes simultaneously at at least two genomic loci. In some embodiments, PASTE has an editing efficiency comparable to or better than its integration based on homology-directed repair or non-homologous end connection, with activity in non-dividing cells and less detectable off-target events.

[0391] In some embodiments, the CRISPR system of the present disclosure includes a TnpB polypeptide. In some embodiments, the TnpB polypeptide may include a Ruv-C-like domain. The RuvC domain may be a split RuvC domain comprising RuvC-I, RuvC-II, and RuvC-III subdomains. In some embodiments, TnpB may further include one or more of an HTH domain, a bridging helical domain, and a zinc finger domain. The TnpB polypeptide does not include an HNH domain. In some embodiments, the TnpB protein includes, starting from the N-terminus, an HTH domain, a RuvC-I subdomain, a bridging helical domain, a RuvC-II subdomain, a zinger finger domain, and a RuvC-III subdomain. In some embodiments, the RuvC-III subdomain forms the C-terminus of the TnpB polypeptide. In some embodiments, the TnpB polypeptide is from an Epsilonproteobacteria bacterium, Actinoplanes lobatus strain DSM 43150, Actinoplanes celluolosilytica strain DSM 45823, Actinoplanes namibiensis strain DSM 44197, Alicyclobacillus macrosprangiidus strain DSM 17980, Lipingzhangella halophila strain DSM 102030, or Ktedonobacter recemifer. In some embodiments, the TnpB polypeptide is from Ktedonobacter racemifer, or comprises a conserved RNA region having similarity to the 5' ITR of the Ktedonobacter racemifer TnpB locus. In some embodiments, TnpB may comprise a Fanzor protein, a TnpB homolog found in eukaryotic genomes. In some embodiments, a CRISPR system comprising a TnpB polypeptide binds to a target adjacent motif (TAM) sequence at the 5' position of a target polynucleotide. In some embodiments, TAM is a transposon-associated motif. In some embodiments, the TAM sequence comprises TCA. In some embodiments, the TAM sequence comprises TTCAN. In some embodiments, the TAM sequence comprises TTGAT. In some embodiments, the TAM sequence comprises ATAAA.

[0392] In some embodiments, the cell colony through engineered approaches causes reduced immune activation or does not cause immune activation after being applied to a recipient subject. In some embodiments, the cell causes reduced systemic TH1 activation or does not cause systemic TH1 activation in a recipient subject. In some embodiments, the cell causes reduced immune activation of peripheral blood mononuclear cells (PBMC) or does not cause immune activation of PBMC in a recipient subject. In some embodiments, the cell causes reduced donor-specific IgG antibodies for the cell or does not cause the donor-specific IgG antibodies after being applied to a recipient subject. In some embodiments, the cell causes reduced IgM and IgG antibodies for the cell in a recipient subject and produces or does not cause the IgM and IgG antibodies to produce. In some embodiments, the cell causes reduced cytotoxic T cells to kill the cell after being applied to a recipient subject.

[0393] In some embodiments, the engineered cells provided herein comprise a "suicide gene" or a "suicide switch". A suicide gene or suicide switch can be incorporated to act as a "safety switch", such as after the engineered cells are administered to a subject and when the cells grow and divide in an undesirable manner, the safety switch can cause the engineered cells (e.g., primary engineered cells or cells differentiated from engineered pluripotent stem cells) to die. The "suicide gene" ablation method includes a suicide gene in a gene transfer vector that encodes a protein that causes cell killing only when activated by a specified compound. The suicide gene can encode an enzyme that selectively converts a non-toxic compound into a highly toxic metabolite. The result is the specific elimination of cells expressing the enzyme. In some embodiments, the suicide gene is the herpes simplex virus thymidine kinase (HSV-tk) gene and the trigger is ganciclovir. In other embodiments, the suicide gene is the Escherichia coli cytosine deaminase (EC-CD) gene and the trigger is 5-fluorocytosine (5-FC) (Barese et al., Mol. Therap. 20(10): 1932-1943 (2012), Xu et al., Cell Res. 8: 73-8 (1998), both of which are herein incorporated by reference in their entirety).

[0394] In other embodiments, the suicide gene is an inducible caspase protein. The inducible caspase protein includes at least a portion of a caspase protein capable of inducing apoptosis. In some embodiments, the inducible caspase protein is iCasp9. It comprises the sequence of a human FK506 binding protein FKBP12 with an F36V mutation, which is connected to the gene encoding human caspase 9 through a series of amino acids. FKBP12-F36V binds to the small molecule dimer API 903 with high affinity. Therefore, the suicide function of iCasp9 is triggered by the administration of a dimerization chemical inducer (CID). In some embodiments, CID is a small molecule drug API 903. Dimerization causes rapid induction of apoptosis. (See WO2011146862; Stasi et al., N. Engl. J. Med 365;18 (2011); Tey et al. Biol. Blood Marrow Transplant. 13:913-924 (2007), each of which is herein incorporated by reference in its entirety.)

[0395] The incorporation of a safety switch or suicide gene allows for controlled killing of cells in the event of cytotoxicity or other negative consequences for the recipient, thereby increasing the safety of cell-based therapies, including those using tolerogens.

[0396] In some embodiments, a safety switch can be incorporated into (such as introduced into) the engineered cells provided herein to provide, for example, the ability to induce cell death or apoptosis when the engineered cells containing the safety switch grow and divide in an undesirable manner or become overly toxic to the host. Therefore, the use of a safety switch enables conditional elimination of abnormal cells in the body and may be a key step in the clinical application of cell therapy. Safety switches and their uses are described, for example, in Duzgune§, Origins of Suicide Gene Therapy (2019); Duzgune§ (ed.), Suicide Gene Therapy. Methods in Molecular Biology, vol. 1895 (Humana Press, New York, NY) (for HSV-tk, cytosine deaminase, nitroreductase, purine nucleoside phosphorylase, and horseradish peroxidase); Zhou and Brenner, Exp Hematol 44(11):1013-1019 (2016) (for iCaspase9); Wang et al., Blood 18(5):1255-1263 (2001) (for huEGFR); U.S. Patent Application Publication No. 20180002397 (for HER1); and Philip et al., Blood 124(8):1277-1287 (2014) (for RQR8).

[0397] In some embodiments, the safety switch can cause cell death in a controlled manner, for example, in the presence of a drug or prodrug or upon activation by a selective exogenous compound. In some embodiments, the safety switch is selected from the group consisting of: herpes simplex virus thymidine kinase (HSV-tk), cytosine deaminase (CyD), nitroreductase (NTR), purine nucleoside phosphorylase (PNP), horseradish peroxidase, inducible caspase 9 (iCasp9), rapamycin-activated caspase 9 (rapaCasp9), CCR4, CD16, CD19, CD20, CD30, EGFR, GD2, HER1, HER2, MUC1, PSMA, and RQR8.

[0398] In some embodiments, the safety switch can be a transgene encoding a product that has cell-killing ability when activated by a drug or prodrug (e.g., by converting a non-toxic prodrug into a toxic metabolite within the cell). In these embodiments, cell killing is activated by contacting the engineered cells with a drug or prodrug. In some cases, the safety switch is HSV-tk, which converts ganciclovir (GCV) into GCV-triphosphate, thereby interfering with DNA synthesis and killing dividing cells. In some cases, the safety switch is CyD or a variant thereof, which converts the antifungal drug 5-fluorocytosine (5-FC) into cytotoxic 5-fluorouracil (5-FU) by catalyzing the hydrolytic deamination of cytosine to uracil. 5-FU is further converted by cellular enzymes into potent antimetabolites (5-FdUMP, 5-FdUTP, 5-FUTP). These compounds inhibit thymidylate synthase and the production of RNA and DNA, leading to cell death. In some cases, the safety switch is NTR or a variant thereof, which can act on the prodrug CB 1954 by reducing the nitro group to a reactive N-hydroxylamine intermediate that is toxic to both proliferating and non-proliferating cells. In some cases, the safety switch is PNP or a variant thereof, which can convert the prodrug 6-methylpurine deoxynucleoside or fludarabine into a metabolite that is toxic to both proliferating and non-proliferating cells. In some cases, the safety switch is horseradish peroxidase or a variant thereof, which can catalyze indole-3-acetic acid (IAA) into a potent cytotoxin, thereby achieving cell killing.

[0399] In some embodiments, the safety switch can be iCasp9. Caspase 9 is a component of the intrinsic mitochondrial apoptosis pathway, which is activated under physiological conditions due to the release of cytochrome C from damaged mitochondria. Activated caspase 9 then activates caspase 3, which triggers the terminal effector molecules to cause apoptosis. iCasp9 can be generated by fusing a truncated caspase 9 (without its physiological dimerization domain or caspase activation domain) to FK506 binding protein (FKBP) FKBP12-F36V via a peptide linker. iCasp9 has low dimer-dependent basal activity and can be stably expressed in host cells (e.g., human T cells) without compromising the phenotype, function, or antigen specificity of the host cells. However, in the presence of chemical dimerization inducers (CIDs) such as rimiducid (AP1903), AP20187, and rapamycin, iCasp9 can undergo induced dimerization and activate downstream caspase molecules, thereby leading to apoptosis of cells expressing iCasp9. See, for example, PCT Application Publication No. WO2011 / 146862; Stasi et al., N.Engl.J.Med.365;18 (2011); Tey et al., Biol.Blood Marrow Transplant 13:913-924 (2007). For example, the rapamycin-inducible caspase 9 variant is referred to as rapaCasp9. See Stavrou et al., Mal.Ther.26(5):1266-1276 (2018). Therefore, iCasp9 can be used as a safety switch for achieving controlled killing of host cells.

[0400] In some embodiments, the safety switch can be a membrane-expressed protein that allows for cell depletion following administration of a specific antibody against that protein. This category of safety switch can include, for example, one or more transgenes encoding CCR4, CD16, CD19, CD20, CD30, EGFR, GD2, HER1, HER2, MUC1, PSMA, or RQR8 for surface expression. These proteins may have surface epitopes that can be targeted by specific antibodies. In some embodiments, the safety switch comprises CCR4, which can be recognized by anti-CCR4 antibodies. Non-limiting examples of suitable anti-CCR4 antibodies include moglizumab and its biosimilars. In some embodiments, the safety switch comprises CD16 or CD30, which can be recognized by anti-CD16 or anti-CD30 antibodies. Non-limiting examples of such anti-CD16 or anti-CD30 antibodies include AFM13 and its biosimilars. In some embodiments, the safety switch comprises CD19, which can be recognized by anti-CD19 antibodies. Non-limiting examples of such anti-CD19 antibodies include MOR208 and its biosimilars. In some embodiments, the safety switch comprises CD20 that can be recognized by an anti-CD20 antibody. Non-limiting examples of such anti-CD20 antibodies include obinutuzumab, utuximab, ocatuzumab, rituximab, rituximab-RIIb, and biosimilars thereof. Thus, cells expressing the safety switch are CD20 positive and can be targeted for killing by administering an anti-CD20 antibody as described above. In some embodiments, the safety switch comprises EGFR that can be recognized by an anti-EGFR antibody. Non-limiting examples of such anti-EGFR antibodies include tomozutuximab, RO5083945 (GA201), cetuximab, and biosimilars thereof. In some embodiments, the safety switch comprises GD2 that can be recognized by an anti-GD2 antibody. Non-limiting examples of such anti-GD2 antibodies include Hu14.18K322A, Hu14.18-IL2, Hu3F8, dexximab, c.60C3-R11c, and biosimilars thereof.

[0401] In some embodiments, the safety switch can be an exogenously administered agent that recognizes one or more tolerogenic factors on the surface of the engineered cells. In some embodiments, the exogenously administered agent is an antibody directed against or specific for the tolerogenic factor, such as an anti-CD47 antibody. By recognizing and blocking the tolerogenic factors on the engineered cells, the exogenously administered antibody can block the immunosuppressive function of the tolerogenic factors, thereby resensitizing the immune system to the engineered cells. For example, for engineered cells that overexpress CD47, an exogenously administered anti-CD47 antibody can be administered to a subject, resulting in masking of CD47 on the engineered cells and triggering an immune response to the engineered cells.

[0402] In some embodiments, provided herein is a method for generating an engineered cell, the method comprising: (a) reducing or eliminating the expression of one or more MHC class I molecules and / or one or more MHC class II molecules in the cell; (b) increasing the expression of a tolerogenic factor in the cell. In some embodiments, the one or more tolerogenic factors are selected from A20 / TNFAIP3, B2M-HLA-E, CD16, CD16 Fc receptor, CD24, CD27, CD35, CD39, CD46, CD47, CD52, CD55, CD59, CD64, CD200, CCL21, CCL22, CTLA4-Ig, C1 inhibitor, CR1, DUX4, FASL, HLA-C, HLA-E, HLA-E heavy chain, HLA-F, HLA-G, H2-M3, IDO1, IL-10, IL15-RF, IL-35, IL-39, MANF, Mfge8, PD-L1, and Serpinb9. In some embodiments, the one or more tolerogenic factors are CD47. In some embodiments, the method comprises reducing or eliminating the expression of one or more MHC class I molecules and one or more MHC class II molecules. In some embodiments, reducing or increasing expression comprises using a guide nuclease (e.g., a CRISPR / Cas system) to perform one or more modifications to the cell. In some embodiments, the method further comprises introducing an expression vector comprising an inducible suicide switch into the cell.

[0403] In some embodiments, reducing or increasing expression comprises performing one or more modifications to the cell using a guide nuclease (e.g., a CRISPR / Cas system). In some embodiments, the method further comprises introducing an expression vector comprising an inducible suicide switch into the cell. In some embodiments, the method further comprises increasing the expression of DAF / CD55 in the cell.

[0404] In some embodiments, the tolerogenic factor is CD47, and the cell comprises an exogenous polynucleotide encoding a CD47 protein. In some embodiments, the cell expresses an exogenous CD47 polypeptide.

[0405] In some embodiments, the methods disclosed herein include administering a CD47-SIRPα blocker to a subject in need thereof, wherein a cell population engineered to express an exogenous CD47 polypeptide has been previously administered to the subject. In some embodiments, the CD47-SIRPα blocker comprises a CD47 binding domain. In some embodiments, the CD47 binding domain comprises signal regulatory protein α (SIRPα) or a fragment thereof. In some embodiments, the CD47-SIRPα blocker comprises an immunoglobulin G (IgG) Fc domain. In some embodiments, the IgG Fc domain comprises an IgG1 Fc domain. In some embodiments, the IgG1 Fc domain comprises a fragment of a human antibody. In some embodiments, the CD47-SIRPα blocker is selected from the group consisting of TTI-621, TTI-622, and ALX148. In some embodiments, the CD47-SIRPα blocker is TTI-621, TTI-622, and ALX148. In some embodiments, the CD47-SIRPα blocker is TTI-622. In some embodiments, the CD47-SIRPα blocker is ALX148. In some embodiments, the IgG Fc domain comprises an IgG4 Fc domain. In some embodiments, the CD47-SIRPα blocker is an antibody. In some embodiments, the antibody is selected from the group consisting of MIAP410, B6H12, and mololimab. In some embodiments, the antibody is MIAP410. In some embodiments, the antibody is B6H12. In some embodiments, the antibody is mololimab. In some embodiments, the antibody is selected from the group consisting of AO-176, IBI188 (sintilimab), STI-6643, and ZL-1201. In some embodiments, the antibody is AO-176 (Arch). In some embodiments, the antibody is IBI188 (sintilimab) (Innovent). In some embodiments, the antibody is STI-6643 (Sorrento). In some embodiments, the antibody is ZL-1201 (Zai).

[0406] In some embodiments, useful antibodies or fragments thereof that bind to CD47 can be selected from the group consisting of mololimab (Hu5F9-G4) (Forty Seven, Inc.; Gilead Sciences, Inc.), urabrelimab, CC-90002 (Celgene; Bristol-Myers Squibb), IBI-188 (Innovent Biologics), IBI-322 (Innovent Biologics), TG-1801 (TG Therapeutics; also known as NI-1701, Novimmune SA), ALX148 (ALX Oncology), TJ011133 (also known as TJC4, I-Mab Biopharma), FA3M3, ZL-1201 (Zai Lab Co., Ltd), AK117 (Akesbio Australia Pty, Ltd.), AO-176 (Arch Oncology), SRF231 (Surface Immunofluorescence ... Oncology), GenSci-059 (GeneScience), C47B157 (Janssen Research and Development), C47B161 (Janssen Research and Development), C47B167 (Janssen Research and Development), C47B222 (Janssen Research and Development), C47B227 (Janssen Research and Development), Vx-1004 (Corvus Pharmaceuticals), HMBD004 (Hummingbird Bioscience Pte Ltd), SHR-1603 (Hengrui), AMMS4-G4 (Beijing Institute of Biotechnology), RTX-CD47 (University of Groningen) and IMC-002. (Samsung Biologics; ImmuneOnciaTherapeutics).In some embodiments, the antibody or fragment thereof does not compete for CD47 binding with an antibody selected from the group consisting of mololimab, ularizumab, CC-90002, IBI-188, IBI-322, TG-1801 (NI-1701), ALX148, TJ011133, FA3M3, ZL1201, AK117, AO-176, SRF231, GenSci-059, C47B157, C47B161, C47B167, C47B222, C47B227, Vx-1004, HMBD004, SHR-1603, AMMS4-G4, RTX-CD47, and IMC-002. In some embodiments, the antibody or fragment thereof competes for CD47 binding with an antibody selected from the group consisting of mololimab, ularizumab, CC-90002, IBI-188, IBI-322, TG-1801 (NI-1701), ALX148, TJ011133, FA3M3, ZL1201, AK117, AO-176, SRF231, GenSci-059, C47B157, C47B161, C47B167, C47B222, C47B227, Vx-1004, HMBD004, SHR-1603, AMMS4-G4, RTX-CD47, and IMC-002. In some embodiments, the antibody or fragment thereof that binds to CD47 is selected from the group consisting of a single-chain Fv fragment (scFv) against CD47, a Fab against CD47, a VHH nanobody against CD47, a DARPin against CD47, and variants thereof. In some embodiments, the scFv to CD47, Fab to CD47, and variants thereof are based on the antigen binding domain of any antibody selected from the group consisting of mololimab, ularimumab, CC-90002, IBI-188, IBI-322, TG-1801 (NI-1701), ALX148, TJ011133, FA3M3, ZL1201, AK117, AO-176, SRF231, GenSci-059, C47B157, C47B161, C47B167, C47B222, C47B227, Vx-1004, HMBD004, SHR-1603, AMMS4-G4, RTX-CD47, and IMC-002.

[0407] In some embodiments, a CD47 antagonist provides CD47 blockade. Methods and agents for CD47 blockade are described in PCT / US2021 / 054326, which is incorporated herein by reference in its entirety.

[0408] Once altered, the presence of expression of any of the molecules described herein can be determined using known techniques, such as Western blots, ELISA assays, FACS assays, and the like.

[0409] In some embodiments, features associated with specific cell types, such as cell marker features, biomarkers, intracellular markers, extracellular markers, cellular cytokine production, antibody production can also be used as readouts of cell quality. In some embodiments, intracellular markers can be changes in intracellular protein levels. In some embodiments, intracellular markers can be changes in intracellular RNA levels. In some embodiments, intracellular markers can be changes in intracellular DNA levels. In some embodiments, extracellular markers can be changes in extracellular peptide levels (e.g., one or more cytokines, one or more hormones, one or more antibodies, etc.). In some embodiments, extracellular markers can be changes in extracellular signaling molecule levels (e.g., one or more signal peptides, one or more metabolites, one or more ligands, one or more organic compounds, one or more ions, etc.).

[0410] A. Reduced target gene expression

[0411] 1. Target gene

[0412] a. MHC class I and / or MHC class II molecules

[0413] In some embodiments, the engineered cells provided comprise modifications (e.g., genetic modifications) of one or more target polynucleotides or protein sequences (also interchangeably referred to as target genes) that regulate (e.g., reduce or eliminate) the expression of one or more MHC class I molecules, one or more MHC class II molecules, or one or more MHC class I molecules and one or more MHC class II molecules. In some embodiments, the cells to be modified or engineered are unmodified cells or non-engineered cells into which one or more modifications have not been previously introduced. In some embodiments, a gene editing system is used to modify one or more target polynucleotide sequences to regulate (e.g., reduce or eliminate) the expression of one or more MHC class I molecules, one or more MHC class II molecules, or one or more MHC class I molecules and MHC class II molecules. In certain embodiments, the genome of the cell has been altered to reduce or delete components required or involved in promoting HLA expression (such as expression of one or more MHC class I molecules and / or one or more MHC class II molecules on the cell surface). For example, in some embodiments, expression of beta-2-microglobulin (B2M), a component of MHC class I molecules, is reduced or eliminated in the cell, thereby reducing or eliminating protein expression (e.g., cell surface expression) of one or more MHC class I molecules in the engineered cell.

[0414] In some embodiments, any of the modifications described that regulate (e.g., reduce or eliminate) expression of one or more target polynucleotides or proteins in an engineered cell can be combined with one or more modifications described in Section II.B for overexpressing a polynucleotide (e.g., a tolerogenic factor, such as CD47).

[0415] In some embodiments, reduction in expression of one or more MHC class I molecules and / or one or more MHC class II molecules can be achieved, for example, by one or more of the following: (1) direct targeting of polymorphic HLA alleles (HLA-A, HLA-B, HLA-C) and MHC class II genes; (2) removal of B2M, which will reduce surface trafficking of all MHC class I molecules; and / or (3) deletion of one or more components of the MHC enhanceosome that are critical for HLA expression, such as LRC5, RFX-5, RFXANK, RFXAP, IRF1, NF-Y (including NFY-A, NFY-B, NFY-C), and CIITA.

[0416] In certain embodiments, HLA expression is interfered with. In some embodiments, HLA expression is interfered with by targeting a single HLA (knocking out the expression of HLA-A, HLA-B and / or HLA-C), targeting transcriptional regulators of HLA expression (e.g., knocking out the expression of NLRC5, CIITA, RFX5, RFXAP, RFXANK, NFY-A, NFY-B, NFY-C and / or IRF-1), blocking the surface transport of MHC class I molecules (e.g., knocking out the expression of B2M and / or TAP1) and / or targeting with HLA-Razor (see, e.g., WO2016183041).

[0417] Human leukocyte antigen (HLA) complex is synonymous with human MHC. In some embodiments, the engineered cell disclosed herein is a human cell. In some aspects, the engineered cell disclosed herein does not express one or more human leukocyte antigens (e.g., HLA-A, HLA-B and / or HLA-C) corresponding to one or more MHC I class molecules and / or one or more MHC II class molecules, and is therefore characterized as low immunogenicity. For example, in some aspects, the engineered cell disclosed herein has been modified to make the cell (including any stem cell or the stem cell differentiated therefrom) not express one or more of the following MHC I class molecules, or show one or more expression of the following MHC I class molecules reduced: HLA-A, HLA-B and HLA-C. In some embodiments, one or more of HLA-A, HLA-B and HLA-C can be "knocked out" from the cell. Cells with knocked-out HLA-A genes, HLA-B genes and / or HLA-C genes can show the expression of each knocked-out gene reduced or eliminated.

[0418] In certain embodiments, the expression of one or more MHC class I molecules and / or one or more MHC class II molecules is modulated by targeting and deleting a stretch of contiguous genomic DNA, thereby reducing or eliminating the expression of a target gene selected from the group consisting of B2M, CIITA, and NLRC5.

[0419] In some embodiments, the engineered cells provided comprise modifications of one or more target polynucleotide sequences that regulate one or more MHC class I molecules. Exemplary methods for reducing the expression of one or more MHC class I molecules are described in the following subsections. In some embodiments, the targeted polynucleotide sequence is one or both of B2M and NLRC5. In some embodiments, the cell comprises genetic editing modifications (e.g., insertions and deletions) to the B2M gene. In some embodiments, the cell comprises genetic editing modifications (e.g., insertions and deletions) to the NLRC5 gene. In some embodiments, the cell comprises genetic editing modifications (e.g., insertions and deletions) to the B2M and CIITA genes.

[0420] In some embodiments, the modification that reduces the expression of one or more MHC class I molecules is a modification that reduces B2M expression. In some embodiments, the modification that reduces B2M expression reduces B2M mRNA expression. In some embodiments, the reduction in B2M mRNA expression is relative to an unmodified or wild-type cell of the same cell type that does not comprise the modification. In some embodiments, B2M mRNA expression is reduced by more than about 5%, such as a reduction of more than about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more. In some embodiments, B2M mRNA expression is reduced by up to about 100%, such as a reduction of up to about 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 10%, 5% or less. In some embodiments, B2M mRNA expression is reduced by about 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100%. In some embodiments, B2M mRNA expression is eliminated (e.g., 0% expression of B2M mRNA). In some embodiments, the modification that reduces B2M mRNA expression eliminates B2M gene activity.

[0421] In some embodiments, the modification that reduces B2M expression reduces B2M protein expression. In some embodiments, the reduction in B2M protein expression is relative to an unmodified or wild-type cell of the same cell type that does not comprise the modification. In some embodiments, B2M protein expression is reduced by more than about 5%, such as reduced by more than about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more. In some embodiments, B2M protein expression is reduced by up to about 100%, such as reduced by up to about 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 10%, 5% or less. In some embodiments, B2M protein expression is reduced by about 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 100%. In some embodiments, protein expression of B2M is eliminated (eg, 0% expression of B2M protein). In some embodiments, the modification that reduces B2M protein expression eliminates B2M gene activity.

[0422] In some embodiments, the modification that reduces B2M expression comprises inactivation or disruption of the B2M gene. In some embodiments, the modification that reduces B2M expression comprises inactivation or disruption of one allele of the B2M gene. In some embodiments, the modification that reduces B2M expression comprises inactivation or disruption of both alleles of the B2M gene.

[0423] In some embodiments, the modification comprises inactivation or destruction of one or more B2M coding sequences in the cell. In some embodiments, the modification comprises inactivation or destruction of all B2M coding sequences in the cell. In some embodiments, the modification comprises inactivation or destruction of an insertion or deletion in the B2M gene. In some embodiments, the modification is a frameshift mutation in the genomic DNA of the B2M gene. In some embodiments, the modification is a deletion of the genomic DNA of the B2M gene. In some embodiments, the modification is a deletion of a continuous section of genomic DNA of the B2M gene. In some embodiments, the B2M gene is knocked out.

[0424] In some embodiments, the engineered cells provided comprise modifications of one or more target polynucleotide sequences that regulate one or more MHC class II molecules. Exemplary methods for reducing the expression of one or more MHC class II molecules are described in the following subsections. In some embodiments, the cells comprise genetic editing modifications to the CIITA gene.

[0425] In some embodiments, the modification that reduces one or more MHC class II molecules is expressed is the modification that reduces CIITA expression.In some embodiments, the modification that reduces CIITA expression reduces CIITA mRNA expression.In some embodiments, the reduction of CIITA mRNA expression is relative to the unmodified or wild-type cell of the same cell type that does not comprise modification.In some embodiments, CIITA mRNA expression is reduced and exceeds about 5%, such as being reduced and exceeds about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more any one.In some embodiments, CIITA mRNA expression is reduced and is up to about 100%, such as being reduced and is up to about 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 10%, 5% or still less any one. In some embodiments, the mRNA expression of CIITA is reduced by about 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 100% any one. In some embodiments, the mRNA expression of CIITA is eliminated (for example, 0% expression of CIITA mRNA). In some embodiments, the modification that reduces CIITA mRNA expression eliminates CIITA gene activity.

[0426] In some embodiments, the modification that reduces CIITA expression reduces CIITA protein expression. In some embodiments, the reduction of CIITA protein expression is relative to the unmodified or wild-type cells of the same cell type that do not comprise modification. In some embodiments, CIITA protein expression is reduced by more than about 5%, such as being reduced by more than about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more any one. In some embodiments, CIITA protein expression is reduced by up to about 100%, such as being reduced by up to about 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 10%, 5% or less any one. In some embodiments, CIITA protein expression is reduced by any one of about 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 100%. In some embodiments, protein expression of CIITA is eliminated (eg, 0% expression of CIITA protein). In some embodiments, the modification that reduces CIITA protein expression eliminates CIITA gene activity.

[0427] In some embodiments, the modification that reduces CIITA expression comprises inactivation or destruction of the CIITA gene. In some embodiments, the modification that reduces CIITA expression comprises inactivation or destruction of one allele of the CIITA gene. In some embodiments, the modification that reduces CIITA expression comprises inactivation or destruction of two alleles of the CIITA gene.

[0428] In some embodiments, the modification comprises inactivation or destruction of one or more B2M coding sequences in the cell. In some embodiments, the modification comprises inactivation or destruction of all B2M coding sequences in the cell. In some embodiments, the modification comprises inactivation or destruction of an insertion or deletion in the B2M gene. In some embodiments, the modification is a frameshift mutation in the genomic DNA of the B2M gene. In some embodiments, the modification is a deletion of the genomic DNA of the B2M gene. In some embodiments, the modification is a deletion of a continuous section of genomic DNA of the B2M gene. In some embodiments, the CIITA gene is knocked out.

[0429] In some embodiments, the engineered cells provided comprise modifications to one or more target polynucleotide sequences that regulate one or more MHC class I molecules and / or one or more MHC class II molecules. Exemplary methods for reducing the expression of one or more MHC class I molecules and / or one or more MHC class II molecules are described in the following subsections. In some embodiments, the cells comprise genetic editing modifications to the B2M and NLRC5 genes. In some embodiments, the cells comprise genetic editing modifications to the CIITA and NLRC5 genes. In multiple embodiments, the cells comprise genetic editing modifications to the B2M, CIITA, and NLRC5 genes.

[0430] 2. Methods to reduce expression

[0431] In some embodiments, provided herein is a cell modified (for example, genetic modification) to reduce the expression of one or more target polynucleotides or proteins as described. In some embodiments, the cell engineered to have one or more modifications for reducing (for example, eliminating) the expression of polynucleotides or proteins is any source cell as described herein. In some embodiments, the source cell is any cell described in Section II.C. In certain embodiments, the cell disclosed herein (for example, stem cell, induced pluripotent stem cell, differentiated cells such as β islet cells or hepatocytes, or primary cells) includes one or more modifications for reducing the expression of one or more target polynucleotides. The non-limiting examples of the one or more target polynucleotides include any one as described above, such as CIITA, B2M, NLRC5, HLA-A, HLA-B, HLA-C, LRC5, RFX-ANK, RFX5, RFX-AP, NFY-A, NFY-B, NFY-C, IRF1 and TAP1. In some embodiments, the modification for reducing the expression of one or more target polynucleotides is combined with one or more modifications for increasing the expression of a desired transgene (such as any transgene described in Section II.B). In some embodiments, the modification produces an engineered cell that is an immune privileged cell or a low immunogenic cell. By regulating (e.g., reducing or lacking) the expression of one or more target polynucleotides, such cells exhibit reduced immune activation when implanted in a recipient subject. In some embodiments, the cell is considered to be low immunogenic, e.g., low immunogenicity in a recipient subject or patient after administration.

[0432] Any method for reducing the expression of target polynucleotide can be used.In some embodiments, this modification causes the expression of target polynucleotide to be permanently eliminated or reduced.For example, in some embodiments, by introducing DNA breakage (such as by using targeting nucleic acid endonuclease) in target polynucleotide, destroy target polynucleotide or gene.In other embodiments, this modification causes the expression of target polynucleotide to be transiently reduced.For example, in some embodiments, by using the inhibitory nucleic acid complementary to the target polynucleotide to selectively suppress or repress the expression of gene (for example using antisense technology, such as by RNA interference (RNAi), short interfering RNA (siRNA), short hairpin (shRNA) and / or ribozyme) realize gene repression.

[0433] In some embodiments, the target polynucleotide sequence is a genomic sequence. In some embodiments, the target polynucleotide sequence is a human genomic sequence. In some embodiments, the target polynucleotide sequence is a mammalian genomic sequence. In some embodiments, the target polynucleotide sequence is a vertebrate genomic sequence.

[0434] In some embodiments, gene disruption is carried out by inducing one or more double-strand breaks and / or one or more single-strand breaks in a gene in a targeted manner. In some embodiments, double-strand or single-strand breaks are produced by nucleases (e.g., endonucleases, such as gene-targeted nucleases). In some embodiments, targeted nucleases are selected from zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and RNA-guided nucleases specifically designed for being targeted to a gene or a portion thereof. In some embodiments, targeted nucleases generate double-strand or single-strand breaks, which are then subjected to the repair performed by fallible non-homologous end joining (NHEJ), or in some cases, by the repair performed by the precise homology-directed repair (HDR) using a template. In some embodiments, targeted nucleases generate DNA double-strand breaks (DSBs). In some embodiments, the process of generating and repairing a break is generally fallible and results in the insertion and deletion (indels) of the DNA bases repaired from NHEJ. In some embodiments, the modification can induce the deletion, insertion, or sudden change of the nucleotide sequence of the target gene. In some cases, the modification may result in a frameshift mutation that may result in premature termination of the codon. In the example of nuclease-mediated gene editing, targeted editing occurs on both alleles of a gene, resulting in biallelic disruption or editing of the gene. In some embodiments, gene editing targets all alleles of a gene. In some embodiments, modification using a targeted nuclease (such as using a CRISPR / Cas system) results in complete knockout of a gene.

[0435] In some embodiments, nuclease (such as rare cutting endonuclease) is introduced into the cell containing the target polynucleotide sequence.Nuclease can be introduced into the cell in the form of nucleic acid encoding nuclease.The process of introducing nucleic acid into the cell can be achieved by any suitable technology.Suitable technology includes calcium phosphate or lipid-mediated transfection, electroporation and transduction or infection using viral vectors.In some embodiments, the nucleic acid introduced into the cell is DNA.In some embodiments, nuclease is introduced into the cell in the form of protein.For example, in the case of CRISPR / Cas system, ribonucleoprotein (RNP) can be introduced into the cell.

[0436] In some embodiments, the CRISPR / Cas system is used for modification. Any CRISPR / Cas system capable of changing the target polynucleotide sequence in a cell can be used. Such CRISPR-Cas systems can employ a variety of Cas proteins (Haft et al., PLoS Comput Biol. 2005; 1 (6) e60). The molecular mechanisms that allow the CRISPR / Cas system to change the target polynucleotide sequence in a cell include RNA binding proteins, endonucleases and exonucleases, helicases, and polymerases. In some embodiments, the CRISPR / Cas system is a type I CRISPR system. In some embodiments, the CRISPR / Cas system is a type II CRISPR system. In some embodiments, the CRISPR / Cas system is a type V CRISPR system.

[0437] The CRISPR / Cas system includes a targeting system that can be used to change any target polynucleotide sequence in a cell. In some embodiments, the CRISPR / Cas system provided herein includes a Cas protein and one or more (such as at least one to two) ribonucleic acids (e.g., guide RNA (gRNA)) that can guide the Cas protein to a target motif of a target polynucleotide sequence and hybridize therewith.

[0438] In some embodiments, the Cas protein comprises one or more amino acid substitutions or modifications. In some embodiments, the one or more amino acid substitutions include conservative amino acid substitutions. In some cases, substitutions and / or modifications can prevent or reduce proteolytic degradation and / or extend the half-life of the polypeptide in the cell. In some embodiments, the Cas protein may include peptide bond replacements (e.g., urea, thiourea, carbamate, sulfonylurea, etc.). In some embodiments, the Cas protein may include naturally occurring amino acids. In some embodiments, the Cas protein may include alternative amino acids (e.g., D-amino acids, β-amino acids, homocysteine, phosphoserine, etc.). In some embodiments, the Cas protein may include modifications incorporated into a portion (e.g., pegylation, glycosylation, lipidation, acetylation, end-capping, etc.).

[0439] In some embodiments, the Cas protein comprises a core Cas protein. Exemplary Cas core proteins include but are not limited to Cas1, Cas2, Cas3, Cas4, Cas5, Cas6, Cas7, Cas8, and Cas9. In some embodiments, the Cas protein comprises a Cas protein of the Escherichia coli subtype (also referred to as CASS2). Exemplary Cas proteins of the Escherichia coli subtype include but are not limited to Cse1, Cse2, Cse3, Cse4, and Cas5e. In some embodiments, the Cas protein comprises a Cas protein of the Ypest subtype (also referred to as CASS3). Exemplary Cas proteins of the Ypest subtype include but are not limited to Csy1, Csy2, Csy3, and Csy4. In some embodiments, the Cas protein comprises a Cas protein of the Nmeni subtype (also referred to as CASS4). Exemplary Cas proteins of the Nmeni subtype include but are not limited to Csn1 and Csn2. In some embodiments, the Cas protein comprises a Cas protein of the Dvulg subtype (also referred to as CASS1). Exemplary Cas proteins of the Dvulg subtype include Csd1, Csd2, and Cas5d. In some embodiments, the Cas protein comprises a Cas protein of the Tneap subtype (also known as CASS7). Exemplary Cas proteins of the Tneap subtype include but are not limited to Cst1, Cst2, and Cas5t. In some embodiments, the Cas protein comprises a Cas protein of the Hmari subtype. Exemplary Cas proteins of the Hmari subtype include but are not limited to Csh1, Csh2, and Cas5h. In some embodiments, the Cas protein comprises a Cas protein of the Apern subtype (also known as CASS5). Exemplary Cas proteins of the Apern subtype include but are not limited to Csa1, Csa2, Csa3, Csa4, Csa5, and Cas5a. In some embodiments, the Cas protein comprises a Cas protein of the Mtube subtype (also known as CASS6). Exemplary Cas proteins of the Mtube subtype include but are not limited to Csm1, Csm2, Csm3, Csm4, and Csm5. In some embodiments, the Cas protein comprises a RAMP module Cas protein. Exemplary RAMP module Cas proteins include but are not limited to Cmr1, Cmr2, Cmr3, Cmr4, Cmr5, and Cmr6. See, e.g., Klompe et al., Nature 571, 219–225 (2019); Strecker et al., Science 365, 48–53 (2019).

[0440] In some embodiments, the CRISPR system of the present disclosure comprises a TnpB polypeptide. In some embodiments, the TnpB polypeptide may comprise a Ruv-C-like domain. The RuvC domain may be a split RuvC domain comprising RuvC-I, RuvC-II, and RuvC-III subdomains. In some embodiments, TnpB may further comprise one or more of an HTH domain, a bridging helical domain, and a zinc finger domain. The TnpB polypeptide does not comprise an HNH domain. In some embodiments, the TnpB protein comprises, starting from the N-terminus, an HTH domain, a RuvC-I subdomain, a bridging helical domain, a RuvC-II subdomain, a zinger finger domain, and a RuvC-III subdomain. In some embodiments, the RuvC-III subdomain forms the C-terminus of the TnpB polypeptide. In some embodiments, the TnpB polypeptide is from epsilon Proteobacterium, Actinoplanes microphylla strain DSM 43150, Actinomadura cellulosus strain DSM 45823, Actinomadura namibia strain DSM 44197, Alicyclobacillus megaterium strain DSM 17980, Zhang's halophilic strain DSM 102030, or Leptotrichia racemosus. In some embodiments, the TnpB polypeptide is from Leptotrichia racemosus, or comprises a conserved RNA region with similarity to the 5'ITR of the Leptotrichia racemosus TnpB locus. In some embodiments, TnpB may comprise a Fanzor protein, a TnpB homolog found in eukaryotic genomes. In some embodiments, a CRISPR system comprising a TnpB polypeptide binds to a target adjacent motif (TAM) sequence at the 5' position of a target polynucleotide. In some embodiments, the TAM is a transposon-associated motif. In some embodiments, the TAM sequence comprises TCA. In some embodiments, the TAM sequence comprises TTCAN. In some embodiments, the TAM sequence comprises TTGAT. In some embodiments, the TAM sequence comprises ATAAA.

[0441] In some embodiments, methods for genetically modifying cells to knock out, knock down, or otherwise modify one or more genes include the use of site-directed nucleases, including, for example, zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), meganucleases, transposases, and clustered regularly interspaced short palindromic repeats (CRISPR) / Cas systems.

[0442] ZFNs are fusion proteins containing a series of site-specific DNA binding domains that are engineered from zinc finger transcription factors linked to the endonuclease domain of the bacterial FokI restriction enzyme. ZFNs can have one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) DNA binding domains or zinc finger domains. See, for example, Carroll et al., Genetics Society of America (2011) 188: 773-782; Kim et al., Proc. Natl. Acad. Sci. USA (1996) 93: 1156-1160. Each zinc finger domain is a small protein structural motif stabilized by one or more zinc ions and typically recognizes a DNA sequence of 3 to 4 bp. Therefore, the tandem domains can potentially bind to a unique extended nucleotide sequence within the cell genome.

[0443] Various zinc fingers of known specificity can be combined to produce multi-finger polypeptides that recognize about 6, 9, 12, 15, or 18-bp sequences. Various selection and modular assembly techniques can be used to generate zinc fingers (and combinations thereof) that recognize specific sequences, including phage display, yeast one-hybrid systems, bacterial one-hybrid and two-hybrid systems, and mammalian cells. Zinc fingers can be engineered to bind to a predetermined nucleic acid sequence. Criteria for engineering zinc fingers to bind to a predetermined nucleic acid sequence are known in the art. See, for example, Sera et al., Biochemistry (2002) 41: 7074-7081; Liu et al., Bioinformatics (2008) 24: 1850-1857.

[0444] ZFNs containing FokI nuclease domains or other dimeric nuclease domains function as dimers. Therefore, a pair of ZFNs is needed to target non-palindromic DNA sites. Two separate ZFNs must bind to the opposite strands of DNA with their appropriately spaced nucleases. See Bitinaite et al., Proc. Natl. Acad. Sci. USA (1998) 95: 10570-10575. In order to cut a specific site in the genome, a pair of ZFNs are designed to recognize two sequences flanking the site, one on the forward strand and the other on the reverse strand. After the ZFN binds on either side of the site, the nuclease domain dimerizes and cuts the DNA at the site, thereby generating a DSB with a 5' overhang. Specific mutations can then be introduced using HDR with the aid of a repair template containing the desired mutation flanked by homology arms. The repair template is typically an exogenous double-stranded DNA vector introduced into the cell. See Miller et al., Nat. Biotechnol. (2011) 29: 143-148; Hockemeyer et al., Nat. Biotechnol. (2011) 29: 731-734.

[0445] TALEN is another example of an artificial nuclease that can be used to edit target genes. TALEN is derived from a DNA binding domain called a TALE repeat sequence, which typically contains a tandem array of 10 to 30 repeat sequences that bind to and recognize extended DNA sequences. Each repeat sequence is 33 to 35 amino acids long, and two adjacent amino acids (called repeat variable diresidues or RVDs) confer specificity to one of four DNA base pairs. Therefore, there is a one-to-one correspondence between the repeat sequence and the base pairs in the target DNA sequence.

[0446] TALENs are artificially created by fusing one or more TALE DNA binding domains (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) to a nuclease domain (e.g., a FokI endonuclease domain). See Zhang, Nature Biotech. (2011) 29: 149-153. In order to use FokI in TALENs, several mutations have been made to FokI; for example, these mutations improve cleavage specificity or activity. See Cermak et al., Nucl. Acids Res. (2011) 39:e82; Miller et al., Nature Biotech. (2011) 29:143-148; Hockemeyer et al., Nature Biotech. (2011) 29:731-734; Wood et al., Science (2011) 333:307; Doyon et al., Nature Methods (2010) 8:74-79; Szczepek et al., Nature Biotech (2007) 25:786-793; Guo et al., J. Mol. Biol. (2010) 200:96. The FokI domain functions as a dimer, requiring two constructs with distinct DNA binding domains to target sites in the genome with the correct orientation and spacing. The number of amino acid residues between the TALE DNA binding domain and the FokI nuclease domain, as well as the number of bases between two individual TALEN binding sites, appear to be important parameters for achieving high levels of activity. Miller et al., Nature Biotech. (2011) 29: 143-148.

[0447] By combining engineered TALE repeats with nuclease domains, site-specific nucleases specific for any desired DNA sequence can be produced. Similar to ZFNs, TALENs can be introduced into cells to generate DSBs at desired target sites in the genome, and therefore can be used to knock out genes or knock in mutations with similar HDR-mediated pathways. See Boch, Nature Biotech. (2011) 29: 135-136; Boch et al., Science (2009) 326: 1509-1512; Moscou et al., Science (2009) 326: 3501.

[0448] Meganucleases are enzymes in the nuclease family that are characterized by their ability to recognize and cut large DNA sequences (14 to 40 base pairs). Based on the structural motifs that affect nuclease activity and / or DNA recognition of meganucleases, meganucleases are divided into multiple families. The most extensive and famous meganucleases are proteins in the LAGLIDADG family, whose names are derived from conserved amino acid sequences. See Chevalier et al., Nucleic Acids Res. (2001) 29 (18): 3757-3774. On the other hand, GIY-YIG family members have a GIY-YIG module with a length of 70-100 residues and include four or five conserved sequence motifs with four invariant residues, two of which are required for activity. See Van Roey et al., Nature Struct.Biol. (2002) 9: 806-811. The His-Cys family of meganucleases is characterized by a series of highly conserved histidines and cysteines in a region encompassing hundreds of amino acid residues. See Chevalier et al., Nucleic Acids Res. (2001) 29(18):3757-3774. Members of the NHN family are defined by a motif containing two pairs of conserved histidines surrounded by asparagine residues. See Chevalier et al., Nucleic Acids Res. (2001) 29(18):3757-3774.

[0449] Because of the high specificity requirement, the chance of identifying a natural meganuclease for a particular target DNA sequence is low, and therefore various methods, including mutagenesis and high-throughput screening methods, have been used to generate meganuclease variants that recognize unique sequences. Strategies for engineering meganucleases with altered DNA binding specificity (e.g., to bind to a predetermined nucleic acid sequence) are known in the art. See, e.g., Chevalier et al., Mol. Cell. (2002) 10:895-905; Epinat et al., Nucleic Acids Res (2003) 31:2952-2962; Silva et al., J Mol. Biol. (2006) 361:744-754; Seligman et al., Nucleic Acids Res (2002) 30:3870-3879; Sussman et al., J Mol Biol (2004) 342:31-41; Doyon et al., J Am Chem Soc (2006) 128:2477-2484; Chen et al., Protein Eng Des Sel (2009) 22:249-256; Arnould et al., J Mol Biol (2008) 34:350-357; Biol. (2006) 355:443-458; Smith et al., Nucleic Acids Res. (2006) 363(2):283-294.

[0450] Like ZFN and TALEN, meganucleases can generate DSBs in genomic DNA. If improperly repaired (e.g., via NHEJ), it can produce frameshift mutations, thereby reducing the expression of the target gene in the cell. Alternatively, foreign DNA can be introduced into the cell together with the meganuclease. Depending on the sequence of the foreign DNA and the chromosomal sequence, this process can be used to modify the target gene. See Silva et al., Current Gene Therapy (2011) 11: 11-27.

[0451] Transposase is an enzyme that is attached to the end of a transposon and catalyzes the transposon to move to another part of the genome by a cut and paste mechanism or a replicative transposition mechanism. By connecting transposase to other systems (such as CRISPER / Cas systems), new gene editing tools can be developed to achieve site-specific insertion or operation of genomic DNA. There are two known DNA integration methods using transposons, which use catalytically inactive Cas effector proteins and Tn7-like transposons. Transposase-dependent DNA integration does not cause DSB in the genome, which can ensure safer and more specific DNA integration.

[0452] The CRISPR system, originally discovered in prokaryotes (e.g., bacteria and archaea) as a form of acquired immunity involved in defense against invading phages and plasmids, has now been adapted and used as a popular gene-editing tool in research and clinical applications.

[0453] CRISPR / Cas systems typically consist of at least two components: one or more guide RNAs (gRNAs) and a Cas protein. The Cas protein is a nuclease that introduces DSBs into the target site. There are two main categories of CRISPR-Cas systems: Type 1 systems use a complex of multiple Cas proteins to degrade nucleic acids; Type 2 systems use a single, large Cas protein to achieve the same goal. Type 1 systems are divided into types I, III, and IV; Type 2 systems are divided into types II, V, and VI. Different Cas proteins suitable for gene editing applications include, but are not limited to, Cas3, Cas4, Cas5, Cas8a, Cas8b, Cas8c, Cas9, Cas10, Cas12, Cas12a (Cpf1), Cas12b (C2c1), Cas12c (C2c3), Cas12d (CasY), Cas12e (CasX), Cas12f (C2c10), Cas12g, Cas12h, Cas12i, Cas12k (C2c5), Cas13, Cas13a (C2c2), Cas13b, Cas13c, Cas13d, C2c4, C2c8, C2c9, Cmr5, Cse1, Cse2, Csf1, Csm2, Csn2, Csx10, Csx11, Csy1, Csy2, Csy3, and Mad7. The most widely used Cas9 is a type II Cas protein and is described herein as exemplary. These Cas proteins can be derived from different source species. For example, Cas9 can be derived from Streptococcus pyogenes (S. pyogenes) or Staphylococcus aureus (S. aureus).

[0454] In the original microbial genome, the type II CRISPR system incorporates sequences from invading DNA into the host genome between CRISPR repeats encoded as an array. Transcripts from the CRISPR repeat array are processed into CRISPR RNA (crRNA), each of which carries a variable sequence transcribed from the invading DNA (called a "protospacer" sequence) and a portion of the CRISPR repeat sequence. Each crRNA hybridizes with a second trans-activated CRISPR RNA (tracrRNA), and the two RNAs form a complex with the Cas9 nuclease. The protospacer-encoding portion of the crRNA guides the Cas9 complex to cut the complementary target DNA sequence, provided that the sequence is adjacent to a short sequence called a "protospacer adjacent motif" (PAM).

[0455] Since its discovery, the CRISPR system has been modified to induce sequence-specific DSBs and targeted genome editing in a wide range of cells and organisms from bacteria to eukaryotic cells (including human cells). In its use in gene editing applications, artificially designed synthetic gRNAs have replaced the original crRNA:tracrRNA complex. For example, gRNA can be a single guide RNA (sgRNA) consisting of crRNA, tetracyclic and tracrRNA. crRNA generally includes a complementary region (also referred to as a spacer, generally about 20 nucleotides in length) designed by the user to identify the target DNA of interest. The tracrRNA sequence includes a scaffold region for Cas nuclease binding. The crRNA sequence and the tracrRNA sequence are connected by tetracyclics and each have a short repeat sequence for hybridizing to each other, thereby generating a chimeric sgRNA. The genomic target of the Cas nuclease can be changed by simply changing the spacer or complementary region sequence present in the gRNA. The complementary region will guide the Cas nuclease to the target DNA site by standard RNA-DNA complementary base pairing rules.

[0456] In order for the Cas nuclease to work, a PAM must be present immediately downstream of the target sequence in the genomic DNA. Recognition of the PAM by the Cas protein is thought to destabilize the adjacent genomic sequence, allowing the gRNA to interrogate the sequence and resulting in gRNA-DNA pairing when a matching sequence is present. The specific sequence of the PAM varies depending on the type of Cas gene. For example, the most commonly used Cas9 nuclease derived from Streptococcus pyogenes recognizes a PAM sequence of 5'-NGG-3', or with lower efficiency a PAM sequence of 5'-NAG-3', where "N" can be any nucleotide. Other Cas nuclease variants with alternative PAMs have also been characterized and successfully used for genome editing, which are summarized in Table 1a below.

[0457] Table 5. Exemplary Cas nuclease variants and their PAM sequences

[0458]

[0459] R = A or G; Y = C or T; W = A or T; V = A or C or G; N = any base

[0460] In some embodiments, the Cas nuclease may comprise one or more mutations to alter their activity, specificity, recognition, and / or other characteristics. For example, the Cas nuclease may have one or more mutations that alter its fidelity to mitigate off-target effects (e.g., eSpCas9, SpCas9-HF1, HypaSpCas9, HeFSpCas9, and evoSpCas9 high-fidelity variants of SpCas9). For another example, the Cas nuclease may have one or more mutations that alter its PAM specificity.

[0461] In some embodiments, Cas protein includes any one of Cas protein described herein or its functional part.As used herein, "functional part" refers to the part of the peptide that retains its ability to compound with at least one ribonucleic acid (e.g., guide RNA (gRNA)) and cut the target polynucleotide sequence. In some embodiments, the functional part includes a combination of operably connected Cas9 protein functional domains, and the Cas9 protein functional domains are selected from the group consisting of DNA binding domain, at least one RNA binding domain, helicase domain and endonuclease domain. In some embodiments, the functional part includes a combination of operably connected Cas12a (also referred to as Cpf1) protein functional domains, and the Cas12a protein functional domains are selected from the group consisting of DNA binding domain, at least one RNA binding domain, helicase domain and endonuclease domain. In some embodiments, the functional domain forms a complex. In some embodiments, the functional part of Cas9 protein includes the functional part of RuvC-like domain. In some embodiments, the functional part of Cas9 protein includes the functional part of HNH nuclease domain. In some embodiments, the functional part of Cas12a protein includes the functional part of RuvC-like domain.

[0462] In some embodiments, suitable Cas proteins include, but are not limited to, Cas0, Cas12a (ie, Cpf1), Cas12b, Cas12i, CasX, and Mad7.

[0463] In some embodiments, an exogenous Cas protein can be introduced into a cell in the form of a polypeptide. In certain embodiments, the Cas protein can be conjugated or fused to a cell-penetrating polypeptide or cell-penetrating peptide. As used herein, "cell-penetrating polypeptide" and "cell-penetrating peptide" refer to polypeptides or peptides that promote the uptake of molecules into cells, respectively. The cell-penetrating polypeptide may contain a detectable label.

[0464] In certain embodiments, the Cas protein can be conjugated or fused to a charged protein (e.g., one that carries a positive charge, a negative charge, or an overall neutral charge). Such a linkage can be covalent. In some embodiments, the Cas protein can be fused to a superpositively charged GFP to significantly increase the ability of the Cas protein to penetrate cells (Cronican et al. ACS Chem Biol. 2010; 5(8): 747-52). In certain embodiments, the Cas protein can be fused to a protein transduction domain (PTD) to facilitate entry of the Cas protein into cells. Exemplary PTDs include Tat, oligoarginine, and penetrating peptides. In some embodiments, the Cas9 protein comprises a Cas9 polypeptide fused to a cell penetrating peptide. In some embodiments, the Cas9 protein comprises a Cas9 polypeptide fused to a PTD. In some embodiments, the Cas9 protein comprises a Cas9 polypeptide fused to a tat domain. In some embodiments, the Cas9 protein comprises a Cas9 polypeptide fused to an oligoarginine domain. In some embodiments, the Cas9 protein comprises a Cas9 polypeptide fused to a penetrating peptide domain. In some embodiments, the Cas9 protein comprises a Cas9 polypeptide fused to a superpositively charged GFP. In some embodiments, the Cas12a protein comprises a Cas12a polypeptide fused to a cell penetrating peptide. In some embodiments, the Cas12a protein comprises a Cas12a polypeptide fused to a PTD. In some embodiments, the Cas12a protein comprises a Cas12a polypeptide fused to a tat domain. In some embodiments, the Cas12a protein comprises a Cas12a polypeptide fused to an oligoarginine domain. In some embodiments, the Cas12a protein comprises a Cas12a polypeptide fused to a penetrating peptide domain. In some embodiments, the Cas12a protein comprises a Cas12a polypeptide fused to a superpositively charged GFP.

[0465] In some embodiments, the Cas protein can be introduced into a cell containing a target polynucleotide sequence in the form of a nucleic acid encoding the Cas protein. The process of introducing nucleic acid into a cell can be achieved by any suitable technique. Suitable techniques include calcium phosphate or lipid-mediated transfection, electroporation, and transduction or infection using a viral vector. In some embodiments, the nucleic acid comprises DNA. In some embodiments, the nucleic acid comprises a modified DNA as described herein. In some embodiments, the nucleic acid comprises mRNA. In some embodiments, the nucleic acid comprises a modified mRNA as described herein (e.g., a synthetic modified mRNA).

[0466] In the embodiments provided, the CRISPR / Cas system generally includes two components: one or more guide RNAs (gRNAs) and Cas proteins. In some embodiments, the Cas protein is compounded with one or more (such as one to two) ribonucleic acids (e.g., guide RNAs (gRNAs)). In some embodiments, the Cas protein is compounded with two ribonucleic acids. In some embodiments, the Cas protein is compounded with one ribonucleic acid. In some embodiments, the Cas protein is encoded by a modified nucleic acid as described herein (e.g., a synthetic modified mRNA).

[0467] In some embodiments, gRNA is a short synthetic RNA consisting of a scaffold sequence for Cas binding and a user-designed spacer or a complementary portion designated as crRNA. cRNA consists of a crRNA targeting sequence (hereinafter also referred to as a gRNA targeting sequence; generally about 20 nucleotides in length) and a crRNA repeat region (e.g., GUUUUAGAGCUA; SEQ ID NO: 19) that defines the genomic target to be modified. The genomic target of the Cas protein can be changed by simply changing the complementary portion sequence (e.g., gRNA targeting sequence) present in the gRNA. In some embodiments, the scaffold sequence for Cas binding is composed of a tracrRNA sequence (e.g., UAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAA AGUGGCACCGAGUCGGUGCUUU) hybridized with the crRNA through its anti-repeat sequence; SEQ ID NO: 20). The complex between crRNA:tracrRNA recruits Cas nucleases (e.g., Cas9) and cuts upstream of the prototype spacer adjacent motif (PAM). In order for the Cas protein to function, PAM must be present downstream of the target sequence in the genomic DNA. The recognition of the PAM by the Cas protein is thought to destabilize adjacent genomic sequences, thereby allowing the gRNA to interrogate the sequence and, when a matching sequence is present, leading to gRNA-DNA pairing. The specific sequence of the PAM varies depending on the type of Cas gene. For example, the most commonly used Cas9 nuclease from Streptococcus pyogenes recognizes a PAM sequence of NGG. Other Cas9 variants and other nucleases with alternative PAMs have also been characterized and successfully used for genome editing. Therefore, the CRISPR / Cas system can be used to generate targeted DSBs at a specified genomic locus that is complementary to the gRNA designed for the target locus. The crRNA and tracrRNA can be linked together with a loop sequence (e.g., a tetraloop; GAAA) to generate a gRNA as a chimeric single guide RNA (sgRNA; Hsu et al. 2013). The sgRNA can be generated for DNA-based expression or by chemical synthesis.

[0468] In some embodiments, the complementary part sequence of gRNA (such as gRNA targeting sequence) will change according to the target site being paid close attention to.In some embodiments, gRNA comprises the complementary part that has specificity to the gene sequence shown in Table 1a.In some embodiments, the genomic locus targeted by gRNA is located within 4000bp, within 3500bp, within 3000bp, within 2500bp, within 2000bp, within 1500bp, within 1000bp or within 500bp of any locus in the locus as described.

[0469] The methods disclosed herein contemplate the use of any ribonucleic acid capable of guiding a Cas protein to and hybridizing with a target motif of a target polynucleotide sequence. In some embodiments, at least one of the ribonucleic acids comprises

[0470] In some embodiments, the Cas protein is complexed with one to two ribonucleic acids (e.g., guide RNA (gRNA)). In some embodiments, the Cas protein is complexed with two ribonucleic acids. In some embodiments, the Cas protein is complexed with one ribonucleic acid. In some embodiments, the Cas protein is encoded by a modified nucleic acid as described herein (e.g., a synthetic modified mRNA).

[0471] The methods disclosed herein contemplate the use of any ribonucleic acid capable of guiding the Cas protein to the target motif of the target polynucleotide sequence and hybridizing therewith. In some embodiments, at least one of the ribonucleic acids comprises tracrRNA. In some embodiments, at least one of the ribonucleic acids comprises CRISPR RNA (crRNA). In some embodiments, a single ribonucleic acid comprises a guide RNA for guiding the Cas protein to the target motif of the target polynucleotide sequence in the cell and hybridizing therewith. In some embodiments, at least one of the ribonucleic acids comprises a guide RNA for guiding the Cas protein to the target motif of the target polynucleotide sequence in the cell and hybridizing therewith. In some embodiments, the one to two ribonucleic acids all comprise a guide RNA for guiding the Cas protein to the target motif of the target polynucleotide sequence in the cell and hybridizing therewith. As will be understood by those skilled in the art, the ribonucleic acids provided herein can be selected to hybridize with a variety of different target motifs, depending on the specific CRISPR / Cas system and the sequence of the target polynucleotide employed. The one to two ribonucleic acids can also be selected to minimize hybridization with nucleic acid sequences other than the target polynucleotide sequence. In some embodiments, when compared to all other genomic nucleotide sequences in the cell, the one to two ribonucleic acids hybridize to a target motif containing at least two mismatches. In some embodiments, when compared to all other genomic nucleotide sequences in the cell, the one to two ribonucleic acids hybridize to a target motif containing at least one mismatch. In some embodiments, the one to two ribonucleic acids are designed to hybridize to a target motif adjacent to a deoxyribonucleic acid motif reco...

Claims

1. A nucleic acid construct comprising one or more nucleic acid sequences encoding an engineered protein, wherein the engineered protein comprises: (a) one or more extracellular domains; and (b) One or more membrane tethers; wherein the one or more extracellular domains comprise a signal regulatory protein alpha (SIRPα) interaction motif, and The nucleic acid construct does not comprise a nucleic acid sequence encoding one or more full-length CD47 intracellular domains. 2 . The nucleic acid construct of claim 1 , wherein the SIRPα interaction motif is or comprises the CD47 extracellular domain or a portion thereof.

3. The nucleic acid construct of claim 2, wherein the CD47 extracellular domain is or comprises a CD47 immunoglobulin variable (IgV)-like domain.

4. The nucleic acid construct of claim 1 or 2, wherein the CD47 extracellular domain is a human CD47 extracellular domain.

5. The nucleic acid construct of any one of claims 2 to 4, wherein the CD47 extracellular domain is encoded by a nucleic acid sequence having at least 80% identity to SEQ ID NO:

52.

6. The nucleic acid construct of any one of claims 2-4, wherein the CD47 extracellular domain is encoded by a nucleic acid sequence having at least 80% identity to SEQ ID NO:

53.

7. The nucleic acid construct of any one of claims 2-4, wherein the CD47 extracellular domain is encoded by a nucleic acid sequence that is at least 80% identical to SEQ ID NO:

57.

8. The nucleic acid construct of any one of claims 2-4, wherein the CD47 extracellular domain is encoded by a nucleic acid sequence that is at least 80% identical to SEQ ID NO:

59. 9 . The nucleic acid construct of claim 1 , wherein the SIRPα interaction motif is or comprises a SIRPα antibody or a portion thereof.

10. The nucleic acid construct of any one of claims 1 to 9, wherein the one or more membrane tethers are or comprise a transmembrane domain.

11. A nucleic acid construct as claimed in claim 10, wherein the membrane spaning domain is or comprises CD3ζ, CD8a, CD16a, CD28, CD32a, CD32c, CD40, CD47, CD64, ICOS, Dectin-1, DNGR1, EGFR, GPCR, MyD88, PDGFR, SLAMF7, TRL1, TLR2, TLR3, TRL4, TLR5, TLR6, TLR7, TLR8, TLR9 or a VEGFR membrane spaning domain.

12. The nucleic acid construct of claim 10 or 11, wherein the transmembrane domain is or comprises a CD47 transmembrane domain.

13. The nucleic acid construct of any one of claims 10-12, wherein the transmembrane domain is encoded by a nucleic acid sequence that is at least 80% identical to SEQ ID NO:

54.

14. The nucleic acid construct of any one of claims 10-12, wherein the transmembrane domain is encoded by a nucleic acid sequence that is at least 80% identical to SEQ ID NO:

56.

15. The nucleic acid construct of any one of claims 10-12, wherein the transmembrane domain is encoded by a nucleic acid sequence that is at least 80% identical to SEQ ID NO:

58.

16. The nucleic acid construct of any one of claims 10-12, wherein the transmembrane domain is encoded by a nucleic acid sequence that is at least 80% identical to SEQ ID NO:

60.

17. The nucleic acid construct of any one of claims 10-12, wherein the transmembrane domain is encoded by a nucleic acid sequence that is at least 80% identical to SEQ ID NO:

62.

18. The nucleic acid construct of claim 10 or 11, wherein the transmembrane domain is or comprises a CD8a transmembrane domain.

19. The nucleic acid construct of claim 10, 11 or 18, wherein the transmembrane domain is encoded by a nucleic acid sequence that is at least 80% identical to SEQ ID NO:

69.

20. The nucleic acid construct of claim 10 or 11, wherein the transmembrane domain is or comprises a CD28 transmembrane domain.

21. The nucleic acid construct of claim 10, 11 or 20, wherein the transmembrane domain is encoded by a nucleic acid sequence that is at least 80% identical to SEQ ID NO:

71.

22. The nucleic acid construct of claim 10 or 11, wherein the transmembrane domain is or comprises a PDGFR transmembrane domain.

23. The nucleic acid construct of claim 10, 11 or 22, wherein the transmembrane domain is encoded by a nucleic acid sequence that is at least 80% identical to SEQ ID NO:

73.

24. The nucleic acid construct of any one of claims 1-9, wherein the one or more membrane tethers are or comprise a glycosylphosphatidylinositol (GPI) anchor.

25. The nucleic acid construct of claim 24, wherein the GPI anchor is or comprises a DAF / CD55 GPI anchor, a TRAILR3 GPI anchor or a CD59 GPI anchor.

26. The nucleic acid construct of claim 24 or 25, wherein the GPI anchor is or comprises a DAF / CD55 GPI anchor.

27. The nucleic acid construct of any one of claims 24-26, wherein the DAF / CD55 GPI anchor is encoded by a nucleic acid sequence that is at least 80% identical to SEQ ID NO:

65.

28. The nucleic acid construct of claim 24 or 25, wherein the GPI anchor is or comprises a TRAILR3 GPI anchor.

29. The nucleic acid construct of any one of claims 24, 25 or 28, wherein the TRAILR3 GPI anchor is encoded by a nucleic acid sequence that is at least 80% identical to SEQ ID NO:

66.

30. The nucleic acid construct of any one of claims 24, 25 or 28, wherein the TRAILR3 GPI anchor is encoded by a nucleic acid sequence that is at least 80% identical to SEQ ID NO:

67.

31. The nucleic acid construct of claim 24 or 25, wherein the GPI anchor is or comprises a CD59 GPI anchor.

32. The nucleic acid construct of any one of claims 24, 25 or 31, wherein the CD59 GPI anchor is encoded by a nucleic acid sequence that is at least 80% identical to SEQ ID NO:

68.

33. The nucleic acid construct of any one of claims 1-24, further comprising one or more control sequences.

34. The nucleic acid construct of claim 33, wherein the one or more control sequences encode an extracellular signal peptide.

35. The nucleic acid construct of claim 33 or 34, wherein the extracellular signal peptide is encoded by a nucleic acid sequence having at least 80% identity to SEQ ID NO:

51.

36. The nucleic acid construct of claim 33, wherein the one or more control sequences comprise a promoter.

37. nucleic acid construct as claimed in claim 36, wherein the promoter is a constitutive promoter or an inducible promoter.

38. A nucleic acid construct as claimed in claim 36 or 37, wherein the promoter is a naturally occurring promoter, a hybrid promoter or a synthetic promoter.

39. A nucleic acid construct as described in any one of claims 36-38, wherein the promoter is or includes EF1α promoter, EF1α short promoter, CAG promoter, ubiquitin / S27a promoter, SV40 early promoter, adenovirus major late promoter, mouse metallothionein-I promoter, RSV promoter, MMTV promoter, Moloney murine leukemia virus long terminal repeat region, CMV promoter, actin promoter, immunoglobulin promoter, heat shock promoter, polyoma promoter. , fowlpox virus promoter, bovine papilloma virus promoter, avian sarcoma virus promoter, retrovirus promoter, hepatitis B virus promoter, PGK promoter, adenovirus late promoter, vaccinia virus 7.5K promoter, SV40 promoter, tk promoter of HSV, mouse mammary tumor virus (MMTV) promoter, LTR promoter of HIV, Moloney virus promoter, Epstein-Barr virus (EBV) promoter, Rous sarcoma virus (RSV) promoter, U6 promoter or UBC promoter.

40. A nucleic acid construct as described in any one of claims 36-39, wherein the promoter is or comprises a CAG promoter.

41. A nucleic acid construct as described in any one of claims 36-40, wherein the promoter comprises a nucleic acid sequence that is at least 80% identical to SEQ ID NO:

49.

42. A nucleic acid construct as described in any one of claims 36-39, wherein the promoter is or comprises an EF1α promoter.

43. The nucleic acid construct of any one of claims 36-40, or 42, wherein the promoter comprises a nucleic acid sequence at least 80% identical to SEQ ID NO:

50.

44. The nucleic acid construct of claim 33, wherein the one or more control sequences comprise a ribosome binding site, an enhancer element, an activator element, a translation initiation sequence, a translation termination sequence, a transcription initiation sequence, a transcription termination sequence, a polyadenylation signal sequence, a replication element, an RNA processing and export element, a transposon sequence, a transposase sequence, an insulator sequence, an internal ribosome entry site (IRES), a 5'UTR, a 3'UTR, an mRNA 3' end processing sequence, a boundary element, a locus control region (LCR), a matrix attachment region (MAR), a recombination or cassette exchange sequence, a linker sequence, a secretion signal, a resistance marker, an anchor peptide, a localization signal, a fusion tag, an affinity tag, a chaperone protein, a protease, or a combination thereof.

45. The nucleic acid construct of any one of claims 1-44, wherein the one or more extracellular domains further comprise an extracellular hinge domain.

46. ​​A nucleic acid construct as described in claim 45, wherein the extracellular hinge domain is or comprises a CD47 hinge, a CD8a hinge, a CD28 hinge, a PDGFR hinge or an IgG4 hinge.

47. The nucleic acid construct of claim 45 or 46, wherein the extracellular hinge domain is or comprises a CD47 hinge.

48. The nucleic acid construct of any one of claims 45-47, wherein the extracellular hinge domain is encoded by a nucleic acid sequence that is at least 80% identical to SEQ ID NO:

75.

49. The nucleic acid construct of claim 45 or 46, wherein the extracellular hinge domain is or comprises a CD8a hinge.

50. The nucleic acid construct of claim 45, 46, or 49, wherein the extracellular hinge domain is encoded by a nucleic acid sequence that is at least 80% identical to SEQ ID NO:

76.

51. The nucleic acid construct of claim 45 or 46, wherein the extracellular hinge domain is or comprises a CD28 hinge.

52. The nucleic acid construct of claim 45, 46, or 7f51, wherein the extracellular hinge domain is encoded by a nucleic acid sequence that is at least 80% identical to SEQ ID NO:

77.

53. nucleic acid construct as claimed in claim 45 or 46, wherein the extracellular hinge domain is or comprises a PDGFR hinge.

54. The nucleic acid construct of claim 45, 46, or 53, wherein the extracellular hinge domain is encoded by a nucleic acid sequence that is at least 80% identical to SEQ ID NO:

78.

55. The nucleic acid construct of claim 45 or 46, wherein the extracellular hinge domain is or comprises an IgG4 hinge.

56. The nucleic acid construct of claim 45, 46, or 55, wherein the extracellular hinge domain is encoded by a nucleic acid sequence that is at least 80% identical to SEQ ID NO:

79.

57. nucleic acid construct as described in any one of the preceding claims, further comprising one or more nucleic acid sequences encoding an intracellular domain.

58. The nucleic acid construct of claim 57, wherein the intracellular domain is or comprises the CD47 intracellular domain or a portion thereof.

59. The nucleic acid construct of claim 57 or 58, wherein the intracellular domain is encoded by a nucleic acid sequence that is at least 80% identical to SEQ ID NO:

55.

60. The nucleic acid construct of claim 57 or 58, wherein the intracellular domain is encoded by a nucleic acid sequence that is at least 80% identical to SEQ ID NO:

59.

61. The nucleic acid construct of claim 57 or 58, wherein the intracellular domain is encoded by a nucleic acid sequence that is at least 80% identical to SEQ ID NO:

63.

62. The nucleic acid construct of claim 57 or 58, wherein the intracellular domain is encoded by a nucleic acid sequence that is at least 80% identical to SEQ ID NO:

64.

63. nucleic acid construct as claimed in claim 57, wherein the intracellular domain is or comprises the CD8a intracellular domain or a portion thereof.

64. The nucleic acid construct of claim 57 or 63, wherein the intracellular domain is encoded by a nucleic acid sequence that is at least 80% identical to SEQ ID NO:

70.

65. nucleic acid construct as claimed in claim 57, wherein the intracellular domain is or comprises the CD28 intracellular domain or a portion thereof.

66. The nucleic acid construct of claim 57 or 58, wherein the intracellular domain is encoded by a nucleic acid sequence that is at least 80% identical to SEQ ID NO:

72.

67. nucleic acid construct as claimed in claim 57, wherein the intracellular domain is or comprises the PDGFR intracellular domain or its part.

68. The nucleic acid construct of claim 57 or 67, wherein the intracellular domain is encoded by a nucleic acid sequence that is at least 80% identical to SEQ ID NO:

74.

69. The nucleic acid construct of any one of claims 57-68, wherein the intracellular domain comprises one or more modifications relative to the wild-type CD47 intracellular domain.

70. The nucleic acid construct of any one of claims 57-69, wherein the intracellular domain comprises one or more deletions relative to the wild-type CD47 intracellular domain.

71. The nucleic acid construct of any one of claims 57-69, wherein the intracellular domain comprises one or more insertions relative to the wild-type CD47 intracellular domain.

72. The nucleic acid construct of any one of claims 57-71, wherein the intracellular domain comprises an altered function relative to the wild-type CD47 intracellular domain.

73. The nucleic acid construct of any one of claims 57-72, wherein the intracellular domain comprises reduced function relative to the wild-type CD47 intracellular domain.

74. The nucleic acid construct of any one of claims 57-73, wherein the intracellular domain comprises a reduced level of CD47 intracellular signaling relative to a wild-type CD47 intracellular domain.

75. nucleic acid construct as described in any one in claim 57-74, wherein said intracellular domain comprises a non-functional intracellular domain.

76. A nucleic acid construct as described in any one of the preceding claims, comprising a nucleic acid sequence that has at least 80% identity to a sequence selected from Table 31.

77. The nucleic acid construct of any one of claims 1-76, comprising a nucleic acid sequence at least 80% identical to SEQ ID NO:

13.

78. The nucleic acid construct of any one of claims 1-76, comprising a nucleic acid sequence at least 80% identical to SEQ ID NO:

14.

79. The nucleic acid construct of any one of claims 1-76, comprising a nucleic acid sequence at least 80% identical to SEQ ID NO:

18.

80. The nucleic acid construct of any one of claims 1-76, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

133.

81. The nucleic acid construct of any one of claims 1-76, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

134.

82. The nucleic acid construct of any one of claims 1-76, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

135.

83. The nucleic acid construct of any one of claims 1-76, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

136.

84. The nucleic acid construct of any one of claims 1-76, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

137.

85. The nucleic acid construct of any one of claims 1-76, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

138.

86. The nucleic acid construct of any one of claims 1-76, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

139.

87. The nucleic acid construct of any one of claims 1-76, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

140.

88. The nucleic acid construct of any one of claims 1-76, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

141.

89. The nucleic acid construct of any one of claims 1-76, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

142.

90. The nucleic acid construct of any one of claims 1-76, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

143.

91. The nucleic acid construct of any one of claims 1-76, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

144.

92. The nucleic acid construct of any one of claims 1-76, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

145.

93. The nucleic acid construct of any one of claims 1-76, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

146.

94. The nucleic acid construct of any one of claims 1-76, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

147.

95. The nucleic acid construct of any one of claims 1-76, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

148.

96. The nucleic acid construct of any one of claims 1-76, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

149.

97. The nucleic acid construct of any one of claims 1-76, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

150.

98. The nucleic acid construct of any one of claims 1-76, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

151.

99. The nucleic acid construct of any one of claims 1-76, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

152.

100. The nucleic acid construct of any one of claims 1-76, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

153.

101. The nucleic acid construct of any one of claims 1-76, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

154.

102. The nucleic acid construct of any one of claims 1-76, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

155.

103. The nucleic acid construct of any one of claims 1-76, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

156.

104. The nucleic acid construct of any one of claims 1-76, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

157.

105. The nucleic acid construct of any one of claims 1-76, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

158.

106. The nucleic acid construct of any one of claims 1-76, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

159.

107. The nucleic acid construct of any one of claims 1-76, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

160.

108. The nucleic acid construct of any one of claims 1-76, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

161.

109. The nucleic acid construct of any one of claims 1-76, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

162.

110. The nucleic acid construct of any one of claims 1-76, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

163.

111. The nucleic acid construct of any one of claims 1-76, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

164.

112. The nucleic acid construct of any one of claims 1-76, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

165.

113. The nucleic acid construct of any one of claims 1-76, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

166.

114. The nucleic acid construct of any one of claims 1-76, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

167.

115. The nucleic acid construct of any one of claims 1-76, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

168.

116. The nucleic acid construct of any one of claims 1-76, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

169.

117. The nucleic acid construct of any one of claims 1-76, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

170.

118. The nucleic acid construct of any one of claims 1-76, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

171.

119. The nucleic acid construct of any one of claims 1-76, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

172.

120. The nucleic acid construct of any one of claims 1-76, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

173.

121. The nucleic acid construct of any one of claims 1-76, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

174.

122. The nucleic acid construct of any one of claims 1-76, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

175.

123. The nucleic acid construct of any one of claims 1-76, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

176.

124. The nucleic acid construct of any one of claims 1-76, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

177.

125. The nucleic acid construct of any one of claims 1-76, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

178.

126. The nucleic acid construct of any one of claims 1-76, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

179.

127. The nucleic acid construct of any one of claims 1-76, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

180.

128. The nucleic acid construct of any one of claims 1-76, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

181.

129. The nucleic acid construct of any one of claims 1-76, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

182.

130. The nucleic acid construct of any one of claims 1-76, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

183.

131. The nucleic acid construct of any one of claims 1-76, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

184.

132. The nucleic acid construct of any one of claims 1-76, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

185.

133. The nucleic acid construct of any one of claims 1-76, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

341.

134. The nucleic acid construct of any one of claims 1-76, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

342.

135. A nucleic acid construct as described in any one of claims 1-68, comprising one or more nucleic acid sequences having at least 80% identity to one or more sequences selected from Table 33.

136. A nucleic acid construct as described in any one of the preceding claims, comprising one or more nucleic acid sequences having at least 80% identity to one or more sequences selected from Table 33 and / or Table 31.

137. The nucleic acid construct of any one of claims 1-68, comprising one or more nucleic acid sequences that are at least 80% identical to SEQ ID NO:49 and SEQ ID NO:

14.

138. The nucleic acid construct of any one of claims 1-68, comprising one or more nucleic acid sequences that are at least 80% identical to SEQ ID NO:

14.

139. The nucleic acid construct of any one of claims 1-68, comprising one or more nucleic acid sequences that are at least 80% identical to SEQ ID NO:49 and SEQ ID NO:

13.

140. The nucleic acid construct of any one of claims 1-68, comprising one or more nucleic acid sequences that are at least 80% identical to SEQ ID NO:

13.

141. The nucleic acid construct of any one of claims 1-68, comprising one or more nucleic acid sequences that are at least 80% identical to SEQ ID NO:49 and SEQ ID NO:

18.

142. The nucleic acid construct of any one of claims 1-68, comprising one or more nucleic acid sequences that are at least 80% identical to SEQ ID NO:

18.

143. A nucleic acid construct as described in any one of claims 1-68, comprising one or more nucleic acid sequences that are at least 80% identical to SEQ ID No:51, 52, 54, 55, 56 and 57.

144. A nucleic acid construct as described in any one of claims 1-68, comprising one or more nucleic acid sequences that are at least 80% identical to SEQ ID No:51, 52, 54, 55 and 56.

145. The nucleic acid construct of any one of claims 1-68, comprising one or more nucleic acid sequences having at least 80% identity to SEQ ID No:51, 52, 54 and 55.

146. A nucleic acid construct as described in any one of claims 1-68, comprising one or more nucleic acid sequences having at least 80% identity to SEQ ID No:51, 52, 54, 55, 56, 57, 58, 59, 60, 61 and 62.

147. A nucleic acid construct as described in any one of claims 1-68, comprising one or more nucleic acid sequences having at least 80% identity to SEQ ID No:51, 52, 54, 55, 56, 57, 58, 59, 60 and 61.

148. A nucleic acid construct as described in any one of claims 1-68, comprising one or more nucleic acid sequences that are at least 80% identical to SEQ ID No:51, 52, 54, 55, 56, 57, 58, 59 and 60.

149. A nucleic acid construct as described in any one of claims 1-68, comprising one or more nucleic acid sequences that are at least 80% identical to SEQ ID No:51, 52, 54, 55, 56, 57, 58 and 59.

150. The nucleic acid construct of any one of claims 1-68, comprising one or more nucleic acid sequences that are at least 80% identical to SEQ ID NOs:49, 53, and 65.

151. The nucleic acid construct of any one of claims 1-68, comprising one or more nucleic acid sequences that are at least 80% identical to SEQ ID NOs:53 and 65.

152. The nucleic acid construct of any one of claims 1-68, comprising one or more nucleic acid sequences that are at least 80% identical to SEQ ID NOs:49, 53, and 66.

153. The nucleic acid construct of any one of claims 1-68, comprising one or more nucleic acid sequences that are at least 80% identical to SEQ ID NOs:53 and 66.

154. The nucleic acid construct of any one of claims 1-68, comprising one or more nucleic acid sequences that are at least 80% identical to SEQ ID NOs:49, 53, and 67.

155. The nucleic acid construct of any one of claims 1-68, comprising one or more nucleic acid sequences that are at least 80% identical to SEQ ID NOs:53 and 67.

156. The nucleic acid construct of any one of claims 1-68, comprising one or more nucleic acid sequences that are at least 80% identical to SEQ ID NOs:49, 53, 69 and 70.

157. The nucleic acid construct of any one of claims 1-68, comprising one or more nucleic acid sequences that are at least 80% identical to SEQ ID NOs:53, 69, and 70.

158. A nucleic acid construct as described in any one of claims 1-8k, comprising one or more nucleic acid sequences that are at least 80% identical to SEQ ID NO:49, 53, 71 and 72.

159. The nucleic acid construct of any one of claims 1-68, comprising one or more nucleic acid sequences that are at least 80% identical to SEQ ID NOs:53, 71 and 72.

160. The nucleic acid construct of any one of claims 1-68, comprising one or more nucleic acid sequences that are at least 80% identical to SEQ ID NOs:49, 53, 73, and 74.

161. A nucleic acid construct as described in any one of claims 1-68, comprising one or more nucleic acid sequences that are at least 80% identical to SEQ ID NO:53, 73 and 74.

162. A nucleic acid construct as described in any one of claims 1-68, comprising one or more nucleic acid sequences that are at least 80% identical to SEQ ID NO:49, 52, 78, 73 and 74.

163. A nucleic acid construct as described in any one of claims 1-68, comprising one or more nucleic acid sequences that are at least 80% identical to SEQ ID NO:52, 78, 73 and 74.

164. A nucleic acid construct as described in any one of claims 1-68, comprising one or more nucleic acid sequences that are at least 80% identical to SEQ ID NO:49, 52, 79, 71 and 72.

165. A nucleic acid construct as described in any one of claims 1-68, comprising one or more nucleic acid sequences that are at least 80% identical to SEQ ID NO:52, 79, 71 and 72.

166. A nucleic acid construct as described in any one of claims 1-68, comprising one or more nucleic acid sequences that are at least 80% identical to SEQ ID NO:49, 52, 79, 69 and 70.

167. The nucleic acid construct of any one of claims 1-68, comprising one or more nucleic acid sequences that are at least 80% identical to SEQ ID NOs:52, 79, 69 and 70.

168. A nucleic acid construct as described in any one of claims 1-68, comprising one or more nucleic acid sequences that are at least 80% identical to SEQ ID NO:49, 52, 77, 71 and 72.

169. A nucleic acid construct as described in any one of claims 1-68, comprising one or more nucleic acid sequences that are at least 80% identical to SEQ ID NO:52, 77, 71 and 72.

170. The nucleic acid construct of any one of claims 1-68, comprising one or more nucleic acid sequences that are at least 80% identical to SEQ ID NOs:49, 52, 77, 69 and 70.

171. The nucleic acid construct of any one of claims 1-68, comprising one or more nucleic acid sequences that are at least 80% identical to SEQ ID NOs:52, 77, 69 and 70.

172. A nucleic acid construct as described in any one of claims 1-68, comprising one or more nucleic acid sequences that are at least 80% identical to SEQ ID NO:49, 52, 76, 71 and 72.

173. A nucleic acid construct as described in any one of claims 1-68, comprising one or more nucleic acid sequences that are at least 80% identical to SEQ ID NOs:52, 76, 71 and 72.

174. A nucleic acid construct as described in any one of claims 1-68, comprising one or more nucleic acid sequences that are at least 80% identical to SEQ ID NO:49, 52, 76, 69 and 70.

175. The nucleic acid construct of any one of claims 1-68, comprising one or more nucleic acid sequences that are at least 80% identical to SEQ ID NOs:52, 76, 69 and 70.

176. The nucleic acid construct of any one of claims 1-68, comprising one or more nucleic acid sequences that are at least 80% identical to SEQ ID NOs: 49 and 200.

177. The nucleic acid construct of any one of claims 1-68, comprising one or more nucleic acid sequences that are at least 80% identical to SEQ ID NOs: 50 and 200.

178. The nucleic acid construct of any one of claims 1-68, comprising one or more nucleic acid sequences that are at least 80% identical to SEQ ID NO:

200.

179. A vector comprising the nucleic acid construct of any one of claims 1-178.

180. The vector of claim 179, wherein the vector is a multicistronic vector.

181. The vector of claim 180, wherein the multicistronic vector is a bicistronic vector or a tricistronic vector.

182. The vector of any one of claims 179-181, wherein the vector is a plasmid or a viral vector.

183. The vector of claim 182, wherein the viral vector is a pseudotyped self-inactivating lentiviral vector.

184. An engineered protein encoded by the nucleic acid construct of any one of claims 1-178.

185. An engineered protein comprising: (a) one or more extracellular domains; and (b) One or more membrane tethers; wherein the one or more extracellular domains comprise a signal regulatory protein alpha (SIRPα) interaction motif, and wherein the engineered protein does not comprise one or more full-length CD47 intracellular domains.

186. The engineered protein of claim 185, wherein the SIRPα interaction motif is or comprises the CD47 extracellular domain or a portion thereof.

187. The engineered protein of claim 186, wherein the CD47 extracellular domain is a CD47 immunoglobulin variable (IgV)-like domain.

188. The engineered protein of claim 185 or 186, wherein the CD47 extracellular domain is a human CD47 extracellular domain.

189. The engineered protein of any one of claims 186-188, wherein the CD47 extracellular domain comprises an amino acid sequence that is at least 80% identical to SEQ ID NO:

21.

190. The engineered protein of any one of claims 186-188, wherein the CD47 extracellular domain comprises an amino acid sequence that is at least 80% identical to SEQ ID NO:

22.

191. The engineered protein of any one of claims 186-188, wherein the CD47 extracellular domain comprises an amino acid sequence that is at least 80% identical to SEQ ID NO:

26.

192. The engineered protein of any one of claims 186-188, wherein the CD47 extracellular domain comprises an amino acid sequence that is at least 80% identical to SEQ ID NO:

30.

193. The engineered protein of claim 185, wherein the SIRPα interaction motif is or comprises a SIRPα antibody or a portion thereof.

194. The engineered protein of claim 193, wherein the SIRPα antibody or portion thereof comprises an amino acid sequence at least 80% identical to SEQ ID NO:

186.

195. The engineered protein of claim 193, wherein the SIRPα antibody or portion thereof comprises an amino acid sequence at least 80% identical to SEQ ID NO:

187.

196. The engineered protein of claim 193, wherein the SIRPα antibody or portion thereof comprises an amino acid sequence at least 80% identical to SEQ ID NO:

188.

197. The engineered protein of claim 193, wherein the SIRPα antibody or portion thereof comprises an amino acid sequence at least 80% identical to SEQ ID NO:

189.

198. The engineered protein of claim 193, wherein the SIRPα antibody or portion thereof comprises an amino acid sequence at least 80% identical to SEQ ID NO:

190.

199. The engineered protein of claim 193, wherein the SIRPα antibody or portion thereof comprises an amino acid sequence at least 80% identical to SEQ ID NO:

191.

200. The engineered protein of claim 193, wherein the SIRPα antibody or portion thereof comprises an amino acid sequence at least 80% identical to SEQ ID NO:

192.

201. The engineered protein of claim 193, wherein the SIRPα antibody or portion thereof comprises an amino acid sequence at least 80% identical to SEQ ID NO:

193.

202. The engineered protein of claim 193, wherein the SIRPα antibody or portion thereof comprises an amino acid sequence at least 80% identical to SEQ ID NO:

194.

203. The engineered protein of claim 193, wherein the SIRPα antibody or portion thereof comprises an amino acid sequence at least 80% identical to SEQ ID NO:

195.

204. The engineered protein of claim 193, wherein the SIRPα antibody or portion thereof comprises an amino acid sequence at least 80% identical to SEQ ID NO:

196.

205. The engineered protein of claim 193, wherein the SIRPα antibody or portion thereof comprises an amino acid sequence at least 80% identical to SEQ ID NO:

197.

206. The engineered protein of claim 193, wherein the SIRPα antibody or portion thereof comprises an amino acid sequence at least 80% identical to SEQ ID NO:

198.

207. The engineered protein of any one of claims 185-193, wherein the one or more membrane tethers is or comprises a transmembrane domain.

208. An engineered protein as described in claim 207, wherein the transmembrane domain is or comprises a CD3ζ, CD8a, CD16a, CD28, CD32a, CD32c, CD40, CD47, CD64, ICOS, Dectin-1, DNGR1, EGFR, GPCR, MyD88, PDGFR, SLAMF7, TRL1, TLR2, TLR3, TRL4, TLR5, TLR6, TLR7, TLR8, TLR9 or VEGFR transmembrane domain.

209. The engineered protein of claim 207 or 208, wherein the transmembrane domain is or comprises a CD47 transmembrane domain.

210. The engineered protein of any one of claims 207-209, wherein the transmembrane domain comprises an amino acid sequence at least 80% identical to SEQ ID NO:

23.

211. The engineered protein of any one of claims 207-209, wherein the transmembrane domain comprises an amino acid sequence at least 80% identical to SEQ ID NO:

25.

212. The engineered protein of any one of claims 207-209, wherein the transmembrane domain comprises an amino acid sequence at least 80% identical to SEQ ID NO:

27.

213. The engineered protein of any one of claims 207-209, wherein the transmembrane domain comprises an amino acid sequence at least 80% identical to SEQ ID NO:

29.

214. The engineered protein of any one of claims 207-209, wherein the transmembrane domain comprises an amino acid sequence at least 80% identical to SEQ ID NO:

31.

215. The engineered protein of claim 207 or 208, wherein the transmembrane domain is or comprises a CD8a transmembrane domain.

216. The engineered protein of claim 207, 208 or 215, wherein the transmembrane domain comprises an amino acid sequence at least 80% identical to SEQ ID NO:

38.

217. The engineered protein of claim 207 or 208, wherein the transmembrane domain is or comprises a CD28 transmembrane domain.

218. The engineered protein of claim 207, 208 or 217, wherein the transmembrane domain comprises an amino acid sequence at least 80% identical to SEQ ID NO:

40.

219. The engineered protein of claim 207 or 208, wherein the transmembrane domain is or comprises a PDGFR transmembrane domain.

220. The engineered protein of claim 207, 208 or 219, wherein the transmembrane domain comprises an amino acid sequence at least 80% identical to SEQ ID NO:

42.

221. The engineered protein of any one of claims 85-193, wherein the one or more membrane tethers are or comprise a glycosylphosphatidylinositol (GPI) anchor.

222. The engineered protein of claim 221, wherein the GPI anchor is or comprises a DAF / CD55 GPI anchor, a TRAILR3 GPI anchor, or a CD59 GPI anchor.

223. The engineered protein of claim 221 or 222, wherein the GPI anchor is or comprises a DAF / CD55 GPI anchor.

224. The engineered protein of any one of claims 221-223, wherein the DAF / CD55 GPI anchor comprises an amino acid sequence at least 80% identical to SEQ ID NO:

34.

225. The engineered protein of claim 221 or 222, wherein the GPI anchor is or comprises a TRAILR3 GPI anchor.

226. The engineered protein of any one of claims 221, 222 or 225, wherein the TRAILR3 GPI anchor comprises an amino acid sequence at least 80% identical to SEQ ID NO:

35.

227. The engineered protein of any one of claims 221, 222 or 225, wherein the TRAILR3 GPI anchor comprises an amino acid sequence at least 80% identical to SEQ ID NO:

36.

228. The engineered protein of claim 221 or 222, wherein the GPI anchor is or comprises a CD59 GPI anchor.

229. The engineered protein of any one of claims 221, 222 or 228, wherein the CD59 GPI anchor comprises an amino acid sequence at least 80% identical to SEQ ID NO:

37.

230. The engineered protein of any one of claims 185-221, further comprising an extracellular signal peptide.

231. The engineered protein of claim 230, wherein the extracellular signal peptide is encoded by a nucleic acid sequence that is at least 80% identical to SEQ ID NO:

20.

232. The engineered protein of any one of claims 185-231, wherein the one or more extracellular domains further comprise an extracellular hinge domain.

233. An engineered protein as described in claim 232, wherein the extracellular hinge domain is or comprises a CD47 hinge, a CD8a hinge, a CD28 hinge, a PDGFR hinge, or an IgG4 hinge.

234. The engineered protein of claim 232 or 17a, wherein the extracellular hinge domain is or comprises a CD47 hinge.

235. The engineered protein of any one of claims 232-234, wherein the extracellular hinge domain comprises an amino acid sequence at least 80% identical to SEQ ID NO:

44.

236. The engineered protein of claim 232 or 233, wherein the extracellular hinge domain is or comprises a CD8a hinge.

237. The engineered protein of claim 232, 233 or 236, wherein the extracellular hinge domain comprises an acid sequence at least 80% identical to SEQ ID NO:

45.

238. The engineered protein of claim 232 or 233, wherein the extracellular hinge domain is or comprises a CD28 hinge.

239. The engineered protein of claim 232, 233 or 238, wherein the extracellular hinge domain comprises an amino acid sequence at least 80% identical to SEQ ID NO:

46.

240. The engineered protein of claim 232 or 233, wherein the extracellular hinge domain is or comprises a PDGFR hinge.

241. The engineered protein of claim 232, 233 or 240, wherein the extracellular hinge domain comprises an amino acid sequence at least 80% identical to SEQ ID NO:

47.

242. The engineered protein of claim 232 or 233, wherein the extracellular hinge domain is or comprises an IgG4 hinge.

243. The engineered protein of claim 232, 233 or 242, wherein the extracellular hinge domain comprises an amino acid sequence at least 80% identical to SEQ ID NO:

48.

244. The engineered protein of any of the preceding claims, further comprising an intracellular domain.

245. The engineered protein of claim 244, wherein the intracellular domain is or comprises the CD47 intracellular domain or a portion thereof.

246. The engineered protein of claim 244 or 245, wherein the intracellular domain comprises an amino acid sequence at least 80% identical to SEQ ID NO:

24.

247. The engineered protein of claim 244 or 245, wherein the intracellular domain comprises an amino acid sequence at least 80% identical to SEQ ID NO:

28.

248. The engineered protein of claim 244 or 245, wherein the intracellular domain comprises an amino acid sequence at least 80% identical to SEQ ID NO:

32.

249. The engineered protein of claim 244 or 245, wherein the intracellular domain comprises an amino acid sequence at least 80% identical to SEQ ID NO:

33.

250. The engineered protein of claim 244, wherein the intracellular domain is or comprises the CD8a intracellular domain or a portion thereof.

251. The engineered protein of claim 244 or 250, wherein the intracellular domain comprises an amino acid sequence at least 80% identical to SEQ ID NO:

39.

252. The engineered protein of claim 244, wherein the intracellular domain is or comprises the CD28 intracellular domain or a portion thereof.

253. The engineered protein construct of claim 244 or 245, wherein the intracellular domain comprises an amino acid sequence at least 80% identical to SEQ ID NO:

41.

254. The engineered protein of claim 244, wherein the intracellular domain is or comprises a PDGFR intracellular domain or a portion thereof.

255. The engineered protein of claim 244 or 254, wherein the intracellular domain comprises an amino acid sequence at least 80% identical to SEQ ID NO:

43.

256. The engineered protein of any one of claims 244-255, wherein the intracellular domain comprises one or more modifications relative to the wild-type CD47 intracellular domain.

257. The engineered protein of any one of claims 244-256, wherein the intracellular domain comprises one or more deletions relative to the wild-type CD47 intracellular domain.

258. The engineered protein of any one of claims 244-256, wherein the intracellular domain comprises one or more insertions relative to the wild-type CD47 intracellular domain.

259. The engineered protein of any one of claims 244-258, wherein the intracellular domain comprises altered function relative to the wild-type CD47 intracellular domain.

260. The engineered protein of any one of claims 244-259, wherein the intracellular domain comprises reduced function relative to the wild-type CD47 intracellular domain.

261. The engineered protein of any one of claims 244-260, wherein the intracellular domain comprises a reduced level of CD47 intracellular signaling relative to a wild-type CD47 intracellular domain.

262. The engineered protein of any one of claims 244-261, wherein the intracellular domain comprises a non-functional intracellular domain.

263. The engineered protein of any one of claims 185-262, comprising an amino acid sequence at least 80% identical to a sequence selected from Table 30.

264. The engineered protein of any one of claims 185-263, comprising an amino acid sequence at least 80% identical to SEQ ID NO:

1.

265. The engineered protein of any one of claims 185-263, comprising an amino acid sequence at least 80% identical to SEQ ID NO:

2.

266. The engineered protein of any one of claims 185-263, comprising an amino acid sequence at least 80% identical to SEQ ID NO:

6.

267. The nucleic acid construct of any one of claims 185-263, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

80.

268. The nucleic acid construct of any one of claims 185-263, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

81.

269. The nucleic acid construct of any one of claims 185-263, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

82.

270. The nucleic acid construct of any one of claims 185-263, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

83.

271. The nucleic acid construct of any one of claims 185-263, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

84.

272. The nucleic acid construct of any one of claims 185-263, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

85.

273. The nucleic acid construct of any one of claims 185-263, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

86.

274. The nucleic acid construct of any one of claims 185-263, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

87.

275. The nucleic acid construct of any one of claims 185-263, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

88.

276. The nucleic acid construct of any one of claims 185-263, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

89.

277. The nucleic acid construct of any one of claims 185-263, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

90.

278. The nucleic acid construct of any one of claims 185-263, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

91.

279. The nucleic acid construct of any one of claims 185-263, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

92.

280. The nucleic acid construct of any one of claims 185-263, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

93.

281. The nucleic acid construct of any one of claims 185-263, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

94.

282. The nucleic acid construct of any one of claims 185-263, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

95.

283. The nucleic acid construct of any one of claims 185-263, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

96.

284. The nucleic acid construct of any one of claims 185-263, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

97.

285. The nucleic acid construct of any one of claims 185-263, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

98.

286. The nucleic acid construct of any one of claims 185-263, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

99.

287. The nucleic acid construct of any one of claims 185-263, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

100.

288. The nucleic acid construct of any one of claims 185-263, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

101.

289. The nucleic acid construct of any one of claims 185-263, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

102.

290. The nucleic acid construct of any one of claims 185-263, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

103.

291. The nucleic acid construct of any one of claims 185-263, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

104.

292. The nucleic acid construct of any one of claims 185-263, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

105.

293. The nucleic acid construct of any one of claims 185-263, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

106.

294. The nucleic acid construct of any one of claims 185-263, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

107.

295. The nucleic acid construct of any one of claims 185-263, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

108.

296. The nucleic acid construct of any one of claims 185-263, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

109.

297. The nucleic acid construct of any one of claims 185-263, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

110.

298. The nucleic acid construct of any one of claims 185-263, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

111.

299. The nucleic acid construct of any one of claims 185-263, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

112.

300. The nucleic acid construct of any one of claims 185-263, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

113.

301. The nucleic acid construct of any one of claims 185-263, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

114.

302. The nucleic acid construct of any one of claims 185-263, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

115.

303. The nucleic acid construct of any one of claims 185-263, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

116.

304. The nucleic acid construct of any one of claims 185-263, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

117.

305. The nucleic acid construct of any one of claims 185-263, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

118.

306. The nucleic acid construct of any one of claims 185-263, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

119.

307. The nucleic acid construct of any one of claims 185-263, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

120.

308. The nucleic acid construct of any one of claims 185-263, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

121.

309. The nucleic acid construct of any one of claims 185-263, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

122.

310. The nucleic acid construct of any one of claims 185-263, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

123.

311. The nucleic acid construct of any one of claims 185-263, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

124.

312. The nucleic acid construct of any one of claims 185-263, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

125.

313. A nucleic acid construct as described in any one of claims 185-263, comprising a nucleotide sequence that is at least 80% identical to SEQ ID NO:

126.

314. The nucleic acid construct of any one of claims 185-263, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

127.

315. The nucleic acid construct of any one of claims 185-263, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

128.

316. The nucleic acid construct of any one of claims 185-263, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

129.

317. The nucleic acid construct of any one of claims 185-263, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

130.

318. The nucleic acid construct of any one of claims 185-263, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

131.

319. The nucleic acid construct of any one of claims 185-263, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

132.

320. The nucleic acid construct of any one of claims 185-263, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

340.

321. The engineered protein of any one of claims 185-255, comprising one or more amino acid sequences that are at least 80% identical to one or more sequences selected from Table 32.

322. An engineered protein as described in any of the preceding claims, comprising one or more nucleic acid sequences having at least 80% identity to one or more sequences selected from Table 32 and / or Table 30.

323. The engineered protein of any one of claims 185-255, comprising one or more amino acid sequences that are at least 80% identical to SEQ ID NOs: 20, 21, 23, 24, 25, and 26.

324. The engineered protein of any one of claims 185-255, comprising one or more amino acid sequences that are at least 80% identical to SEQ ID NOs: 20, 21, 23, 24, and 25.

325. The engineered protein of any one of claims 185-255, comprising one or more amino acid sequences that are at least 80% identical to SEQ ID NOs: 20, 21, 23, and 24.

326. The engineered protein of any one of claims 185-255, comprising one or more amino acid sequences that are at least 80% identical to SEQ ID NOs: 20, 21, 23, 24, 25, 26, 27, 28, 29, 30, and 31.

327. The engineered protein of any one of claims 185-255, comprising one or more amino acid sequences that are at least 80% identical to SEQ ID NOs: 20, 21, 23, 24, 25, 26, 27, 28, 29, and 30.

328. The engineered protein of any one of claims 185-255, comprising one or more amino acid sequences that are at least 80% identical to SEQ ID NOs: 20, 21, 23, 24, 25, 26, 27, 28, and 29.

329. The engineered protein of any one of claims 185-255, comprising one or more amino acid sequences that are at least 80% identical to SEQ ID NOs: 20, 21, 23, 24, 25, 26, 27, and 28.

330. The engineered protein of any one of claims 185-255, comprising one or more amino acid sequences that are at least 80% identical to SEQ ID NOs: 22 and 34.

331. The engineered protein of any one of claims 185-255, comprising one or more amino acid sequences that are at least 80% identical to SEQ ID NOs: 22 and 35.

332. The engineered protein of any one of claims 185-255, comprising one or more amino acid sequences that are at least 80% identical to SEQ ID NOs: 22 and 36.

333. The engineered protein of any one of claims 185-255, comprising one or more amino acid sequences that are at least 80% identical to SEQ ID NOs: 22, 38, and 39.

334. The engineered protein of any one of claims 185-255, comprising one or more amino acid sequences that are at least 80% identical to SEQ ID NOs: 22, 40, and 41.

335. The engineered protein of any one of claims 185-255, comprising one or more amino acid sequences that are at least 80% identical to SEQ ID NOs: 22, 42, and 43.

336. The engineered protein of any one of claims 185-255, comprising one or more amino acid sequences that are at least 80% identical to SEQ ID NOs: 21, 47, 42, and 43.

337. The engineered protein of any one of claims 185-255, comprising one or more amino acid sequences that are at least 80% identical to SEQ ID NOs: 21, 48, 40, and 41.

338. The engineered protein of any one of claims 185-255, comprising one or more amino acid sequences that are at least 80% identical to SEQ ID NOs: 21, 48, 38, and 39.

339. The engineered protein of any one of claims 185-255, comprising one or more amino acid sequences that are at least 80% identical to SEQ ID NOs: 21, 46, 40, and 41.

340. The engineered protein of any one of claims 185-255, comprising one or more amino acid sequences that are at least 80% identical to SEQ ID NOs: 21, 46, 38, and 39.

341. The engineered protein of any one of claims 185-255, comprising one or more amino acid sequences that are at least 80% identical to SEQ ID NOs: 21, 45, 40, and 41.

342. The engineered protein of any one of claims 185-255, comprising one or more amino acid sequences that are at least 80% identical to SEQ ID NOs: 21, 45, 38, and 39.

343. The engineered protein of any one of claims 185-342, comprising fewer glycosylation modification sites than wild-type human CD47 protein.

344. The engineered protein of claim 343, wherein the engineered protein does not comprise an N206 glycosylation site.

345. A genetically engineered cell comprising the engineered protein of any one of claims 185-344.

346. A genetically engineered cell comprising a first transgene encoding an engineered protein, in, The engineered protein comprises: (a) one or more extracellular domains; and (b) one or more membrane tethers; wherein the one or more extracellular domains comprise a signal regulatory protein alpha (SIRPα) interaction motif, and wherein the engineered protein does not comprise one or more full-length CD47 intracellular domains.

347. The genetically engineered cell of claim 346, wherein the SIRPα interaction motif is or comprises the CD47 extracellular domain or a portion thereof.

348. The genetically engineered cell of claim 347, wherein the CD47 extracellular domain is a CD47 immunoglobulin variable (IgV)-like domain.

349. The genetically engineered cell of claim 23 or 347, wherein the CD47 extracellular domain is a human CD47 extracellular domain.

350. The genetically engineered cell of any one of claims 347-349, wherein the CD47 extracellular domain is encoded by the first transgene, wherein the first transgene comprises a nucleic acid sequence that is at least 80% identical to SEQ ID NO:

52.

351. The genetically engineered cell of any one of claims 347-349, wherein the CD47 extracellular domain is encoded by the first transgene, wherein the first transgene comprises a nucleic acid sequence that is at least 80% identical to SEQ ID NO:

53.

352. The genetically engineered cell of any one of claims 347-349, wherein the CD47 extracellular domain is encoded by a nucleic acid sequence that is at least 80% identical to SEQ ID NO:

57.

353. The genetically engineered cell of any one of claims 347-349, wherein the CD47 extracellular domain is encoded by a nucleic acid sequence that is at least 80% identical to SEQ ID NO:

59.

354. The genetically engineered cell of claim 346, wherein the SIRPα interaction motif is or comprises a SIRPα antibody or a portion thereof.

355. The genetically engineered cell of any one of claims 346-354, wherein the one or more membrane tethers are or comprise a transmembrane domain.

356. The genetically engineered cell of claim 355, wherein the transmembrane domain is or comprises a CD3ζ, CD8a, CD16a, CD28, CD32a, CD32c, CD40, CD47, CD64, ICOS, Dectin-1, DNGR1, EGFR, GPCR, MyD88, PDGFR, SLAMF7, TRL1, TLR2, TLR3, TRL4, TLR5, TLR6, TLR7, TLR8, TLR9, or VEGFR transmembrane domain.

357. The genetically engineered cell of claim 355 or 356, wherein the transmembrane domain is or comprises a CD47 transmembrane domain.

358. The genetically engineered cell of any one of claims 355-357, wherein the transmembrane domain is encoded by the first transgene, wherein the first transgene comprises a nucleic acid sequence at least 80% identical to SEQ ID NO:

54.

359. The genetically engineered cell of any one of claims 355-357, wherein the transmembrane domain is encoded by the first transgene, wherein the first transgene comprises a nucleic acid sequence that is at least 80% identical to SEQ ID NO:

56.

360. The genetically engineered cell of any one of claims 355-357, wherein the transmembrane domain is encoded by the first transgene, wherein the first transgene comprises a nucleic acid sequence at least 80% identical to SEQ ID NO:

58.

361. The genetically engineered cell of any one of claims 355-357, wherein the transmembrane domain is encoded by the first transgene, wherein the first transgene comprises a nucleic acid sequence that is at least 80% identical to SEQ ID NO:

60.

362. The genetically engineered cell of any one of claims 355-357, wherein the transmembrane domain is encoded by the first transgene, wherein the first transgene comprises a nucleic acid sequence at least 80% identical to SEQ ID NO:

62.

363. The genetically engineered cell of claim 355 or 356, wherein the transmembrane domain is or comprises a CD8a transmembrane domain.

364. The genetically engineered cell of claim 355, 356 or 363, wherein the transmembrane domain is encoded by the first transgene, wherein the first transgene comprises a nucleic acid sequence at least 80% identical to SEQ ID NO:

69.

365. The genetically engineered cell of claim 355 or 356, wherein the transmembrane domain is or comprises a CD28 transmembrane domain.

366. The genetically engineered cell of claim 355, 356 or 365, wherein the transmembrane domain is encoded by the first transgene, wherein the first transgene comprises a nucleic acid sequence at least 80% identical to SEQ ID NO:

71.

367. The genetically engineered cell of claim 355 or 356, wherein the transmembrane domain is or comprises a PDGFR transmembrane domain.

368. The genetically engineered cell of claim 355, 356 or 367, wherein the transmembrane domain is encoded by the first transgene, wherein the first transgene comprises a nucleic acid sequence at least 80% identical to SEQ ID NO:

73.

369. The genetically engineered cell of any one of claims 346-354, wherein the one or more membrane tethers is or comprises a glycosylphosphatidylinositol (GPI) anchor.

370. The genetically engineered cell of claim 369, wherein the GPI anchor is or comprises a DAF / CD55 GPI anchor, a TRAILR3 GPI anchor or a CD59 GPI anchor.

371. The genetically engineered cell of claim 369 or 370, wherein the GPI anchor is or comprises a DAF / CD55 GPI anchor.

372. The genetically engineered cell of any one of claims 369-371, wherein the DAF / CD55 GPI anchor is encoded by the first transgene, wherein the first transgene comprises a nucleic acid sequence at least 80% identical to SEQ ID NO:

65.

373. The genetically engineered cell of claim 369 or 370, wherein the GPI anchor is or comprises a TRAILR3 GPI anchor.

374. The genetically engineered cell of any one of claims 369, 370 or 373, wherein the TRAILR3 GPI anchor is encoded by the first transgene, wherein the first transgene comprises a nucleic acid sequence at least 80% identical to SEQ ID NO:

66.

375. The genetically engineered cell of any one of claims 369, 370 or 373, wherein the TRAILR3 GPI anchor is encoded by the first transgene, wherein the first transgene comprises a nucleic acid sequence at least 80% identical to SEQ ID NO:

67.

376. The genetically engineered cell of claim 369 or 370, wherein the GPI anchor is or comprises a CD59 GPI anchor.

377. The genetically engineered cell of any one of claims 369, 370 or 376, wherein the CD59 GPI anchor is encoded by the first transgene, wherein the first transgene comprises a nucleic acid sequence that is at least 80% identical to SEQ ID NO:

68.

378. The genetically engineered cell of any one of claims 346-369, further comprising one or more control sequences.

379. The genetically engineered cell of claim 378, wherein the one or more control sequences encode an extracellular signal peptide.

380. The genetically engineered cell of claim 378 or 379, wherein the extracellular signal peptide is encoded by the first transgene, wherein the first transgene comprises a nucleic acid sequence at least 80% identical to SEQ ID NO:

51.

381. The genetically engineered cell of claim 378, wherein the one or more control sequences comprise a promoter.

382. The genetically engineered cell of claim 381, wherein the promoter is a constitutive promoter or an inducible promoter.

383. The genetically engineered cell of claim 381 or 382, ​​wherein the promoter is a naturally occurring promoter, a hybrid promoter, or a synthetic promoter.

384. The genetically engineered cell of any one of claims 381-383, wherein the promoter is or comprises an EF1α promoter, an EF1α short promoter, a CAG promoter, an ubiquitin / S27a promoter, an SV40 early promoter, an adenovirus major late promoter, a mouse metallothionein-I promoter, an RSV promoter, an MMTV promoter, a Moloney murine leukemia virus long terminal repeat, a CMV promoter, an actin promoter, an immunoglobulin promoter, a heat shock promoter, a polyadenylin promoter, or a polyadenylin promoter. tumor virus promoter, fowl pox virus promoter, bovine papilloma virus promoter, avian sarcoma virus promoter, retrovirus promoter, hepatitis B virus promoter, PGK promoter, adenovirus late promoter, vaccinia virus 7.5K promoter, SV40 promoter, tk promoter of HSV, mouse mammary tumor virus (MMTV) promoter, LTR promoter of HIV, Moloney virus promoter, Epstein-Barr virus (EBV) promoter, Rous sarcoma virus (RSV) promoter, or UBC promoter.

385. The genetically engineered cell of any one of claims 381-384, wherein the promoter is or comprises a CAG promoter.

386. The genetically engineered cell of any one of claims 381-385, wherein the first transgene comprises the promoter, and wherein the promoter comprises a nucleic acid sequence at least 80% identical to SEQ ID NO:

49.

387. The genetically engineered cell of any one of claims 381-384, wherein the promoter is or comprises the EF1α promoter.

388. The genetically engineered cell of any one of claims 381-385, or 387, wherein the first transgene comprises the promoter, and wherein the promoter comprises a nucleic acid sequence at least 80% identical to SEQ ID NO:

50.

389. The genetically engineered cell of claim 378, wherein the one or more control sequences comprise a ribosome binding site, an enhancer element, an activator element, a translation initiation sequence, a translation termination sequence, a transcription initiation sequence, a transcription termination sequence, a polyadenylation signal sequence, a replication element, an RNA processing and export element, a transposon sequence, a transposase sequence, an insulator sequence, an internal ribosome entry site (IRES), a 5'UTR, a 3'UTR, an mRNA 3' end processing sequence, a boundary element, a locus control region (LCR), a matrix attachment region (MAR), a recombination or cassette exchange sequence, a linker sequence, a secretion signal, a resistance marker, an anchor peptide, a localization signal, a fusion tag, an affinity tag, a chaperone protein, a protease, or a combination thereof.

390. The genetically engineered cell of any one of claims 346-389, wherein the one or more extracellular domains further comprise an extracellular hinge domain.

391. The genetically engineered cell of claim 390, wherein the extracellular hinge domain is or comprises a CD47 hinge, a CD8a hinge, a CD28 hinge, a PDGFR hinge, or an IgG4 hinge.

392. The genetically engineered cell of claim 390 or 391, wherein the extracellular hinge domain is or comprises a CD47 hinge.

393. The genetically engineered cell of any one of claims 390-392, wherein the extracellular hinge domain is encoded by the first transgene, wherein the first transgene comprises a nucleic acid sequence that is at least 80% identical to SEQ ID NO:

75.

394. The genetically engineered cell of claim 390 or 391, wherein the extracellular hinge domain is or comprises a CD8a hinge.

395. The genetically engineered cell of claim 390, 391 or 394, wherein the extracellular hinge domain is encoded by the first transgene, wherein the first transgene comprises a nucleic acid sequence at least 80% identical to SEQ ID NO:

76.

396. The genetically engineered cell of claim 390 or 391, wherein the extracellular hinge domain is or comprises a CD28 hinge.

397. The genetically engineered cell of claim 390, 391 or 396, wherein the extracellular hinge domain is encoded by the first transgene, wherein the first transgene comprises a nucleic acid sequence at least 80% identical to SEQ ID NO:

77.

398. The genetically engineered cell of claim 390 or 391, wherein the extracellular hinge domain is or comprises a PDGFR hinge.

399. The genetically engineered cell of claim 390, 391 or 398, wherein the extracellular hinge domain is encoded by the first transgene, wherein the first transgene comprises a nucleic acid sequence that is at least 80% identical to SEQ ID NO:

78.

400. The genetically engineered cell of claim 390 or 391, wherein the extracellular hinge domain is or comprises an IgG4 hinge.

401. The genetically engineered cell of claim 390, 391 or 400, wherein the extracellular hinge domain is encoded by the first transgene, wherein the first transgene comprises a nucleic acid sequence at least 80% identical to SEQ ID NO:

79.

402. The genetically engineered cell of any one of claims 346-401, wherein the first transgene further comprises one or more nucleic acid sequences encoding an intracellular domain.

403. The genetically engineered cell of claim 402, wherein the intracellular domain is or comprises the CD47 intracellular domain or a portion thereof.

404. The genetically engineered cell of claim 402 or 403, wherein the intracellular domain is encoded by the first transgene, wherein the first transgene comprises a nucleic acid sequence at least 80% identical to SEQ ID NO:

55.

405. The genetically engineered cell of claim 402 or 403, wherein the intracellular domain is encoded by the first transgene, wherein the first transgene comprises a nucleic acid sequence at least 80% identical to SEQ ID NO:

59.

406. The genetically engineered cell of claim 402 or 403, wherein the intracellular domain is encoded by the first transgene, wherein the first transgene comprises a nucleic acid sequence at least 80% identical to SEQ ID NO:

63.

407. The genetically engineered cell of claim 402 or 403, wherein the intracellular domain is encoded by the first transgene, wherein the first transgene comprises a nucleic acid sequence at least 80% identical to SEQ ID NO:

64.

408. The genetically engineered cell of claim 402, wherein the intracellular domain is or comprises the CD8a intracellular domain or a portion thereof.

409. The genetically engineered cell of claim 402 or 408, wherein the intracellular domain is encoded by the first transgene, wherein the first transgene comprises a nucleic acid sequence at least 80% identical to SEQ ID NO:

70.

410. The genetically engineered cell of claim 402, wherein the intracellular domain is or comprises the CD28 intracellular domain or a portion thereof.

411. The genetically engineered cell of claim 402 or 403, wherein the intracellular domain is encoded by the first transgene, wherein the first transgene comprises a nucleic acid sequence at least 80% identical to SEQ ID NO:

72.

412. The genetically engineered cell of claim 402, wherein the intracellular domain is or comprises a PDGFR intracellular domain or a portion thereof.

413. The genetically engineered cell of claim 402 or 412, wherein the intracellular domain is encoded by the first transgene, wherein the first transgene comprises a nucleic acid sequence at least 80% identical to SEQ ID NO:

74.

414. The genetically engineered cell of any one of claims 402-413, wherein the intracellular domain comprises one or more modifications relative to a wild-type CD47 intracellular domain.

415. The genetically engineered cell of any one of claims 402-414, wherein the intracellular domain comprises one or more deletions relative to the wild-type CD47 intracellular domain.

416. The genetically engineered cell of any one of claims 402-414, wherein the intracellular domain comprises one or more insertions relative to the wild-type CD47 intracellular domain.

417. The genetically engineered cell of any one of claims 402-416, wherein the intracellular domain comprises altered function relative to a wild-type CD47 intracellular domain.

418. The genetically engineered cell of any one of claims 402-417, wherein the intracellular domain comprises reduced function relative to the wild-type CD47 intracellular domain.

419. The genetically engineered cell of any one of claims 402-418, wherein the intracellular domain comprises a reduced level of CD47 intracellular signaling relative to a wild-type CD47 intracellular domain.

420. The genetically engineered cell of any one of claims 402-419, wherein the intracellular domain comprises a non-functional intracellular domain.

421. The genetically engineered cell of any one of claims 346-420, wherein the first transgene comprises a nucleic acid sequence that is at least 80% identical to a sequence selected from Table 31.

422. The genetically engineered cell of any one of claims 346-421, wherein the first transgene comprises a nucleic acid sequence that is at least 80% identical to SEQ ID NO:

13.

423. The genetically engineered cell of any one of claims 346-421, wherein the first transgene comprises a nucleic acid sequence that is at least 80% identical to SEQ ID NO:

14.

424. The genetically engineered cell of any one of claims 346-421, wherein the first transgene comprises a nucleic acid sequence that is at least 80% identical to SEQ ID NO:

18.

425. The genetically engineered cell of any one of claims 346-421, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

133.

426. The genetically engineered cell of any one of claims 346-421, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

134.

427. The genetically engineered cell of any one of claims 346-421, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

135.

428. The genetically engineered cell of any one of claims 346-421, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

136.

429. The genetically engineered cell of any one of claims 346-421, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

137.

430. The genetically engineered cell of any one of claims 346-421, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

138.

431. The genetically engineered cell of any one of claims 346-421, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

139.

432. The genetically engineered cell of any one of claims 346-421, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

140.

433. The genetically engineered cell of any one of claims 346-421, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

141.

434. The genetically engineered cell of any one of claims 346-421, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

142.

435. The genetically engineered cell of any one of claims 346-421, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

143.

436. The genetically engineered cell of any one of claims 346-421, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

144.

437. The genetically engineered cell of any one of claims 346-421, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

145.

438. The genetically engineered cell of any one of claims 346-421, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

146.

439. The genetically engineered cell of any one of claims 346-421, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

147.

440. The genetically engineered cell of any one of claims 346-421, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

148.

441. The genetically engineered cell of any one of claims 346-421, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

149.

442. The genetically engineered cell of any one of claims 346-421, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

150.

443. The genetically engineered cell of any one of claims 346-421, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

151.

444. The genetically engineered cell of any one of claims 346-421, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

152.

445. The genetically engineered cell of any one of claims 346-421, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

153.

446. The genetically engineered cell of any one of claims 346-421, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

154.

447. The genetically engineered cell of any one of claims 346-421, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

155.

448. The genetically engineered cell of any one of claims 346-421, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

156.

449. The genetically engineered cell of any one of claims 346-421, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

157.

450. The genetically engineered cell of any one of claims 346-421, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

158.

451. The genetically engineered cell of any one of claims 346-421, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

159.

452. The genetically engineered cell of any one of claims 346-421, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

160.

453. The genetically engineered cell of any one of claims 346-421, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

161.

454. The genetically engineered cell of any one of claims 346-421, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

162.

455. The genetically engineered cell of any one of claims 346-421, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

163.

456. The genetically engineered cell of any one of claims 346-421, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

164.

457. The genetically engineered cell of any one of claims 346-421, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

165.

458. The genetically engineered cell of any one of claims 346-421, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

166.

459. The genetically engineered cell of any one of claims 346-421, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

167.

460. The genetically engineered cell of any one of claims 346-421, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

168.

461. The genetically engineered cell of any one of claims 346-421, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

169.

462. The genetically engineered cell of any one of claims 346-421, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

170.

463. The genetically engineered cell of any one of claims 346-421, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

171.

464. The genetically engineered cell of any one of claims 346-421, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

172.

465. The genetically engineered cell of any one of claims 346-421, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

173.

466. The genetically engineered cell of any one of claims 346-421, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

174.

467. The genetically engineered cell of any one of claims 346-421, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

175.

468. The genetically engineered cell of any one of claims 346-421, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

176.

469. The genetically engineered cell of any one of claims 346-421, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

177.

470. The genetically engineered cell of any one of claims 346-421, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

178.

471. The genetically engineered cell of any one of claims 346-421, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

179.

472. The genetically engineered cell of any one of claims 346-421, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

180.

473. The genetically engineered cell of any one of claims 346-421, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

181.

474. The genetically engineered cell of any one of claims 346-421, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

182.

475. The genetically engineered cell of any one of claims 346-421, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

183.

476. The genetically engineered cell of any one of claims 346-421, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

184.

477. The genetically engineered cell of any one of claims 346-421, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

185.

478. The genetically engineered cell of any one of claims 346-421, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

341.

479. The genetically engineered cell of any one of claims 346-421, comprising a nucleotide sequence at least 80% identical to SEQ ID NO:

342.

480. The genetically engineered cell of any one of claims 346-413, wherein the first transgene comprises one or more nucleic acid sequences that are at least 80% identical to one or more sequences selected from Table 33.

481. The genetically engineered cell of any one of claims 346, wherein the first transgene comprises one or more nucleic acid sequences that are at least 80% identical to one or more sequences selected from Table 33 and / or Table 31.

482. The genetically engineered cell of any one of claims 346-413, wherein the first transgene comprises one or more nucleic acid sequences that are at least 80% identical to SEQ ID NO:49 and SEQ ID NO:

14.

483. The genetically engineered cell of any one of claims 346-413, wherein the first transgene comprises one or more nucleic acid sequences that are at least 80% identical to SEQ ID NO:

14.

484. The genetically engineered cell of any one of claims 346-413, wherein the first transgene comprises one or more nucleic acid sequences that are at least 80% identical to SEQ ID NO:49 and SEQ ID NO:

13.

485. The genetically engineered cell of any one of claims 346-413, wherein the first transgene comprises one or more nucleic acid sequences that are at least 80% identical to SEQ ID NO:

13.

486. The genetically engineered cell of any one of claims 346-413, wherein the first transgene comprises one or more nucleic acid sequences that are at least 80% identical to SEQ ID NO:49 and SEQ ID NO:

18.

487. The genetically engineered cell of any one of claims 346-413, wherein the first transgene comprises one or more nucleic acid sequences that are at least 80% identical to SEQ ID NO:

18.

488. The genetically engineered cell of any one of claims 346-413, wherein the first transgene comprises one or more nucleic acid sequences that are at least 80% identical to SEQ ID NOs:51, 52, 54, 55, 56, and 57.

489. The genetically engineered cell of any one of claims 346-413, wherein the first transgene comprises one or more nucleic acid sequences that are at least 80% identical to SEQ ID NOs: 51, 52, 54, 55, and 56.

490. The genetically engineered cell of any one of claims 346-413, wherein the first transgene comprises one or more nucleic acid sequences that are at least 80% identical to SEQ ID NOs:51, 52, 54, and 55.

491. The genetically engineered cell of any one of claims 346-413, wherein the first transgene comprises one or more nucleic acid sequences that are at least 80% identical to SEQ ID NOs: 51, 52, 54, 55, 56, 57, 58, 59, 60, 61, and 62.

492. The genetically engineered cell of any one of claims 346-413, wherein the first transgene comprises one or more nucleic acid sequences that are at least 80% identical to SEQ ID NOs: 51, 52, 54, 55, 56, 57, 58, 59, 60, and 61.

493. The genetically engineered cell of any one of claims 346-413, wherein the first transgene comprises one or more nucleic acid sequences that are at least 80% identical to SEQ ID NOs: 51, 52, 54, 55, 56, 57, 58, 59, and 60.

494. The genetically engineered cell of any one of claims 346-413, wherein the first transgene comprises one or more nucleic acid sequences that are at least 80% identical to SEQ ID NOs: 51, 52, 54, 55, 56, 57, 58, and 59.

495. The genetically engineered cell of any one of claims 346-413, wherein the first transgene comprises one or more nucleic acid sequences that are at least 80% identical to SEQ ID NOs:49, 53, and 65.

496. The genetically engineered cell of any one of claims 346-413, wherein the first transgene comprises one or more nucleic acid sequences that are at least 80% identical to SEQ ID NOs:53 and 65.

497. The genetically engineered cell of any one of claims 346-413, wherein the first transgene comprises one or more nucleic acid sequences that are at least 80% identical to SEQ ID NOs: 49, 53, and 66.

498. The genetically engineered cell of any one of claims 346-413, wherein the first transgene comprises one or more nucleic acid sequences that are at least 80% identical to SEQ ID NOs: 53 and 66.

499. The genetically engineered cell of any one of claims 346-413, wherein the first transgene comprises one or more nucleic acid sequences that are at least 80% identical to SEQ ID NOs:49, 53, and 67.

500. The genetically engineered cell of any one of claims 346-413, wherein the first transgene comprises one or more nucleic acid sequences that are at least 80% identical to SEQ ID NOs: 53 and 67.

501. The genetically engineered cell of any one of claims 346-413, wherein the first transgene comprises one or more nucleic acid sequences that are at least 80% identical to SEQ ID NOs:49, 53, 69, and 70.

502. The genetically engineered cell of any one of claims 346-413, wherein the first transgene comprises one or more nucleic acid sequences that are at least 80% identical to SEQ ID NOs: 53, 69, and 70.

503. The genetically engineered cell of any one of claims 346-413, wherein the first transgene comprises one or more nucleic acid sequences that are at least 80% identical to SEQ ID NOs: 49, 53, 71, and 72.

504. The genetically engineered cell of any one of claims 346-413, wherein the first transgene comprises one or more nucleic acid sequences that are at least 80% identical to SEQ ID NOs: 53, 71, and 72.

505. The genetically engineered cell of any one of claims 346-413, wherein the first transgene comprises one or more nucleic acid sequences that are at least 80% identical to SEQ ID NOs: 49, 53, 73, and 74.

506. The genetically engineered cell of any one of claims 346-413, wherein the first transgene comprises one or more nucleic acid sequences that are at least 80% identical to SEQ ID NOs: 53, 73, and 74.

507. The genetically engineered cell of any one of claims 346-413, wherein the first transgene comprises one or more nucleic acid sequences that are at least 80% identical to SEQ ID NOs: 49, 52, 78, 73, and 74.

508. The genetically engineered cell of any one of claims 346-413, wherein the first transgene comprises one or more nucleic acid sequences that are at least 80% identical to SEQ ID NOs: 52, 78, 73, and 74.

509. The genetically engineered cell of any one of claims 346-413, wherein the first transgene comprises one or more nucleic acid sequences that are at least 80% identical to SEQ ID NOs: 49, 52, 79, 71, and 72.

510. The genetically engineered cell of any one of claims 346-413, wherein the first transgene comprises one or more nucleic acid sequences that are at least 80% identical to SEQ ID NOs: 52, 79, 71, and 72.

511. The genetically engineered cell of any one of claims 346-413, wherein the first transgene comprises one or more nucleic acid sequences that are at least 80% identical to SEQ ID NOs:49, 52, 79, 69, and 70.

512. The genetically engineered cell of any one of claims 346-413, wherein the first transgene comprises one or more nucleic acid sequences that are at least 80% identical to SEQ ID NOs: 52, 79, 69, and 70.

513. The genetically engineered cell of any one of claims 346-413, wherein the first transgene comprises one or more nucleic acid sequences that are at least 80% identical to SEQ ID NOs: 49, 52, 77, 71, and 72.

514. The genetically engineered cell of any one of claims 346-413, wherein the first transgene comprises one or more nucleic acid sequences that are at least 80% identical to SEQ ID NOs: 52, 77, 71, and 72.

515. The genetically engineered cell of any one of claims 346-413, wherein the first transgene comprises one or more nucleic acid sequences that are at least 80% identical to SEQ ID NOs: 49, 52, 77, 69, and 70.

516. The genetically engineered cell of any one of claims 346-413, wherein the first transgene comprises one or more nucleic acid sequences that are at least 80% identical to SEQ ID NOs: 52, 77, 69, and 70.

517. The genetically engineered cell of any one of claims 346-413, wherein the first transgene comprises one or more nucleic acid sequences that are at least 80% identical to SEQ ID NOs: 49, 52, 76, 71, and 72.

518. The genetically engineered cell of any one of claims 346-413, wherein the first transgene comprises one or more nucleic acid sequences that are at least 80% identical to SEQ ID NOs: 52, 76, 71, and 72.

519. The genetically engineered cell of any one of claims 346-413, wherein the first transgene comprises one or more nucleic acid sequences that are at least 80% identical to SEQ ID NOs: 49, 52, 76, 69, and 70.

520. The genetically engineered cell of any one of claims 346-413, wherein the first transgene comprises one or more nucleic acid sequences that are at least 80% identical to SEQ ID NOs: 52, 76, 69, and 70.

521. The genetically engineered cell of any one of claims 346-413, wherein the first transgene comprises one or more nucleic acid sequences that are at least 80% identical to SEQ ID NOs: 49 and 200.

522. The genetically engineered cell of any one of claims 346-413, wherein the first transgene comprises one or more nucleic acid sequences that are at least 80% identical to SEQ ID NOs: 50 and 200.

523. The genetically engineered cell of any one of claims 346-413, wherein the first transgene comprises one or more nucleic acid sequences that are at least 80% identical to SEQ ID NO:

200.

524. The genetically engineered cell of any one of claims 346-523, comprising in its genome the first transgene located at a first insertion site.

525. The genetically engineered cell of claim 524, wherein the first insertion site is a T cell receptor (TCR) locus.

526. The genetically engineered cell of claim 525, wherein the TCR locus is or include: TRAC locus, TRBC1 locus or TRBC2 locus.

527. The genetically engineered cell of claim 525, wherein the first insertion site is the β2 microglobulin (B2M) locus.

528. The genetically engineered cell of claim 525, wherein the first insertion site is the class II transactivator (CIITA) locus.

529. The genetically engineered cell of claim 525, wherein the first insertion site is a safe harbor locus.

530. The genetically engineered cell of claim 529, wherein the safe harbor locus is an AAVS1, ABO, CCR5, CLYBL, CXCR4, F3, FUT1, HMGB1, KDM5D, LRP1, MICA, MICB, RHD, ROSA26, or SHS231 locus.

531. The genetically engineered cell of any one of claims 525-530, wherein the first insertion site is an exon.

532. The genetically engineered cell of any one of claims 525-530, wherein the first insertion site is an intron.

533. The genetically engineered cell of any one of claims 525-530, wherein the first insertion site is located between an intron and an exon.

534. The genetically engineered cell of any one of claims 525-530, wherein the first insertion site is located in a regulatory region.

535. The genetically engineered cell of any one of claims 346-534, wherein the genetically engineered cell has cell surface expression of the engineered protein.

536. The genetically engineered cell of any one of claims 346-535, wherein the genetically engineered cell has reduced TCR cell surface expression compared to a comparable cell that has not been genetically engineered.

537. The genetically engineered cell of any one of claims 346-536, wherein the genetically engineered cell has reduced cell surface expression of B2M compared to a comparable cell that has not been genetically engineered.

538. The genetically engineered cell of any one of claims 346-537, wherein the genetically engineered cell has reduced expression of CIITA compared to a comparable cell that has not been genetically engineered.

539. The genetically engineered cell of any one of claims 346-538, wherein the genetically engineered cell comprises a modification at a TCR locus, a B2M locus, a TAP I locus, a NLRC5 locus, a CIITA locus, a HLA-A locus, a HLA-B locus, a HLA-C locus, a HLA-DP locus, a HLA-DM locus, a HLA-DOA locus, a HLA-DOB locus, a HLA-DQ locus, a HLA-DR locus, a RFX5 locus, a RFXANK locus, a RFXAP locus, a NFY-A locus, a NFY-B locus, a NFY-C locus, or a combination thereof.

540. The genetically engineered cell of any one of claims 346-539, wherein the genetically engineered cell has been genetically engineered to knock out the HLA-A locus, the HLA-B locus, the HLA-C locus, or a combination thereof.

541. The genetically engineered cell of any one of claims 346-539, wherein the genetically engineered cell has been genetically engineered to knock out the HLA-DM locus, the HLA-DO locus, the HLA-DP locus, the HLA-DQ locus, the HLA-DR locus, or a combination thereof.

542. The genetically engineered cell of any one of claims 346-541, wherein the genetically engineered cell has been genetically engineered to knock out a TCR locus.

543. The genetically engineered cell of any one of claims 346-542, wherein the genetically engineered cell has been genetically engineered to knock out the B2M locus.

544. The genetically engineered cell of any one of claims 346-543, wherein the genetically engineered cell has been genetically engineered to knock out the CIITA locus.

545. The genetically engineered cell of any one of claims 346-544, wherein the cell comprises one or more modifications that inactivate or disrupt one or more alleles of: (a) one or more major histocompatibility complex (MHC) class I molecules or one or more molecules that regulate the expression of said one or more MHC class I molecules, and / or (b) one or more MHC class II molecules or one or more molecules that regulate the expression of the one or more MHC class II molecules.

546. A genetically engineered cell as described in any one of claims 346-545, wherein the cell comprises one or more modifications that inactivate or destroy one or more alleles of one or more MHC class I molecules or one or more molecules that regulate the expression of the one or more MHC class I molecules.

547. The genetically engineered cell of any one of claims 346-546, wherein the cell comprises one or more modifications that inactivate or disrupt one or more alleles of one or more MHC class II molecules or one or more molecules that regulate the expression of the one or more MHC class II molecules.

548. The genetically engineered cell of any one of claims 346-547, wherein the cell comprises one or more modifications that inactivate or disrupt one or more alleles of: (a) one or more MHC class I molecules or one or more molecules that regulate the expression of the one or more MHC class I molecules, and (b) one or more MHC class II molecules or one or more molecules that regulate the expression of the one or more MHC class II molecules.

549. The genetically engineered cell of any one of claims 346-548, wherein the one or more modifications reduce cell surface protein expression of the one or more MHC class I molecules.

550. The genetically engineered cell of any one of claims 346-549, wherein the one or more modifications reduce cell surface trafficking of the one or more MHC class I molecules.

551. The genetically engineered cell of any one of claims 346-550, wherein the one or more modifications reduce the function of the one or more MHC class I molecules, optionally wherein the function is antigen presentation.

552. The genetically engineered cell of any one of claims 346-551, wherein the one or more MHC class I molecules are one or more human leukocyte antigen (HLA) class I molecules.

553. The genetically engineered cell of claim 552, wherein the one or more HLA class I molecules are selected from the group consisting of HLA-A, HLA-B, and HLA-C.

554. The genetically engineered cell of any one of claims 346-551, wherein the one or more molecules that regulate the expression of the one or more MHC class I molecules are selected from the group consisting of B2M, NLRC5, and TAP1.

555. The genetically engineered cell of any one of claims 346-554, wherein the one or more modifications reduce cell surface protein expression of the one or more MHC class II molecules.

556. The genetically engineered cell of any one of claims 346-555, wherein the one or more modifications reduce cell surface trafficking of the one or more MHC class II molecules.

557. The genetically engineered cell of any one of claims 346-556, wherein the one or more modifications reduce the function of the one or more MHC class II molecules, optionally wherein the function is antigen presentation.

558. The genetically engineered cell of any one of claims 346-557, wherein the one or more MHC class II molecules are one or more human leukocyte antigen (HLA) class II molecules.

559. The genetically engineered cell of claim 558, wherein the one or more HLA class II molecules are selected from the group consisting of HLA-DP, HLA-DQ, and / or HLA-DR.

560. The genetically engineered cell of any one of claims 346-557, wherein the one or more molecules that regulate the expression of the one or more MHC class II molecules are selected from the group consisting of CIITA and CD74.

561. The genetically engineered cell of any one of claims 346-547, further comprising a second transgene encoding a tolerogenic factor.

562. The genetically engineered cell of claim 561, wherein the tolerogenic factor is or includes A20 / TNFAIP3, B2M-HLA-E, CD16, CD16 Fc receptor, CD24, CD27, CD35, CD39, CD46, CD47, CD52, CD55, CD59, CD64, CD200, CCL21, CCL22, CTLA4-Ig, C1 inhibitor, CR1, DUX4, FASL, HLA-C, HLA-E, HLA-E heavy chain, HLA-F, HLA-G, H2-M3, IDO1, IL-10, IL15-RF, IL-35, IL-39, MANF, Mfge8, PD-L1 or Serpinb9.

563. The genetically engineered cell of claim 561 or 562, wherein the second transgene encoding the tolerogenic factor is inserted at an insertion site located at the TCR locus.

564. The genetically engineered cell of claim 561 or 562, wherein the second transgene encoding the tolerogenic factor is inserted at an insertion site located at the B2M locus.

565. The genetically engineered cell of claim 561 or 562, wherein the second transgene encoding the tolerogenic factor is inserted at an insertion site located at the CIITA locus.

566. The genetically engineered cell of claim 561 or 562, wherein the second transgene encoding the tolerogenic factor is inserted at an insertion site located at a safe harbor locus.

567. The genetically engineered cell of claim 566, wherein the safe harbor locus is an AAVS1, ABO, CCR5, CLYBL, CXCR4, F3, FUT1, HMGB1, KDM5D, LRP1, MICA, MICB, RHD, ROSA26, or SHS231 locus.

568. The genetically engineered cell of any one of claims 561-565, wherein the genetically engineered cell has cell surface expression of the tolerogenic factor.

569. The genetically engineered cell of any one of claims 346-568, further comprising a third transgene encoding a chimeric antigen receptor (CAR).

570. The genetically engineered cell of claim 569, wherein the CAR is or includes a CD5-specific CAR, a CD19-specific CAR, a CD20-specific CAR, a CD22-specific CAR, a CD23-specific CAR, a CD30-specific CAR, a CD33-specific CAR, a CD38-specific CAR, a CD70-specific CAR, a CD123-specific CAR, a CD138-specific CAR, a κ, λ, B cell maturation agent (BCMA)-specific CAR, a G protein-coupled receptor family group C 5 member D (GPRC5D)-specific CAR, a CD123-specific CAR, a LeY-specific CAR, a NKG2D ligand-specific CAR, a WT1-specific CAR, a GD2-specific CAR, a HER2-specific CAR, an EGFR-specific CAR, an EGFRvIII-specific CAR, a B7H3-specific CAR, a PSMA-specific CAR, a PSCA-specific CAR, a CAIX-specific CAR, CD171-specific CAR, CEA-specific CAR, CSPG4-specific CAR, EPHA2-specific CAR, FAP-specific CAR, FRα-specific CAR, IL-13Rα-specific CAR, mesothelin-specific CAR, MUC1-specific CAR, MUC16-specific CAR, ROR1-specific CAR, C-Met-specific CAR, CD133-specific CAR, Ep-CAM-specific CAR, GPC3-specific CAR, HPV16-E6-specific CAR, IL13Ra2-specific CAR, MAGEA3-specific CAR, MAGEA4-specific CAR, MART1-specific CAR, NY-ESO-1-specific CAR, VEGFR2-specific CAR, α-folate receptor-specific CAR, CD24-specific CAR, CD44v7 / 8-specific CAR, EGP-2-specific CAR, EGP-40-specific CAR, erb-B2-specific CAR, erb-B 2,3,4-specific CAR, FBP-specific CAR, fetal acetylcholine e receptor-specific CAR, GD2-specific CAR, GD3-specific CAR, HMW-MAA-specific CAR, IL-11Rα-specific CAR, KDR-specific CAR, Lewis Y-specific CAR, L1-cell adhesion molecule-specific CAR, MAGE-A1-specific CAR, carcinoembryonic antigen (h5T4)-specific CAR, TAG-72-specific CAR, or CD19 / CD22 bispecific CAR.

571. The genetically engineered cell of claim 569 or 570, wherein the CAR is or includes a CD19-specific CAR, a CD20-specific CAR, a CD22-specific CAR, a CD38-specific CAR, a CD123-specific CAR, a CD138-specific CAR, a BCMA-specific CAR, or a CD19 / CD22 bispecific CAR.

572. A genetically engineered cell as described in any one of claims 569-571, wherein the genetically engineered cell has cell surface expression of the CAR.

573. The genetically engineered cell of any one of claims 346-567, further comprising a third transgene encoding a chimeric autoantigen receptor (CAAR).

574. A genetically engineered cell as described in claim 573, wherein the CAAR comprises an antigen selected from the group consisting of pancreatic beta cell antigen, synovial joint antigen, myelin basic protein, proteolipid protein, myelin oligodendrocyte glycoprotein, MuSK, keratinocyte adhesion protein desmoglein 3 (Dsg3), Ro-RNP complex, La antigen, myeloperoxidase, proteinase 3, cardiolipin, citrullinated protein, carbamylated protein and basement membrane collagen α3 chain.

575. The genetically engineered cell of claim 573 or 574, wherein the genetically engineered cell has cell surface expression of the CAAR.

576. The genetically engineered cell of any one of claims 346-567, further comprising a third transgene encoding a B cell autoantibody receptor (BAR).

577. The genetically engineered cell of claim 576, wherein the genetically engineered cell has cell surface expression of the BAR.

578. The genetically engineered cell of any one of claims 569-577, wherein the third transgene is inserted at a safe harbor locus.

579. The genetically engineered cell of any one of claims 569-578, wherein the third transgene is inserted at a TRAC locus, a TRBC1 locus, a TRBC2 locus, a B2M locus, a CIITA locus, a MICA locus, a MICB locus or a safe harbor locus.

580. The genetically engineered cell of any one of claims 569-579, wherein the third transgene is inserted at the AAVS1 locus, the ABO locus, the CCR5 locus, the CLYBL locus, the CXCR4 locus, the F3 locus, the FUT1 locus, the HMGB1 locus, the KDM5D locus, the LRP1 locus, the RHD locus, the ROSA26 locus, or the SHS231 locus.

581. The genetically engineered cell of any one of claims 346-566, wherein the first transgene and the second transgene are inserted into the same insertion site.

582. The genetically engineered cell of any one of claims 346-566 or 576-580, wherein the first transgene and the third transgene are inserted into the same insertion site.

583. The genetically engineered cell of any one of claims 561-580, wherein the second transgene and the third transgene are inserted into the same insertion site.

584. The genetically engineered cell of any one of claims 346-580, wherein the first transgene, the second transgene, and the third transgene are inserted into the same insertion site.

585. The genetically engineered cell of any one of claims 346-584, wherein the first transgene, the second transgene, and the third transgene are encoded by three separate constructs.

586. The genetically engineered cell of any one of claims 346-584, wherein the first transgene, the second transgene, and the third transgene are encoded by two separate constructs.

587. The genetically engineered cell of any one of claims 346-584, wherein the first transgene, the second transgene, and the third transgene are encoded by a polycistronic construct.

588. The genetically engineered cell of any one of claims 346-587, wherein the first transgene and / or the second transgene and / or the third transgene encodes a genome editing complex.

589. A genetically engineered cell as described in 588, wherein the genome editing complex comprises a genome targeting entity and a genome modifying entity.

590. The genetically engineered cell of 589, wherein the genome targeting entity is a nucleic acid-guided targeting entity.

591. The genetically engineered cell of claim 589 or 590, wherein the genome targeting entity is selected from the group consisting of: a sequence-specific nuclease, a nucleic acid-programmable DNA-binding protein, an RNA-guided nuclease, an RNA-guided nuclease comprising a Cas nuclease and a guide RNA (CRISPR-Cas combination), a ribonucleoprotein (RNP) complex comprising a gRNA and a Cas nuclease, a homing endonuclease, a zinc finger nuclease (ZF) nucleic acid binding entity, a transcription activator-like effector (TALE) nucleic acid binding entity, a meganuclease, a Cas nuclease, a core Cas protein, a homing endonuclease, an endonuclease-deficient Cas protein, an enzymatically inactive Cas protein, a CRISPR-associated transposase (CAST), a type II or type V Cas protein, or a functional portion thereof.

592. The genetically engineered cell of any one of claims 589-591, wherein the genome targeting entity is selected from the group consisting of: Cas1, Cas2, Cas3, Cas4, Cas5, Cas6, Cas7, Cas8a, Cas8b, Cas8c, Cas9, Cas10, Cas12, Cas12a (Cpf1), Cas12b (C2c1), Cas12c (C2c3), Cas12d (CasY), Cas12e (CasX), Cas12f (C2c10), Cas12g, Cas12h, Cas12i, Cas12k (C2c5), Cas13, Cas13a (C2c2), Cas13b, Cas13c, Cas13d, C2c4, C2c8, C2c9, Cmr1, Cmr2, Cmr3, Cmr4, Cmr5, Cmr6, Csd1, Csd2, Cas5d, Cse1, Cse2, Cse3, Cse4, Cas5e, Csf1, Csm1, Csm2, Csm3, Csm4, Csm5, Csn1, Csn 2. Cst1, Cst2, Cas5t, Csh1, Csh2, Cas5h, Csa1, Csa2, Csa3, Csa4, Csa5, Cas5a, Csx10, Csx11, Csy1 , Csy2, Csy3, Csy4, Mad7, SpCas9, eSpCas9 of SpCas9, SpCas9-HF1, HypaSpCas9, HeFSpCas9 and evoSpCas9 high-fidelity variants, SaCas9, NmeCas9, CjCas9, StCas9, TdCas9, LbCas12a, AsCas12a, AacCas12b, BhCas12b v4, TnpB, dCas(D10A), dCas(H840A), dCas13a, dCas13b, or functional parts thereof.

593. The genetically engineered cell of any one of claims 589-592, wherein the genome modifying entity cleaves, deaminates, nicks, polymerizes, interrogates, integrates, cuts, unwinds, breaks, alters, methylates, demethylates, or otherwise destabilizes the target locus.

594. The genetically engineered cell of any one of claims 589-593, wherein the genome modifying entity comprises a recombinase, an integrase, a transposase, an endonuclease, an exonuclease, a nickase, a helicase, a DNA polymerase, an RNA polymerase, a reverse transcriptase, a deaminase, a flippase, a methylase, a demethylase, an acetylase, a nucleic acid modifying protein, an RNA modifying protein, a DNA modifying protein, an Argonaute protein, an epigenetic modifying protein, a histone modifying protein, or a functional part thereof.

595. The genetically engineered cell of any one of claims 589-594, wherein the genome targeting entity is selected from the group consisting of: a sequence-specific nuclease, a nucleic acid-programmable DNA-binding protein, an RNA-guided nuclease, an RNA-guided nuclease comprising a Cas nuclease and a guide RNA (CRISPR-Cas combination), a ribonucleoprotein (RNP) complex comprising a gRNA and a Cas nuclease, a homing endonuclease, a zinc finger nuclease (ZFN), a transcription activator-like effector nuclease (TALEN), a meganuclease, a Cas nuclease, a core Cas protein, a TnpB nuclease, an endonuclease-deficient Cas protein, an enzymatically inactive Cas protein, a CRISPR-associated transposase (CAST), a type II or type V Cas protein, base editing, lead editing, programmable addition via site-specific targeting elements (PASTE), or a functional part thereof.

596. The genetically engineered cell of any one of claims 589-595, wherein the genome modifying entity is selected from the group consisting of Cas1, Cas2, Cas3, Cas4, Cas5, Cas6, Cas7, Cas8a, Cas8b, Cas8c, Cas9, Cas10, Cas12, Cas12a (Cpf1), Cas12b (C2c1), Cas12c (C2c3), Cas12d (CasY), Cas12e (CasX), Cas12f (C2c10), Cas12g, Cas12h, Cas12i, Cas12k (C2c5), Cas13, Cas13a (C2c2), Cas13b, Cas13c, Cas13d, C2c4, C2c8, C2c9, Cmr1, Cmr2, Cmr3, Cmr4, Cmr5, Cmr6, Csd1, Csd2, Cas5d, Cse1, Cse2, Cse3, Cse4, Cas5e, Csf1, Csm1, Csm2, Csm3, Csm4, Csm5, Csn1, Csn 2. Cst1, Cst2, Cas5t, Csh1, Csh2, Cas5h, Csa1, Csa2, Csa3, Csa4, Csa5, Cas5a, Csx10, Csx11, Csy1 , Csy2, Csy3, Csy4, Mad7, SpCas9, eSpCas9 of SpCas9, SpCas9-HF1, HypaSpCas9, HeFSpCas9 and evoSpCas9 high-fidelity variants, SaCas9, NmeCas9, CjCas9, StCas9, TdCas9, LbCas12a, AsCas12a, AacCas12b, BhCas12b v4, TnpB, FokI, dCas(D10A), dCas(H840A), dCas13a, dCas13b, base editor, prime editor, target-primed reverse transcription (TPRT) editor, APOBEC1, cytidine deaminase, adenosine deaminase, uracil glycosylase inhibitor (UGI), adenine base editor (ABE), cytosine base editor (CBE), reverse transcriptase, serine integrase, recombinase, transposase, polymerase, adenine to thymine or "ATBE" (or thymine to adenine or "TABE") transversion base editor, ten-eleven translocation methylcytosine dioxygenase (TET), TET1, TET3, TET1CD, histone acetyltransferase p300, histone methyltransferase SMYD3, histone methyltransferase PRDM9, H3K79 methyltransferase DOT1L, transcriptional repressor or a functional part thereof.

597. The genetically engineered cell of any one of claims 589-596, wherein the genome targeting entity and the genome modifying entity are different domains of a single polypeptide.

598. The genetically engineered cell of any one of claims 589-597, wherein the genome targeting entity and the genome modifying entity are two different polypeptides operably linked together.

599. The genetically engineered cell of any one of claims 589-597, wherein the genome targeting entity and the genome modifying entity are two different polypeptides that are not linked together.

600. The genetically engineered cell of any one of claims 589-599, wherein the genome editing complex comprises a guide nucleic acid having a targeting domain complementary to at least one target locus, optionally wherein the guide nucleic acid is a guide RNA (gRNA).

601. The genetically engineered cell of any one of claims 588-598, wherein the genome editing complex comprises an RNA-guided nuclease.

602. The genetically engineered cell of claim 601, wherein the RNA-guided nuclease comprises a Cas nuclease.

603. The genetically engineered cell of claim 602, wherein the genome editing complex comprises a ribonucleoprotein (RNP) complex comprising the Cas nuclease and the gRNA.

604. The genetically engineered cell of claim 602 or 603, wherein the Cas nuclease is a type II or type V Cas protein.

605. The genetically engineered cell of any one of claims 602-604, wherein the Cas nuclease is selected from the group consisting of Cas3, Cas4, Cas5, Cas8a, Cas8b, Cas8c, Cas9, Cas10, Cas12, Cas12a (Cpf1), Cas12b (C2c1), Cas12c (C2c3), Cas12d (CasY), Cas12e (CasX), Cas12f (C2c10), Cas12g, Cas12h, Cas12i, Cas12k (C2c5), Cas13, Cas13a (C2c2), Cas13b, Cas13c, Cas13d, C2c4, C2c8, C2c9, Cmr5, Cse1, Cse2, Csf1, Csm2, Csn2, Csx10, Csx11, Csy1, Csy2, Csy3, and Mad7.

606. The genetically engineered cell of any one of claims 346-587, wherein the genetically engineered cell is a human cell or a non-human animal cell.

607. The genetically engineered cell of claim 606, wherein the non-human animal cell is a pig, cow or sheep cell.

608. The genetically engineered cell of claim 606, wherein the genetically engineered cell is a human cell.

609. The genetically engineered cell of any one of claims 346-608, wherein the genetically engineered cell is a differentiated cell derived from a stem cell or a progenitor cell.

610. The genetically engineered cell of claim 609, wherein the stem cell is a pluripotent stem cell.

611. The genetically engineered cell of claim 610, wherein the pluripotent stem cell is an induced pluripotent stem cell (iPSC).

612. The genetically engineered cell of claim 610, wherein the pluripotent stem cell is an embryonic stem cell (ESC).

613. The genetically engineered cell of any one of claims 346-612, wherein the cell is a primary cell isolated from a donor.

614. The genetically engineered cells of claim 613, wherein the donor is healthy and / or not suspected of having a disease or disorder when the primary cells are obtained from the donor.

615. The genetically engineered cell of any one of claims 346-614, wherein the genetically engineered cell is part of a primary cell population isolated from a plurality of donors.

616. The genetically engineered cell of any one of claims 346-615, wherein the plurality of donors are healthy and / or not suspected of having a disease or disorder when the primary cells are obtained from the donors.

617. The genetically engineered cell of any one of claims 346-616, wherein the cell is an islet cell, a beta islet cell, a pancreatic islet cell, an immune cell, a B cell, a T cell, a natural killer (NK) cell, a natural killer T (NKT) cell, a macrophage, an endothelial cell, a muscle cell, a cardiac muscle cell, a smooth muscle cell, a skeletal muscle cell, a dopaminergic neuron, a retinal pigment epithelial cell, a visual cell, a hepatocyte, a thyroid cell, a skin cell, a glial progenitor cell, a neural cell, a cardiac cell, a stem cell, a hematopoietic stem cell, an induced pluripotent stem cell (iPSC), a mesenchymal stem cell (MSC), an embryonic stem cell (ESC), a pluripotent stem cell (PSC), a blood cell, or a combination thereof.

618. The genetically engineered cell of any one of claims 346-617, wherein the cell is a T cell.

619. The genetically engineered cells of claim 618, wherein the T cells are CD3+T cells, CD4+T cells, CDS+T cells, naive T cells, regulatory T (Treg) cells, non-regulatory T cells, Th1 cells, Th2 cells, Th9 cells, Th17 cells, follicular helper T (Tfh) cells, cytotoxic T lymphocytes (CTLs), effector T (Teff) cells, central memory T cells, effector memory T cells, effector memory T cells expressing CD45RA (TEMRA cells), tissue-resident memory (Trm) cells, virtual memory T cells, innate memory T cells, memory stem cells (Tse), γδ T cells, or a combination thereof.

620. The genetically engineered cell of claim 618 or 619, wherein the T cell is a cytotoxic T cell, a helper T cell, a memory T cell, a regulatory T cell, a tumor infiltrating lymphocyte, or a combination thereof.

621. The genetically engineered cell of any one of claims 618-620, wherein the cell is a human T cell.

622. The genetically engineered cell of any one of claims 618-621, wherein the cell is an autologous T cell.

623. The genetically engineered cell of any one of claims 618-621, wherein the cell is an allogeneic T cell.

624. The genetically engineered cell of claim 623, wherein the allogeneic T cells are primary T cells.

625. The genetically engineered cell of 623 or 624, wherein the allogeneic T cells have been differentiated from embryonic stem cells (ESCs) or induced pluripotent stem cells (iPSCs).

626. The genetically engineered cell of any one of claims 346-625, wherein the engineered protein is expressed in the genetically engineered cell at a level that is at least about 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, 20-fold, 25-fold, 30-fold, 40-fold, 50-fold, 60-fold, 70-fold, 80-fold, 90-fold, 100-fold, 150-fold, 200-fold, 300-fold, 400-fold, 500-fold, 600-fold, 700-fold, 800-fold, 900-fold, 1000-fold, 1100-fold, 1200-fold, 1300-fold, 1400-fold, 1500-fold, 2000-fold, 2500-fold, 3000-fold, 3500-fold, 4000-fold, 4500-fold, or 5000-fold higher than endogenous CD47 protein in a control cell of the same cell type as the genetically engineered cell.

627. The genetically engineered cell of any one of claims 346-625, wherein the engineered protein is expressed in the genetically engineered cell at a level that is at least about 1-fold to at least about 15-fold higher than endogenous CD47 protein in a control cell of the same cell type as the genetically engineered cell.

628. The genetically engineered cell of any one of claims 346-625, wherein the engineered protein is expressed in the genetically engineered cell at a level that is at least about 1-fold to at least about 10-fold higher than endogenous CD47 protein in a control cell of the same cell type as the genetically engineered cell.

629. The genetically engineered cell of any one of claims 346-625, wherein the engineered protein is expressed in the genetically engineered cell at a level that is at least about 1-fold to at least about 5-fold higher than endogenous CD47 protein in a control cell of the same cell type as the genetically engineered cell.

630. The genetically engineered cell of any one of claims 346-625, wherein the engineered protein is expressed in the genetically engineered cell at a level that is at least about 3-fold to at least about 4-fold higher than endogenous CD47 protein in a control cell of the same cell type as the genetically engineered cell.

631. The genetically engineered cell of any one of claims 346-625, wherein the engineered protein is expressed in the genetically engineered cell at a level that is at least about 3-fold to at least about 10-fold higher than endogenous CD47 protein in a control cell of the same cell type as the genetically engineered cell.

632. The genetically engineered cell of any one of claims 346-625, wherein the engineered protein is expressed in the genetically engineered cell at a level that is at least about 4-fold to at least about 10-fold higher than endogenous CD47 protein in a control cell of the same cell type as the genetically engineered cell.

633. The genetically engineered cell of any one of claims 346-625, wherein the engineered protein is expressed in the genetically engineered cell at a level that is at least about 500-fold to at least about 2000-fold higher than the endogenous CD47 protein in a control cell of the same cell type as the genetically engineered cell.

634. The genetically engineered cell of any one of claims 346-625, wherein the engineered protein is expressed in the genetically engineered cell at a level that is at least about 500-fold to at least about 1500-fold higher than the endogenous CD47 protein in a control cell of the same cell type as the genetically engineered cell.

635. The genetically engineered cell of any one of claims 346-625, wherein the engineered protein is expressed in the genetically engineered cell at a level that is at least about 900-fold to at least about 1000-fold higher than the endogenous CD47 protein in a control cell of the same cell type as the genetically engineered cell.

636. The genetically engineered cell of any one of claims 346-625, wherein the engineered protein is expressed in the genetically engineered cell at a level that is at least about 1000-fold higher than endogenous CD47 protein in a control cell of the same cell type as the genetically engineered cell.

637. A composition comprising the genetically engineered cells of any one of claims 345-636.

638. A pharmaceutical composition comprising (i) the genetically engineered cell of any one of claims 345-636, and (ii) a pharmaceutically acceptable excipient.

639. A method comprising administering to a subject the genetically engineered cell of any one of claims 345-636, the composition of claim 637, or the pharmaceutical composition of claim 638.

640. The method of claim 639, wherein the method is a method of treating a disease in a subject.

641. A cell population comprising the genetically engineered cells of any one of claims 345-636 for use in treating a disease in a subject.

642. The composition of claim 637, for use in treating a disease in a subject.

643. A pharmaceutical composition as described in claim 638, for use in treating a disease in a subject.

644. Use of the genetically modified cells of any one of claims 345-636, the cell population of claim 56, the composition of claim 54 or 56a, or the pharmaceutical composition of claim 54a or 54b for treating a disease in a subject.

645. Use of the genetically modified cells of any one of claims 345-636, the cell population of claim 56, the composition of claim 54 or 56a, or the pharmaceutical composition of claim 54a or 54b in the manufacture of a medicament for treating a disease.

646. The genetically modified cell, cell colony, composition, pharmaceutical composition or use of any of the preceding claims, wherein the disease is cancer.

647. A genetically modified cell, cell population, composition, pharmaceutical composition or use as described in any of the preceding claims, wherein the cancer is associated with CD5, CD19, CD20, CD22, CD23, CD30, CD33, CD70, κ, λ, B cell maturation agent (BCMA), G protein coupled receptor family group C 5 member D (GPRC5D), CD123, LeY, NKG2D ligand, WT1, GD2, HER2, EGFR, EGFRvIII, B7H3, PSMA , PSCA, CAIX, CD171, CEA, CSPG4, EPHA2, FAP, FRα, IL-13Rα, mesothelin, MUC1, MUC16, ROR1, C-Met, CD133, Ep-CAM, GPC3, HPV16-E6, IL13Ra2, MAGEA3, MAGEA4, MART1, NY-ESO-1, VEGFR2, α-folate receptor, CD24, CD44v7 / 8, EGP-2, EGP-40, erb-B2, erb-B 2,3,4, FBP, fetal acetylcholine e receptor, GD2, GD3, HMW-MAA, IL-11Rα, KDR, Lewis Y, L1 cell adhesion molecule, MAGE-A1, carcinofemoral antigen (h5T4), and / or TAG-72 expression.

648. The genetically modified cell, cell population, composition, pharmaceutical composition or use of any of the preceding claims, wherein the cancer is a hematological malignancy.

649. The genetically modified cell, cell population, composition, pharmaceutical composition or use of any of the preceding claims, wherein the hematological malignancy is selected from the group consisting of: a myeloid neoplasm, a myelodysplastic syndrome (MDS), a myelodysplastic / myelodysplastic syndrome, an acute lymphoblastic leukemia (ALL), a chronic lymphocytic leukemia (CLL), an acute myeloid leukemia (AML), a chronic myeloid leukemia (CML), a blast crisis chronic myeloid leukemia (bcCML), a B-cell acute lymphoblastic leukemia (B-ALL), a T-cell acute lymphoblastic leukemia (T-ALL), a T-cell lymphoma, and a B-cell lymphoma.

650. The genetically modified cell, cell population, composition, pharmaceutical composition or use of any of the preceding claims, wherein the cancer is a solid malignant disease.

651. The genetically modified cell, cell population, composition, pharmaceutical composition or use of any of the preceding claims, wherein the solid malignancy is selected from breast cancer, ovarian cancer, colon cancer, prostate cancer, epithelial cancer, renal cell carcinoma, pancreatic adenocarcinoma, cervical cancer, colorectal cancer, glioblastoma, rhabdomyosarcoma, neuroblastoma, melanoma, Ewing's sarcoma, osteosarcoma, mesothelioma and adenocarcinoma.

652. The genetically modified cell, cell colony, composition, pharmaceutical composition or use of any of the preceding claims, wherein the disease is an autoimmune disease.

653. The genetically modified cell, cell population, composition, pharmaceutical composition or use of any of the preceding claims, wherein the autoimmune disease is selected from the group consisting of lupus, systemic lupus erythematosus, rheumatoid arthritis, psoriasis, psoriatic arthritis, multiple sclerosis, Crohn's disease, ulcerative colitis, Addison's disease, Grave's disease, Sjogren's syndrome, Hashimoto's thyroiditis and celiac disease.

654. The genetically modified cell of any of the preceding claims, the cell colony of any of the preceding claims, the composition of any of the preceding claims, the pharmaceutical composition of any of the preceding claims, or the use of any of the preceding claims, wherein the disease is diabetes.

655. The genetically modified cell, cell population, composition, pharmaceutical composition or use of any of the preceding claims, wherein the diabetes is selected from the group consisting of type I diabetes, type II diabetes, prediabetes and gestational diabetes.

656. The genetically modified cell, cell colony, composition, pharmaceutical composition or use of any of the preceding claims, wherein the disease is a neurological disease.

657. The genetically modified cell, cell population, composition, pharmaceutical composition or use of any of the preceding claims, wherein the neurological disease is selected from the group consisting of: catalepsy, epilepsy, encephalitis, meningitis, migraine, Huntington's disease, Alzheimer's disease, Parkinson's disease, Pellizais-Merzbacher's disease and multiple sclerosis.

658. A method for producing a genetically engineered cell comprising a nucleic acid construct, the method comprising: include: The nucleic acid construct of any one of claims 1-184 is delivered to a cell to produce a genetically engineered cell.

659. The method of claim 658, wherein the nucleic acid construct comprises a first transgene encoding the engineered protein.

660. The method of claim 658 or 659, wherein the method comprises inserting a first transgene encoding the engineered protein into a first insertion site in the genome of the cell.

661. The method of claim 660, wherein the first insertion site is a T cell receptor (TCR) locus.

662. The method of claim 661, wherein the TCR locus is or include: TRAC locus, TRBC1 locus or TRBC2 locus.

663. The method of claim 661, wherein the first insertion site is the β2 microglobulin (B2M) locus.

664. The method of claim 661, wherein the first insertion site is the class II transactivator (CIITA) locus.

665. The method of claim 661, wherein the first insertion site is a safe harbor locus.

666. The method of claim 665, wherein the safe harbor locus is an AAVS1, ABO, CCR5, CLYBL, CXCR4, F3, FUT1, HMGB1, KDM5D, LRP1, MICA, MICB, RHD, ROSA26, or SHS231 locus.

667. The method of any one of claims 660-664, wherein the first insertion site is an exon.

668. The method of any one of claims 660-664, wherein the first insertion site is an intron.

669. The method of any one of claims 660-664, wherein the first insertion site is located between an intron and an exon.

670. The method of any one of claims 660-664, wherein the first insertion site is located in a regulatory region.

671. The method of any one of claims 660-670, wherein the inserting step comprises inserting using a gene therapy vector, a transposase, a lentiviral vector, a retrovirus, a fusion, a PiggyBac transposon, a Sleeping Beauty (SB11) transposon, a Mos1 transposon, or a Tol2 transposon.

672. The method of any one of claims 660-671, wherein the inserting step comprises inserting using a lentiviral vector.

673. The method of any one of claims 660-670, wherein the inserting step comprises homology directed repair (HDR)-mediated insertion using a genome modifying protein.

674. The method of any one of claims 658-673, further comprising introducing a genome editing complex into the cell.

675. The method of claim 674, wherein the genome editing complex comprises a genome targeting entity and a genome modifying entity.

676. The method of claim 675, wherein the genome targeting entity localizes the genome editing complex to a safe harbor site, optionally wherein the genome targeting entity is a nucleic acid-guided targeting entity.

677. A method as described in 675 or 676, wherein the genome targeting entity is selected from the group consisting of: sequence-specific nucleases, nucleic acid-programmable DNA-binding proteins, RNA-guided nucleases, RNA-guided nucleases comprising a Cas nuclease and a guide RNA (CRISPR-Cas combination), a ribonucleoprotein (RNP) complex comprising a gRNA and a Cas nuclease, a homing endonuclease, a zinc finger nuclease (ZF) nucleic acid binding entity, a transcription activator-like effector (TALE) nucleic acid binding entity, a large range of nucleases, Cas nucleases, core Cas proteins, homing endonucleases, endonucleases Defective Cas proteins, Cas proteins without enzymatic activity, CRISPR-associated transposases (CAST), type II or type V Cas proteins, or functional parts thereof.

678. The method of any one of claims 675-677, wherein the genome targeting entity is selected from the group consisting of: Cas1, Cas2, Cas3, Cas4, Cas5, Cas6, Cas7, Cas8a, Cas8b, Cas8c, Cas9, Cas10, Cas12, Cas12a (Cpf1), Cas12b (C2c1), Cas12c (C2c3), Cas12d (CasY), Cas12e (CasX), Cas12f (C2c10), Cas12g, Cas12h, Cas12i, Cas12k (C2c5), Cas13, Cas13a (C2c2), Cas13b, Cas13c, Cas13d, C2c4, C2c8, C2c9, Cmr1, Cmr2, Cmr3, Cmr4, Cmr5, Cmr6, Csd1 、Csd2、Cas5d、Cse1、Cse2、Cse3、Cse4、Cas5e、Csf1、Csm1、Csm2、Csm3、Csm4、Csm5、Csn1、Csn2、Cst1、Cst2、Cas5t、Csh1、Csh2、Cas5h、Csa1、Csa2、Csa3、Csa4、Csa5、Cas5a、Csx10、Csx11、Csy1、Csy2、Csy3、Csy4、Mad7、SpCas9、eSpCas9 of SpCas9、SpCas9-HF1、HypaSpCas9、HeFSpCas9 and evoSpCas9 high-fidelity variants、SaCas9、NmeCas9、CjCas9、StCas9、TdCas9、LbCas12a、AsCas12a、AacCas12b、BhCas12b v4, TnpB, dCas(D10A), dCas(H840A), dCas13a, dCas13b, or functional parts thereof.

679. The method of any one of claims 675-678, wherein the genome modifying entity cleaves, deaminates, incises, polymerizes, interrogates, integrates, cuts, unwinds, breaks, alters, methylates, demethylates, or otherwise destabilizes the target locus.

680. The method of any one of claims 675-679, wherein the genome modifying entity comprises a recombinase, an integrase, a transposase, an endonuclease, an exonuclease, a nickase, a helicase, a DNA polymerase, an RNA polymerase, a reverse transcriptase, a deaminase, a flippase, a methylase, a demethylase, an acetylase, a nucleic acid modifying protein, an RNA modifying protein, a DNA modifying protein, an Argonaute protein, an epigenetic modifying protein, a histone modifying protein, or a functional portion thereof.

681. The method of any one of claims 675-680, wherein the genome modification entity is selected from the group consisting of: a sequence-specific nuclease, a nucleic acid-programmable DNA-binding protein, an RNA-guided nuclease, an RNA-guided nuclease comprising a Cas nuclease and a guide RNA (CRISPR-Cas combination), a ribonucleoprotein (RNP) complex comprising a gRNA and a Cas nuclease, a homing endonuclease, a zinc finger nuclease (ZFN), a transcription activator-like effector nuclease (TALEN), a meganuclease, a Cas nuclease, a core Cas protein, a TnpB nuclease, an endonuclease-deficient Cas protein, an enzymatically inactive Cas protein, a CRISPR-associated transposase (CAST), a type II or type V Cas protein, base editing, lead editing, programmable addition via site-specific targeting elements (PASTE), or a functional portion thereof.

682. The method of any one of claims 675-681, wherein the genome modifying entity is selected from the group consisting of Cas1, Cas2, Cas3, Cas4, Cas5, Cas6, Cas7, Cas8a, Cas8b, Cas8c, Cas9, Cas10, Cas12, Cas12a (Cpf1), Cas12b (C2c1), Cas12c (C2c3), Cas12d (CasY), Cas12e (CasX), Cas12f (C2c10), Cas12g, Cas12h, Cas12i, Cas12k (C2c5), Cas13, Cas13a (C2c2), Cas13b, Cas13c, Cas13d, C2c4, C2c8, C2c9, Cmr1, Cmr2, Cmr3, Cmr4, Cmr5, Cmr6, Csd1 、Csd2、Cas5d、Cse1、Cse2、Cse3、Cse4、Cas5e、Csf1、Csm1、Csm2、Csm3、Csm4、Csm5、Csn1、Csn2、Cst1、Cst2、Cas5t、Csh1、Csh2、Cas5h、Csa1、Csa2、Csa3、Csa4、Csa5、Cas5a、Csx10、Csx11、Csy1、Csy2、Csy3、Csy4、Mad7、SpCas9、eSpCas9 of SpCas9、SpCas9-HF1、HypaSpCas9、HeFSpCas9 and evoSpCas9 high-fidelity variants、SaCas9、NmeCas9、CjCas9、StCas9、TdCas9、LbCas12a、AsCas12a、AacCas12b、BhCas12b v4, TnpB, FokI, dCas(D10A), dCas(H840A), dCas13a, dCas13b, base editor, prime editor, target-primed reverse transcription (TPRT) editor, APOBEC1, cytidine deaminase, adenosine deaminase, uracil glycosylase inhibitor (UGI), adenine base editor (ABE), cytosine base editor (CBE), reverse transcriptase, serine integrase, recombinase, transposase, polymerase, adenine to thymine or "ATBE" (or thymine to adenine or "TABE") transversion base editor, ten-eleven translocation methylcytosine dioxygenase (TET), TET1, TET3, TET1CD, histone acetyltransferase p300, histone methyltransferase SMYD3, histone methyltransferase PRDM9, H3K79 methyltransferase DOT1L, transcriptional repressor or a functional part thereof.

683. The method of any one of claims 675-682, wherein the genome targeting entity and the genome modifying entity are different domains of a single polypeptide.

684. The method of any one of claims 675-683, wherein the genome targeting entity and the genome modifying entity are two different polypeptides operably linked together.

685. The method of any one of claims 675-683, wherein the genome targeting entity and the genome modifying entity are two different polypeptides that are not linked together.

686. The method of any one of claims 674-685, wherein the genome editing complex comprises a guide nucleic acid having a targeting domain complementary to at least one sequence within a genomic safe harbor site, optionally wherein the guide nucleic acid is a guide RNA (gRNA).

687. The method of any one of claims 674-686, wherein the genome editing complex comprises an RNA-guided nuclease.

688. The method of claim 687, wherein the RNA-guided nuclease comprises a Cas nuclease.

689. The method of claim 688, wherein the genome editing complex comprises a ribonucleoprotein (RNP) complex comprising the Cas nuclease and the gRNA.

690. The method of claim 688 or 689, wherein the Cas nuclease is a type II or type V Cas protein.

691. The method of any one of claims 688-690, wherein the Cas nuclease is selected from the group consisting of Cas3, Cas4, Cas5, Cas8a, Cas8b, Cas8c, Cas9, Cas10, Cas12, Cas12a (Cpf1), Cas12b (C2c1), Cas12c (C2c3), Cas12d (CasY), Cas12e (CasX), Cas12f (C2c10), Cas12g, Cas12h, Cas12i, Cas12k (C2c5), Cas13, Cas13a (C2c2), Cas13b, Cas13c, Cas13d, C2c4, C2c8, C2c9, Cmr5, Cse1, Cse2, Csf1, Csm2, Csn2, Csx10, Csx11, Csy1, Csy2, Csy3, and Mad7.

692. The method of claim 678, wherein the gRNA comprises a complementary region, wherein the complementary region comprises a nucleic acid sequence complementary to a target nucleic acid sequence within a locus, and wherein the target nucleic acid sequence comprises the insertion site.

693. The method of claim 692, wherein the locus is a TCR locus.

694. The method of claim 692, wherein the locus is the B2M locus.

695. The method of claim 692, wherein the locus is the CIITA locus.

696. The method of any one of claims 660-695, wherein the first insertion site is 25 nucleotides or fewer from a protospacer adjacent motif (PAM) sequence, wherein the PAM sequence is ngg, nag, ngrrt, ngrrn, nnnngatt, nnnnryac, nnagaaw, naaaac, tttv, ttn, attn, tttn, gttn, or yttn, and in: (i)r=a or g, (ii) y = c or t, (iii) w = a or t, (iv) v = a or c or g, and (v) n = a, c, t or g.

697. The method of any one of claims 660-696, wherein the inserting step comprises homology-directed repair (HDR)-mediated insertion using SpCas9 and the PAM is ngg or nag, wherein n=a, c, t or g.

698. The method of any one of claims 660-696, wherein the inserting step comprises homology directed repair (HDR)-mediated insertion using SaCas9 and the PAM is ngrrt or ngrrn, in: (i) r = a or g, and (ii) n = a, c, t or g.

699. The method of any one of claims 660-696, wherein the inserting step comprises homology-directed repair (HDR)-mediated insertion using NmeCas9 and the PAM is nnnngatt, wherein n=a, c, t or g.

700. The method of any one of claims 660-696, wherein the inserting step comprises homology-directed repair (HDR)-mediated insertion using CjCas9 and the PAM is nnnnryac, in: (i)r=a or g, (ii) y = c or t, and (iii) n = a, c, t or g.

701. The method of any one of claims 660-696, wherein the inserting step comprises homology-directed repair (HDR)-mediated insertion using StCas9 and the PAM is nnagaaw, in: (i) w = a or t, and (ii) n = a, c, t or g.

702. The method of any one of claims 660-696, wherein the inserting step comprises homology-directed repair (HDR)-mediated insertion using TdCas9 and the PAM is naaaac, wherein n=a, c, t or g.

703. The method of any one of claims 660-696, wherein the inserting step comprises homology-directed repair (HDR)-mediated insertion using LbCas12a and the PAM is tttv, where v = a or c or g.

704. The method of any one of claims 660-696, wherein the inserting step comprises homology-directed repair (HDR)-mediated insertion using AsCas12a and the PAM is tttv, wherein v = a or c or g.

705. The method of any one of claims 660-696, wherein the inserting step comprises homology-directed repair (HDR)-mediated insertion using AacCas12b and the PAM is ttn, wherein n=a, c, t or g.

706. The method of any one of claims 660-696, wherein the inserting step comprises homology-directed repair (HDR)-mediated insertion using BhCas12b and the PAM is attn., tttn or gttn, wherein n=a, c, t or g.

707. The method of any one of claims 660-696, wherein the inserting step comprises homology-directed repair (HDR)-mediated insertion using MAD7 (ErCas12a) and the PAM is yttn, in: (i) y = c or t, and (ii) n = a, c, t or g.

708. The method of any one of claims 660, 678, or 697-707, wherein homology directed repair (HDR)-mediated insertion using a site-directed nuclease is performed with an HDR efficiency equal to or greater than HDR insertion using a lentivirus.

709. The method of any one of claims 660-673, 675, 676 or 677, wherein the inserting step comprises homology-directed repair (HDR)-mediated insertion using a ZFN.

710. The method of any one of claims 660-673, 675, 676, 677 or 709, wherein the first insertion site is 25 nucleotides or less from the zinc finger binding sequence.

711. The method of any one of claims 660-673, 675, 676 or 677, wherein the inserting step comprises homology-directed repair (HDR)-mediated insertion using TALENs.

712. The method of any one of claims 660-673, 675, 676, 677 or 711, wherein the first insertion site is 25 nucleotides or fewer from a transcription activator-like effector (TALE) binding sequence.

713. The method of any one of claims 660-675 or 677, wherein the inserting step comprises homology-directed repair (HDR)-mediated insertion using a guide RNA (gRNA) and a TnpB polypeptide.

714. The method of claim 713, wherein the gRNA comprises a complementary region, wherein the complementary region comprises a nucleic acid sequence complementary to a target nucleic acid sequence within a locus, and wherein the target nucleic acid sequence comprises the insertion site.

715. The method of claim 714, wherein the locus is a TCR locus.

716. The method of claim 714, wherein the locus is the B2M locus.

717. The method of claim 714, wherein the locus is the CIITA locus.

718. The method of claim 714, wherein the locus is a safe harbor locus.

719. The method of claim 718, wherein the safe harbor locus is an AAVS1, ABO, CCR5, CLYBL, CXCR4, F3, FUT1, HMGB1, KDM5D, LRP1, MICA, MICB, RHD, ROSA26, or SHS231 locus.

720. The method of any one of claims 713-719, wherein the insertion site is 25 nucleotides or less from a target adjacent motif (TAM) sequence, wherein the TAM sequence is tca, tcac, tcag, tcat, tcaa, ttcan, ttcaa, ttcag, or ttgat, and in: (i) n = a, c, t or g.

721. The method of any one of claims 713-720, wherein the inserting step comprises homology directed repair (HDR)-mediated insertion using a TnpB polypeptide and the TAM is tca.

722. The method of any one of claims 713-720, wherein the inserting step comprises homology directed repair (HDR)-mediated insertion using a TnpB polypeptide and the TAM is tcac.

723. The method of any one of claims 713-720, wherein the inserting step comprises homology directed repair (HDR)-mediated insertion using a TnpB polypeptide and the TAM is tcag.

724. The method of any one of claims 713-720, wherein the inserting step comprises homology directed repair (HDR)-mediated insertion using a TnpB polypeptide and the TAM is tcat.

725. The method of any one of claims 713-720, wherein the inserting step comprises homology directed repair (HDR)-mediated insertion using a TnpB polypeptide and the TAM is tcaa.

726. The method of any one of claims 713-720, wherein the inserting step comprises homology directed repair (HDR)-mediated insertion using a TnpB polypeptide and the TAM is ttcan, wherein n = a, c, t or g.

727. The method of any one of claims 713-720, wherein the inserting step comprises homology directed repair (HDR)-mediated insertion using a TnpB polypeptide and the TAM is ttcaa.

728. The method of any one of claims 713-720, wherein the inserting step comprises homology directed repair (HDR)-mediated insertion using a TnpB polypeptide and the TAM is ttcag.

729. The method of any one of claims 713-720, wherein the inserting step comprises homology directed repair (HDR)-mediated insertion using a TnpB polypeptide and the TAM is ttgat.

730. The method of claim 658 or 659, wherein the step of delivering the nucleic acid construct to the cell comprises viral transduction using a retroviral or adeno-associated viral (AAV) vector.

731. The method of claim 730, wherein the retrovirus is or comprises Moloney murine leukemia virus (M-MuLV), Moloney murine sarcoma virus (MoMSV), Harvey murine sarcoma virus (HaMuSV), mouse mammary tumor virus (MuMTV), Gibbon ape leukemia virus (GaLV), feline leukemia virus (FLV), foamy virus, Friedreid murine leukemia virus, murine stem cell virus (MSCV), Rous sarcoma virus (RSV), a lentivirus, a gamma retrovirus, an epsilon retrovirus, an alpha retrovirus, a beta retrovirus, a delta retrovirus or a foamy retrovirus.

732. The method of claim 730, wherein the AAV vector is an AAV6 vector or an AAV9 vector.

733. The method of any one of claims 660, 661, 662, 673-693, 696-715, or 720-732, wherein the first transgene encoding the engineered protein at the insertion site at the TCR locus reduces expression of a functional TCR.

734. The method of any one of claims 660, 661, 662, 673-693, 696-715, or 720-733, wherein the first transgene encoding the engineered protein at the insertion site at the TCR locus disrupts expression of a functional TCR.

735. The method of any one of claims 660, 661, 662, 673-693, 696-715, or 720-732, wherein the first transgene encoding the engineered protein at the insertion site at the B2M locus reduces expression of functional B2M.

736. The method of any one of claims 660, 661, 662, 673-693, 696-715 or 720-732, or 735, wherein the first transgene encoding the engineered protein at the insertion site at the B2M locus reduces expression of functional MHC I molecules.

737. The method of any one of claims 660, 661, 662, 673-693, 696-715 or 720-732, or 735-736, wherein the first transgene encoding the engineered protein at the insertion site located at the B2M locus disrupts expression of functional B2M.

738. The method of any one of claims 660, 661, 662, 673-693, 696-715 or 720-732, or 735-737, wherein the first transgene encoding the engineered protein at the insertion site at the B2M locus disrupts expression of a functional MHC I molecule.

739. The method of any one of claims 660, 661, 662, 673-693, 696-715, or 720-732, wherein the first transgene encoding the engineered protein at the insertion site at the CIITA locus reduces expression of functional CIITA.

740. The method of any one of claims 660, 661, 662, 673-693, 696-715 or 720-732, or 739, wherein the first transgene encoding the engineered protein at the insertion site at the CIITA locus reduces expression of functional MHC II molecules.

741. The method of any one of claims 660, 661, 662, 673-693, 696-715 or 720-732, or 739-740, wherein the first transgene encoding the engineered protein at the insertion site at the CIITA locus disrupts expression of functional CIITA.

742. The method of any one of claims 660, 661, 662, 673-693, 696-715 or 720-732, or 739-741, wherein the first transgene encoding the engineered protein at the insertion site at the CIITA locus disrupts expression of functional MHC II molecules.

743. The method of any one of claims 658-742, wherein the cell comprises one or more modifications that inactivate or disrupt one or more alleles of: (a) one or more major histocompatibility complex (MHC) class I molecules or one or more molecules that regulate the expression of said one or more MHC class I molecules, and / or (b) one or more MHC class II molecules or one or more molecules that regulate the expression of the one or more MHC class II molecules.

744. The method of any one of claims 658-743, wherein the cell comprises one or more modifications that inactivate or disrupt one or more alleles of one or more MHC class I molecules or one or more molecules that regulate expression of the one or more MHC class I molecules.

745. The method of any one of claims 658-744, wherein the cell comprises one or more modifications that inactivate or disrupt one or more alleles of one or more MHC Class II molecules or one or more molecules that regulate expression of the one or more MHC Class II molecules.

746. The method of any one of claims 658-745, wherein the cell comprises one or more modifications that inactivate or disrupt one or more alleles of: (a) one or more MHC class I molecules or one or more molecules that regulate the expression of the one or more MHC class I molecules, and (b) one or more MHC class II molecules or one or more molecules that regulate the expression of the one or more MHC class II molecules.

747. The method of any one of claims 743-746, wherein the one or more modifications reduce cell surface protein expression of the one or more MHC class I molecules.

748. The method of any one of claims 743-747, wherein the one or more modifications reduce cell surface trafficking of the one or more MHC class I molecules.

749. The method of any one of claims 743-748, wherein the one or more modifications reduce a function of the one or more MHC class I molecules, optionally wherein the function is antigen presentation.

750. v as described in any of claims 743-749, wherein the one or more MHC class I molecules are one or more human leukocyte antigen (HLA) class I molecules.

751. The method of claim 750, wherein the one or more HLA class I molecules are selected from the group consisting of HLA-A, HLA-B, and HLA-C.

752. The method of any one of claims 743-751, wherein the one or more molecules that regulate the expression of the one or more MHC class I molecules are selected from the group consisting of B2M, NLRC5 and TAP1.

753. The method of any one of claims 743-752, wherein the one or more modifications reduce cell surface protein expression of the one or more MHC class II molecules.

754. The method of any one of claims 743-753, wherein the one or more modifications reduce cell surface trafficking of the one or more MHC class II molecules.

755. The method of any one of claims 743-754, wherein the one or more modifications reduce a function of the one or more MHC class II molecules, optionally wherein the function is antigen presentation.

756. The method of any one of claims 743-755, wherein the one or more MHC class II molecules are one or more human leukocyte antigen (HLA) class II molecules.

757. The method of claim 756, wherein the one or more HLA class II molecules are selected from the group consisting of HLA-DP, HLA-DQ and / or HLA-DR.

758. The method of any one of claims 743-757, wherein the one or more molecules that regulate the expression of the one or more MHC class II molecules are selected from the group consisting of CIITA and CD74.

759. The method of any one of claims 660-758, wherein the first transgene encoding the engineered protein at the insertion site at the safe harbor locus disrupts expression of functional AAVS1, ABO, CCR5, CLYBL, CXCR4, F3, FUT1, HMGB1, KDM5D, LRP1, MICA, MICB, RHD, ROSA26 or SHS231.

760. The method of any one of claims 660-758, wherein the first transgene encoding the engineered protein at the insertion site at the safe harbor locus disrupts expression of a functional AAVS1, ABO, CCR5, CLYBL, CXCR4, F3, FUT1, HMGB1, KDM5D, LRP1, MICA, MICB, RHD, ROSA26 or SHS231 molecule.

761. The method of any one of claims 658-760, wherein the genetically engineered cells have cell surface expression of the engineered protein.

762. The method of any one of claims 658-761, wherein the nucleic acid construct further comprises a second transgene encoding a tolerogenic factor.

763. The method of claim 762, wherein the method further comprises inserting the second transgene into a second insertion site in the genome of the cell.

764. The method of claim 762, wherein the tolerogenic factor is or includes A20 / TNFAIP3, B2M-HLA-E, CD16, CD16 Fc receptor, CD24, CD27, CD35, CD39, CD46, CD47, CD52, CD55, CD59, CD64, CD200, CCL21, CCL22, CTLA4-Ig, C1 inhibitor, CR1, DUX4, FASL, HLA-C, HLA-E, HLA-E heavy chain, HLA-F, HLA-G, H2-M3, IDO1, IL-10, IL15-RF, IL-35, IL-39, MANF, Mfge8, PD-L1 or Serpinb9.

765. The method of any one of claims 762-764, wherein the second transgene encoding the tolerogenic factor is inserted at a second insertion site located at the TCR locus.

766. The method of any one of claims 762-764, wherein the second transgene encoding the tolerogenic factor is inserted at a second insertion site located at the B2M locus.

767. The method of any one of claims 762-121b764, wherein the second transgene encoding the tolerogenic factor is inserted at a second insertion site located at the CIITA locus.

768. The method of any one of claims 762-764, wherein the second transgene encoding the tolerogenic factor is inserted at a second insertion site located at a safe harbor locus.

769. The method of claim 768, wherein the safe harbor locus is an AAVS1, ABO, CCR5, CLYBL, CXCR4, F3, FUT1, HMGB1, KDM5D, LRP1, MICA, MICB, RHD, ROSA26, or SHS231 locus.

770. The method of any one of claims 762-769, wherein the genetically engineered cells have cell surface expression of the tolerogenic factor.

771. The method of any one of claims 658-770, wherein the nucleic acid construct further comprises a third transgene encoding a chimeric antigen receptor (CAR).

772. The method of claim 771, wherein the method further comprises inserting the third transgene into a third insertion site in the genome of the cell.

773. A method as described in claim 771, wherein the CAR is or includes CD5-specific CAR, CD19-specific CAR, CD20-specific CAR, CD22-specific CAR, CD23-specific CAR, CD30-specific CAR, CD33-specific CAR, CD38-specific CAR, CD70-specific CAR, CD123-specific CAR, CD138-specific CAR, κ, λ, B cell maturation agent (BCMA)-specific CAR, G protein-coupled receptor family group C 5 member D (GPRC5D)-specific CAR, CD123-specific CAR, LeY-specific CAR, NKG2D ligand-specific CAR, WT1-specific CAR, GD2-specific CAR, HER2-specific CAR, EGFR-specific CAR, EGFRvIII-specific CAR, B7H3-specific CAR, PSMA-specific CAR, PSCA-specific CAR, CAIX-specific CAR, CD1 71-specific CAR, CEA-specific CAR, CSPG4-specific CAR, EPHA2-specific CAR, FAP-specific CAR, FRα-specific CAR, IL-13Rα-specific CAR, mesothelin-specific CAR, MUC1-specific CAR, MUC16-specific CAR, ROR1-specific CAR, C-Met-specific CAR, CD133-specific CAR, Ep-CAM-specific CAR, GPC3-specific CAR, HPV16-E6-specific CAR, IL13Ra2-specific CAR, MAGEA3-specific CAR, MAGEA4-specific CAR, MART1-specific CAR, NY-ESO-1-specific CAR, VEGFR2-specific CAR, α-folate receptor-specific CAR, CD24-specific CAR, CD44v7 / 8-specific CAR, EGP-2-specific CAR, EGP-40-specific CAR, erb-B2-specific CAR, erb-B 2,3,4-specific CAR, FBP-specific CAR, fetal acetylcholine e receptor-specific CAR, GD2-specific CAR, GD3-specific CAR, HMW-MAA-specific CAR, IL-11Rα-specific CAR, KDR-specific CAR, Lewis Y-specific CAR, L1 cell adhesion molecule-specific CAR, MAGE-A1-specific CAR, carcinoembryonic antigen (h5T4)-specific CAR, TAG-72-specific CAR, or CD19 / CD22 bispecific CAR.

774. A method as described in any one of claims 771-773, wherein the CAR is or includes a CD19-specific CAR, a CD20-specific CAR, a CD22-specific CAR, a CD38-specific CAR, a CD123-specific CAR, a CD138-specific CAR, a BCMA-specific CAR or a CD19 / CD22 bispecific CAR.

775. The method of any one of claims 771-774, wherein the genetically engineered cells have cell surface expression of the CAR.

776. The method of any one of claims 658-770, wherein the nucleic acid construct further comprises a third transgene encoding a chimeric autoantigen receptor (CAAR).

777. The method of claim 776, wherein the method further comprises inserting the third transgene into a third insertion site in the genome of the cell.

778. The method of claim 776, wherein the CAAR comprises an antigen selected from the group consisting of pancreatic β cell antigen, synovial joint antigen, myelin basic protein, proteolipid protein, myelin oligodendrocyte glycoprotein, MuSK, keratinocyte adhesion protein desmoglein 3 (Dsg3), Ro-RNP complex, La antigen, myeloperoxidase, proteinase 3, cardiolipin, citrullinated protein, carbamylated protein and basement membrane collagen α3 chain.

779. The method of any one of claims 776-778, wherein the genetically engineered cells have cell surface expression of the CAAR.

780. The method of any one of claims 658-770, wherein the nucleic acid construct further comprises a third transgene encoding a B cell autoantibody receptor (BAR).

781. The method of claim 780, wherein the method further comprises inserting the third transgene into a third insertion site in the genome of the cell.

782. The method of claim 780, wherein the genetically engineered cells have cell surface expression of the BAR.

783. The method of any one of claims 771-782, wherein the third transgene is inserted at a safe harbor locus.

784. The method of any one of claims 771-783, wherein the third transgene is inserted at a TRAC locus, a TRBC1 locus, a TRBC2 locus, a B2M locus, a CIITA locus, a MICA locus, a MICB locus, or a safe harbor locus.

785. The method of any one of claims 771-784, wherein the third transgene is inserted at the AAVS1 locus, the ABO locus, the CCR5 locus, the CLYBL locus, the CXCR4 locus, the F3 locus, the FUT1 locus, the HMGB1 locus, the KDM5D locus, the LRP1 locus, the RHD locus, the ROSA26 locus, or the SHS231 locus.

786. The method of any one of claims 658-785, wherein the first transgene and the second transgene are inserted into the same insertion site.

787. The method of any one of claims 658-768 or 780-785, wherein the first transgene and the third transgene are inserted into the same insertion site.

788. The method of any one of claims 762-785, wherein the second transgene and the third transgene are inserted into the same insertion site.

789. The method of any one of claims 658-785, wherein the first transgene, the second transgene, and the third transgene are inserted into the same insertion site.

790. The method of any one of claims 658-789, wherein the first transgene, the second transgene, and the third transgene are encoded by three separate constructs.

791. The method of any one of claims 658-789, wherein the first transgene, the second transgene, and the third transgene are encoded by two separate constructs.

792. The method of any one of claims 658-789, wherein the first transgene, the second transgene, and the third transgene are encoded by a polycistronic construct.

793. The method of any one of claims 658-792, wherein the genetically engineered cell is a human cell or a non-human animal cell.

794. The method of claim 793, wherein the non-human animal cell is a pig, cow or sheep cell.

795. The method of claim 793, wherein the genetically engineered cells are human cells.

796. The method of any one of claims 658-795, wherein the genetically engineered cells are differentiated cells derived from stem cells or progenitor cells.

797. The method of any one of claims 658-796, wherein the cell is a stem cell or a progenitor cell.

798. The method of any one of claims 658-796, wherein the cell is a differentiated cell derived from a stem cell or a progenitor cell.

799. The method of claim 796, wherein the stem cells are pluripotent stem cells.

800. The method of claim 799, wherein the pluripotent stem cell is an induced pluripotent stem cell (iPSC).

801. The method of claim 799, wherein the pluripotent stem cells are embryonic stem cells (ESC).

802. The method of any one of claims 658-801, wherein the cells are primary cells isolated from a donor.

803. The method of claim 802, wherein the donor is healthy and / or not suspected of having a disease or illness when the primary cells are obtained from the donor.

804. The method of any one of claims 658-803, wherein the cell is a pancreatic islet cell, a beta islet cell, a pancreatic islet cell, an immune cell, a B cell, a T cell, a natural killer (NK) cell, a natural killer T (NKT) cell, a macrophage, an endothelial cell, a muscle cell, a cardiac muscle cell, a smooth muscle cell, a skeletal muscle cell, a dopaminergic neuron, a retinal pigment epithelial cell, a visual cell, a hepatocyte, a thyroid cell, a skin cell, a glial progenitor cell, a neural cell, a cardiac cell, a stem cell, a hematopoietic stem cell, an induced pluripotent stem cell (iPSC), a mesenchymal stem cell (MSC), an embryonic stem cell (ESC), a pluripotent stem cell (PSC), a blood cell, or a combination thereof.

805. The method of any one of claims 658-804, wherein the cell is a T cell.

806. The method of claim 805, wherein the T cells are CD3+T cells, CD4+T cells, CDS+T cells, naive T cells, regulatory T (Treg) cells, non-regulatory T cells, Th1 cells, Th2 cells, Th9 cells, Th17 cells, follicular helper T (Tfh) cells, cytotoxic T lymphocytes (CTLs), effector T (Teff) cells, central memory T cells, effector memory T cells, effector memory T cells expressing CD45RA (TEMRA cells), tissue-resident memory (Trm) cells, virtual memory T cells, innate memory T cells, memory stem cells (Tse), γδ T cells, or a combination thereof.

807. The method of claim 805 or 806, wherein the T cell is a cytotoxic T cell, a helper T cell, a memory T cell, a regulatory T cell, a tumor infiltrating lymphocyte, or a combination thereof.

808. The method of any one of claims 805-807, wherein the cell is a human T cell.

809. The method of any one of claims 805-808, wherein the cell is an autologous T cell.

810. The method of any one of claims 805-808, wherein the cell is an allogeneic T cell.

811. The method of claim 810, wherein the allogeneic T cells are primary T cells.

812. The method of 810 or 811, wherein the allogeneic T cells have been differentiated from embryonic stem cells (ESCs) or induced pluripotent stem cells (iPSCs).

Citation Information

Patent Citations

  • Coupled hydrocarbon polymers and process for their preparation

    EP0002012A1

  • Generation of neuronal cells from pluripotent stem cells

    US10093897B2

  • Methods and reagents for riboswitch analysis

    US10421989B2

  • Culture scaffold for enhancing differentiation of osteoblast using pattern

    US10626373B2

  • Human liver scaffolds

    US10688221B2

Cited By

  • Chimeric antigen receptor for expressing CD47-CD28 costimulatory conversion receptor and application of chimeric antigen receptor

    CN121537531A

  • Chimeric antigen receptors expressing cd47-cd28 costimulatory switching receptors and uses thereof

    CN121537531B